ES2573778T3 - Derivados de pirrolopiridinamino como inhibidores de MPS1 - Google Patents
Derivados de pirrolopiridinamino como inhibidores de MPS1 Download PDFInfo
- Publication number
- ES2573778T3 ES2573778T3 ES12711433.8T ES12711433T ES2573778T3 ES 2573778 T3 ES2573778 T3 ES 2573778T3 ES 12711433 T ES12711433 T ES 12711433T ES 2573778 T3 ES2573778 T3 ES 2573778T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- pyrrolo
- alkyl
- chloro
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title 1
- -1 cyano, nitro, hydroxy, mercapto, amino, carboxy, carbamoyl Chemical group 0.000 claims abstract description 234
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 67
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 35
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 12
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims description 10
- PWUBQFAXBPLSTN-UHFFFAOYSA-N n-(2-chlorophenyl)-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=NN(C)C=C1C(NC1=C2)=CC1=CN=C2NC1=CC=CC=C1Cl PWUBQFAXBPLSTN-UHFFFAOYSA-N 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- OKMPZTKIBTVWLX-UHFFFAOYSA-N (3-methoxyazetidin-1-yl)-[3-methoxy-4-[[2-(1,3-oxazol-5-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]phenyl]methanone Chemical compound C1C(OC)CN1C(=O)C(C=C1OC)=CC=C1NC(N=C1)=CC2=C1C=C(C=1OC=NC=1)N2 OKMPZTKIBTVWLX-UHFFFAOYSA-N 0.000 claims description 2
- ZSOGRCABYJFSOS-UHFFFAOYSA-N [3-chloro-4-[[2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]phenyl]-(1,1-dioxo-1,4-thiazinan-4-yl)methanone Chemical compound C1=NN(C)C=C1C(NC1=C2)=CC1=CN=C2NC1=CC=C(C(=O)N2CCS(=O)(=O)CC2)C=C1Cl ZSOGRCABYJFSOS-UHFFFAOYSA-N 0.000 claims description 2
- CNFIWHONPHOWNL-UHFFFAOYSA-N [3-chloro-4-[[2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]phenyl]-(3-methoxyazetidin-1-yl)methanone Chemical compound C1C(OC)CN1C(=O)C(C=C1Cl)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 CNFIWHONPHOWNL-UHFFFAOYSA-N 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- FFKWEZNKLOXVQS-UHFFFAOYSA-N 3-chloro-4-[[1-cyclopentyl-2-(1-methylpyrazol-4-yl)pyrrolo[3,2-c]pyridin-6-yl]amino]-n,n-dimethylbenzamide Chemical compound ClC1=CC(C(=O)N(C)C)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2C1CCCC1 FFKWEZNKLOXVQS-UHFFFAOYSA-N 0.000 claims 1
- XGKBNMQHSZWDMT-UHFFFAOYSA-N 3-chloro-n-(2-chlorophenyl)-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=NN(C)C=C1C1=C(Cl)C2=CN=C(NC=3C(=CC=CC=3)Cl)C=C2N1 XGKBNMQHSZWDMT-UHFFFAOYSA-N 0.000 claims 1
- LHWVEASUMBCYJH-UHFFFAOYSA-N 6-[2-chloro-4-(1-methylpyrazol-4-yl)anilino]-2-(1-methylpyrazol-4-yl)pyrrolo[3,2-c]pyridine-1-carboxylic acid Chemical compound C1=NN(C)C=C1C(N(C1=C2)C(O)=O)=CC1=CN=C2NC1=CC=C(C2=CN(C)N=C2)C=C1Cl LHWVEASUMBCYJH-UHFFFAOYSA-N 0.000 claims 1
- AOEZXFDFUBEONI-UHFFFAOYSA-N C1=NN(C)C=C1C1=C(Cl)C2=CN=C(NC=3C(=CC(=CC=3)C3=CN(C)N=C3)Cl)C=C2N1 Chemical compound C1=NN(C)C=C1C1=C(Cl)C2=CN=C(NC=3C(=CC(=CC=3)C3=CN(C)N=C3)Cl)C=C2N1 AOEZXFDFUBEONI-UHFFFAOYSA-N 0.000 claims 1
- YMJOQQJSTABYFM-UHFFFAOYSA-N n,n-dimethyl-4-[[2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]-3-(trifluoromethoxy)benzamide Chemical compound FC(F)(F)OC1=CC(C(=O)N(C)C)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 YMJOQQJSTABYFM-UHFFFAOYSA-N 0.000 claims 1
- UPWGYYWCIKNSTC-UHFFFAOYSA-N n-(2-chlorophenyl)-1-(cyclohexylmethyl)-2-(1-methylpyrazol-4-yl)pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=NN(C)C=C1C(N(C1=C2)CC3CCCCC3)=CC1=CN=C2NC1=CC=CC=C1Cl UPWGYYWCIKNSTC-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 11
- 239000001257 hydrogen Substances 0.000 abstract description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract description 8
- 125000001424 substituent group Chemical group 0.000 abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 40
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 125000001589 carboacyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000003709 fluoroalkyl group Chemical group 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229920001774 Perfluoroether Polymers 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052703 rhodium Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 238000000034 method Methods 0.000 description 274
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 196
- 238000000746 purification Methods 0.000 description 181
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 178
- 238000005481 NMR spectroscopy Methods 0.000 description 160
- 238000002360 preparation method Methods 0.000 description 137
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 91
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 55
- 238000005160 1H NMR spectroscopy Methods 0.000 description 48
- 238000000547 structure data Methods 0.000 description 48
- 235000019439 ethyl acetate Nutrition 0.000 description 37
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 20
- 239000000460 chlorine Chemical group 0.000 description 20
- 229910052801 chlorine Chemical group 0.000 description 20
- UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 15
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 13
- 238000012746 preparative thin layer chromatography Methods 0.000 description 13
- YIYBPEDZAUFQLO-UHFFFAOYSA-N 4-amino-3-chlorobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1Cl YIYBPEDZAUFQLO-UHFFFAOYSA-N 0.000 description 10
- HFISPJNCOWPCHR-UHFFFAOYSA-N 7h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1C(N)=NC=C2C=CN=C21 HFISPJNCOWPCHR-UHFFFAOYSA-N 0.000 description 10
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WMKYKQWKLILFBM-UHFFFAOYSA-N 2h-pyridine-1-carboxylic acid Chemical compound OC(=O)N1CC=CC=C1 WMKYKQWKLILFBM-UHFFFAOYSA-N 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- JNFGLYJROFAOQP-UHFFFAOYSA-N 4-amino-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1N JNFGLYJROFAOQP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- VMPITZXILSNTON-UHFFFAOYSA-N o-anisidine Chemical compound COC1=CC=CC=C1N VMPITZXILSNTON-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 125000004304 oxazol-5-yl group Chemical group O1C=NC=C1* 0.000 description 4
- 238000002953 preparative HPLC Methods 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 3
- 238000004293 19F NMR spectroscopy Methods 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 3
- AVPAYFOQPGPSCC-UHFFFAOYSA-N 3-methoxyazetidine Chemical compound COC1CNC1 AVPAYFOQPGPSCC-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- XITQUSLLOSKDTB-UHFFFAOYSA-N nitrofen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(Cl)C=C1Cl XITQUSLLOSKDTB-UHFFFAOYSA-N 0.000 description 3
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 3
- VOWUGYAENFWGMB-UHFFFAOYSA-N pyrrolo[3,2-c]pyridine-1-carboxylic acid Chemical compound N1=CC=C2N(C(=O)O)C=CC2=C1 VOWUGYAENFWGMB-UHFFFAOYSA-N 0.000 description 3
- USJBBWBDVIPXEQ-UHFFFAOYSA-N (4-amino-3-chlorophenyl)-(1,1-dioxo-1,4-thiazinan-4-yl)methanone Chemical compound C1=C(Cl)C(N)=CC=C1C(=O)N1CCS(=O)(=O)CC1 USJBBWBDVIPXEQ-UHFFFAOYSA-N 0.000 description 2
- OEUCIOPQYBRFKZ-UHFFFAOYSA-N (4-amino-3-chlorophenyl)-(3,3-difluoroazetidin-1-yl)methanone Chemical compound C1=C(Cl)C(N)=CC=C1C(=O)N1CC(F)(F)C1 OEUCIOPQYBRFKZ-UHFFFAOYSA-N 0.000 description 2
- RTEHLSCIEVIFCS-UHFFFAOYSA-N (4-amino-3-chlorophenyl)-(3-methoxyazetidin-1-yl)methanone Chemical compound C1C(OC)CN1C(=O)C1=CC=C(N)C(Cl)=C1 RTEHLSCIEVIFCS-UHFFFAOYSA-N 0.000 description 2
- SEWIYPJLPXWZCR-UHFFFAOYSA-N (4-amino-3-chlorophenyl)-(4-methoxypiperidin-1-yl)methanone Chemical compound C1CC(OC)CCN1C(=O)C1=CC=C(N)C(Cl)=C1 SEWIYPJLPXWZCR-UHFFFAOYSA-N 0.000 description 2
- DPYZQYLHPWYIBU-UHFFFAOYSA-N (4-amino-3-chlorophenyl)-(azetidin-1-yl)methanone Chemical compound C1=C(Cl)C(N)=CC=C1C(=O)N1CCC1 DPYZQYLHPWYIBU-UHFFFAOYSA-N 0.000 description 2
- WNJYNDPEAYEIFH-UHFFFAOYSA-N (4-amino-3-chlorophenyl)-[4-(dimethylamino)piperidin-1-yl]methanone Chemical compound C1CC(N(C)C)CCN1C(=O)C1=CC=C(N)C(Cl)=C1 WNJYNDPEAYEIFH-UHFFFAOYSA-N 0.000 description 2
- DCSODXNIMLJEGQ-UHFFFAOYSA-N (4-amino-3-chlorophenyl)-pyrrolidin-1-ylmethanone Chemical compound C1=C(Cl)C(N)=CC=C1C(=O)N1CCCC1 DCSODXNIMLJEGQ-UHFFFAOYSA-N 0.000 description 2
- XEEIAKZYRGDRLW-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-(3-methoxyazetidin-1-yl)methanone Chemical compound C1C(OC)CN1C(=O)C1=CC=C(N)C(OC)=C1 XEEIAKZYRGDRLW-UHFFFAOYSA-N 0.000 description 2
- GPRUBQPFDXFIJN-UHFFFAOYSA-N (4-amino-3-methoxyphenyl)-morpholin-4-ylmethanone Chemical compound C1=C(N)C(OC)=CC(C(=O)N2CCOCC2)=C1 GPRUBQPFDXFIJN-UHFFFAOYSA-N 0.000 description 2
- GIWQSPITLQVMSG-UHFFFAOYSA-N 1,2-dimethylimidazole Chemical compound CC1=NC=CN1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 description 2
- YTQOFNKESZDBSW-UHFFFAOYSA-N 1-(4-amino-3-chlorophenyl)pyrrolidin-2-one Chemical compound C1=C(Cl)C(N)=CC=C1N1C(=O)CCC1 YTQOFNKESZDBSW-UHFFFAOYSA-N 0.000 description 2
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- ZDMISTLJKQDGTB-UHFFFAOYSA-N 4-(bromomethyl)-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(CBr)=CC=C1[N+]([O-])=O ZDMISTLJKQDGTB-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- MNKKSPAMTAZDOX-UHFFFAOYSA-N cyclopentyl 2h-pyridine-1-carboxylate Chemical compound C1C=CC=CN1C(=O)OC1CCCC1 MNKKSPAMTAZDOX-UHFFFAOYSA-N 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- JSMKGNLEGNDKSV-UHFFFAOYSA-N n-(2,4-dimethoxyphenyl)-2-[1-[(5-methyl-1,2-oxazol-3-yl)methyl]pyrazol-4-yl]-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(CC3=NOC(C)=C3)N=C1)N2 JSMKGNLEGNDKSV-UHFFFAOYSA-N 0.000 description 2
- XVXDUWJDAATNHT-UHFFFAOYSA-N n-(2-methoxyphenyl)-2-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(CC(F)(F)F)N=C1)N2 XVXDUWJDAATNHT-UHFFFAOYSA-N 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- SDRXHGYWVWITSL-UHFFFAOYSA-N propan-2-yl 2h-pyridine-1-carboxylate Chemical compound CC(C)OC(=O)N1CC=CC=C1 SDRXHGYWVWITSL-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- AADYWCBPJZAJNU-UHFFFAOYSA-N (3-methoxy-4-nitrophenyl)methanol Chemical compound COC1=CC(CO)=CC=C1[N+]([O-])=O AADYWCBPJZAJNU-UHFFFAOYSA-N 0.000 description 1
- DOLYNZNTIJDJDX-UHFFFAOYSA-N (3-methoxyazetidin-1-yl)-[3-methoxy-4-[[2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]phenyl]methanone Chemical compound C1C(OC)CN1C(=O)C(C=C1OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 DOLYNZNTIJDJDX-UHFFFAOYSA-N 0.000 description 1
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 1
- REXGGJAEJCDHDD-UHFFFAOYSA-N 1-methoxypiperidine Chemical compound CON1CCCCC1 REXGGJAEJCDHDD-UHFFFAOYSA-N 0.000 description 1
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 description 1
- DRKFYSQWMCNNQA-UHFFFAOYSA-N 2-(1-methylpyrazol-4-yl)-1H-pyrrolo[3,2-c]pyridine Chemical compound CN1N=CC(=C1)C1=CC=2C=NC=CC2N1 DRKFYSQWMCNNQA-UHFFFAOYSA-N 0.000 description 1
- BIHMHFUQWCIATN-UHFFFAOYSA-N 2-(3-aminophenoxy)acetonitrile Chemical compound NC1=CC=CC(OCC#N)=C1 BIHMHFUQWCIATN-UHFFFAOYSA-N 0.000 description 1
- UNVSMSCAFUYXNO-UHFFFAOYSA-N 2-[1-(difluoromethyl)pyrazol-4-yl]-n-(2-methoxyphenyl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(N=C1)C(F)F)N2 UNVSMSCAFUYXNO-UHFFFAOYSA-N 0.000 description 1
- URARUGFTGBFIOG-UHFFFAOYSA-N 2-[3-[[2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]phenoxy]acetonitrile Chemical compound C1=NN(C)C=C1C(NC1=C2)=CC1=CN=C2NC1=CC=CC(OCC#N)=C1 URARUGFTGBFIOG-UHFFFAOYSA-N 0.000 description 1
- CWBDYJGKCOBHTF-UHFFFAOYSA-N 2-[4-[6-(2,4-dimethoxyanilino)-1h-pyrrolo[3,2-c]pyridin-2-yl]pyrazol-1-yl]-n,n-dimethylacetamide Chemical compound COC1=CC(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(CC(=O)N(C)C)N=C1)N2 CWBDYJGKCOBHTF-UHFFFAOYSA-N 0.000 description 1
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 1
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 1
- DCXLTFUQSSRVAL-UHFFFAOYSA-N 2-chloro-4-(1,2,4-triazol-1-yl)aniline Chemical compound C1=C(Cl)C(N)=CC=C1N1N=CN=C1 DCXLTFUQSSRVAL-UHFFFAOYSA-N 0.000 description 1
- BDNJAXRMZYBDIC-UHFFFAOYSA-N 2-chloro-4-(1,3-dimethylpyrazol-4-yl)aniline Chemical compound CC1=NN(C)C=C1C1=CC=C(N)C(Cl)=C1 BDNJAXRMZYBDIC-UHFFFAOYSA-N 0.000 description 1
- HGGMCQWMZHEDEP-UHFFFAOYSA-N 2-chloro-4-(1,3-oxazol-5-yl)aniline Chemical compound C1=C(Cl)C(N)=CC=C1C1=CN=CO1 HGGMCQWMZHEDEP-UHFFFAOYSA-N 0.000 description 1
- YPJQAYAXHPRJBW-UHFFFAOYSA-N 2-chloro-4-(1,3-thiazol-5-yl)aniline Chemical compound C1=C(Cl)C(N)=CC=C1C1=CN=CS1 YPJQAYAXHPRJBW-UHFFFAOYSA-N 0.000 description 1
- RHHFESMLMQZUTO-UHFFFAOYSA-N 2-chloro-4-(1,5-dimethylpyrazol-4-yl)aniline Chemical compound C1=NN(C)C(C)=C1C1=CC=C(N)C(Cl)=C1 RHHFESMLMQZUTO-UHFFFAOYSA-N 0.000 description 1
- SRTVBZMVFKUPRM-UHFFFAOYSA-N 2-chloro-4-(1-methylimidazol-2-yl)aniline Chemical compound CN1C=CN=C1C1=CC=C(N)C(Cl)=C1 SRTVBZMVFKUPRM-UHFFFAOYSA-N 0.000 description 1
- WGBSSISEKIBTFC-UHFFFAOYSA-N 2-chloro-4-(1-methylpyrazol-3-yl)aniline Chemical compound CN1C=CC(C=2C=C(Cl)C(N)=CC=2)=N1 WGBSSISEKIBTFC-UHFFFAOYSA-N 0.000 description 1
- LOCABMSMAIYOHU-UHFFFAOYSA-N 2-chloro-4-(1-methylpyrazol-4-yl)aniline Chemical compound C1=NN(C)C=C1C1=CC=C(N)C(Cl)=C1 LOCABMSMAIYOHU-UHFFFAOYSA-N 0.000 description 1
- VDMAJZMHUYTYTC-UHFFFAOYSA-N 2-chloro-4-(2,3-dimethylimidazol-4-yl)aniline Chemical compound CN1C(C)=NC=C1C1=CC=C(N)C(Cl)=C1 VDMAJZMHUYTYTC-UHFFFAOYSA-N 0.000 description 1
- CLRNAKMWAVBJLU-UHFFFAOYSA-N 2-chloro-4-(2,4-dimethyl-1,3-thiazol-5-yl)aniline Chemical compound S1C(C)=NC(C)=C1C1=CC=C(N)C(Cl)=C1 CLRNAKMWAVBJLU-UHFFFAOYSA-N 0.000 description 1
- KEOQKEKBUQUGKN-UHFFFAOYSA-N 2-chloro-4-(2-methoxypyridin-4-yl)aniline Chemical compound C1=NC(OC)=CC(C=2C=C(Cl)C(N)=CC=2)=C1 KEOQKEKBUQUGKN-UHFFFAOYSA-N 0.000 description 1
- BMMOHZHCQIHJML-UHFFFAOYSA-N 2-chloro-4-(2-methylpyrazol-3-yl)aniline Chemical compound CN1N=CC=C1C1=CC=C(N)C(Cl)=C1 BMMOHZHCQIHJML-UHFFFAOYSA-N 0.000 description 1
- YFPGZAKBDWCVCM-UHFFFAOYSA-N 2-chloro-4-(3,5-dimethylimidazol-4-yl)aniline Chemical compound N1=CN(C)C(C=2C=C(Cl)C(N)=CC=2)=C1C YFPGZAKBDWCVCM-UHFFFAOYSA-N 0.000 description 1
- LXQHTFFWNFQBIU-UHFFFAOYSA-N 2-chloro-4-(3-methylimidazol-4-yl)aniline Chemical compound CN1C=NC=C1C1=CC=C(N)C(Cl)=C1 LXQHTFFWNFQBIU-UHFFFAOYSA-N 0.000 description 1
- XSHGELNVWKJNCX-UHFFFAOYSA-N 2-chloro-4-(4-methyl-1,2,4-triazol-3-yl)aniline Chemical compound CN1C=NN=C1C1=CC=C(N)C(Cl)=C1 XSHGELNVWKJNCX-UHFFFAOYSA-N 0.000 description 1
- IEAYNXWZTAFYMW-UHFFFAOYSA-N 2-chloro-4-(5-methyl-1,2-oxazol-4-yl)aniline Chemical compound O1N=CC(C=2C=C(Cl)C(N)=CC=2)=C1C IEAYNXWZTAFYMW-UHFFFAOYSA-N 0.000 description 1
- MJRWVINYEIYUPL-UHFFFAOYSA-N 2-chloro-4-(6-methoxypyridin-3-yl)aniline Chemical compound C1=NC(OC)=CC=C1C1=CC=C(N)C(Cl)=C1 MJRWVINYEIYUPL-UHFFFAOYSA-N 0.000 description 1
- LCRTVRIBSIBSSW-UHFFFAOYSA-N 2-chloro-4-(6-methylpyridin-3-yl)aniline Chemical compound C1=NC(C)=CC=C1C1=CC=C(N)C(Cl)=C1 LCRTVRIBSIBSSW-UHFFFAOYSA-N 0.000 description 1
- INMPKLBAJFDEKI-UHFFFAOYSA-N 2-chloro-4-(difluoromethoxy)aniline Chemical compound NC1=CC=C(OC(F)F)C=C1Cl INMPKLBAJFDEKI-UHFFFAOYSA-N 0.000 description 1
- XRAKCYJTJGTSMM-UHFFFAOYSA-N 2-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1Cl XRAKCYJTJGTSMM-UHFFFAOYSA-N 0.000 description 1
- VLMRGLCBIFWPGL-UHFFFAOYSA-N 2-chloro-4-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=C(N)C(Cl)=C1 VLMRGLCBIFWPGL-UHFFFAOYSA-N 0.000 description 1
- VWTHAQDJHDZNCV-UHFFFAOYSA-N 2-chloro-4-pyrazin-2-ylaniline Chemical compound C1=C(Cl)C(N)=CC=C1C1=CN=CC=N1 VWTHAQDJHDZNCV-UHFFFAOYSA-N 0.000 description 1
- MIZPVMDYXJFSQC-UHFFFAOYSA-N 2-chloro-4-pyridin-3-ylaniline Chemical compound C1=C(Cl)C(N)=CC=C1C1=CC=CN=C1 MIZPVMDYXJFSQC-UHFFFAOYSA-N 0.000 description 1
- BIYSELUWLOOVOH-UHFFFAOYSA-N 2-chloro-4-pyrimidin-5-ylaniline Chemical compound C1=C(Cl)C(N)=CC=C1C1=CN=CN=C1 BIYSELUWLOOVOH-UHFFFAOYSA-N 0.000 description 1
- ZXFAYJZPEXCJMB-UHFFFAOYSA-N 2-chloro-5-(1-methylpyrazol-4-yl)aniline Chemical compound C1=NN(C)C=C1C1=CC=C(Cl)C(N)=C1 ZXFAYJZPEXCJMB-UHFFFAOYSA-N 0.000 description 1
- YWUVOJJHVFLNJA-UHFFFAOYSA-N 2-fluoro-4-methoxyaniline Chemical compound COC1=CC=C(N)C(F)=C1 YWUVOJJHVFLNJA-UHFFFAOYSA-N 0.000 description 1
- LWKZYZZCYQWRTJ-UHFFFAOYSA-N 2-methoxy-4-(trifluoromethyl)aniline Chemical compound COC1=CC(C(F)(F)F)=CC=C1N LWKZYZZCYQWRTJ-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- YXFAOWYMDGUFIQ-UHFFFAOYSA-N 2-methoxypyridin-3-amine Chemical compound COC1=NC=CC=C1N YXFAOWYMDGUFIQ-UHFFFAOYSA-N 0.000 description 1
- IWTFOFMTUOBLHG-UHFFFAOYSA-N 2-methoxypyridine Chemical compound COC1=CC=CC=N1 IWTFOFMTUOBLHG-UHFFFAOYSA-N 0.000 description 1
- QUHVRXKSQHIZNV-UHFFFAOYSA-N 3,3-difluoroazetidine Chemical compound FC1(F)CNC1 QUHVRXKSQHIZNV-UHFFFAOYSA-N 0.000 description 1
- CDBAEFXTCRKJPZ-UHFFFAOYSA-N 3,3-difluoroazetidine;hydron;chloride Chemical compound Cl.FC1(F)CNC1 CDBAEFXTCRKJPZ-UHFFFAOYSA-N 0.000 description 1
- FDGAEAYZQQCBRN-UHFFFAOYSA-N 3-amino-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1N FDGAEAYZQQCBRN-UHFFFAOYSA-N 0.000 description 1
- KSXGQRBTBLQJEF-UHFFFAOYSA-N 3-methoxyazetidine;hydrochloride Chemical compound Cl.COC1CNC1 KSXGQRBTBLQJEF-UHFFFAOYSA-N 0.000 description 1
- OTPGDVFVXLLPSQ-UHFFFAOYSA-N 4-[(3-methoxy-4-nitrophenyl)methyl]-1,4-thiazinane 1,1-dioxide Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(CN2CCS(=O)(=O)CC2)=C1 OTPGDVFVXLLPSQ-UHFFFAOYSA-N 0.000 description 1
- DPQIBVKVVGXAPI-UHFFFAOYSA-N 4-[(dimethylamino)methyl]-2-methoxyaniline Chemical compound COC1=CC(CN(C)C)=CC=C1N DPQIBVKVVGXAPI-UHFFFAOYSA-N 0.000 description 1
- QXHXDPWTMRKNDO-UHFFFAOYSA-N 4-[[2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]benzonitrile Chemical compound C1=CC(C#N)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2 QXHXDPWTMRKNDO-UHFFFAOYSA-N 0.000 description 1
- IXJFWBNYFTWBOR-UHFFFAOYSA-N 4-amino-3-(trifluoromethoxy)benzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1OC(F)(F)F IXJFWBNYFTWBOR-UHFFFAOYSA-N 0.000 description 1
- DQGWARKSLZMCJF-UHFFFAOYSA-N 4-amino-3-chloro-n,n-dimethylbenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(N)C(Cl)=C1 DQGWARKSLZMCJF-UHFFFAOYSA-N 0.000 description 1
- BNRRMRUVYDETQC-UHFFFAOYSA-N 4-fluoro-2-methoxyaniline Chemical compound COC1=CC(F)=CC=C1N BNRRMRUVYDETQC-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- ZEYSHALLPAKUHG-UHFFFAOYSA-N 4-methoxypiperidine Chemical compound COC1CCNCC1 ZEYSHALLPAKUHG-UHFFFAOYSA-N 0.000 description 1
- XILPCSMEKCBYFO-UHFFFAOYSA-N 4-methyl-1,2,4-triazole Chemical compound CN1C=NN=C1 XILPCSMEKCBYFO-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- GPKKCNOGMPCITH-UHFFFAOYSA-N 7-[(2-chlorophenyl)methyl]-8-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-1,3-dimethylpurine-2,6-dione Chemical compound C1=CC(OC)=CC=C1N1CCN(CC=2N(C=3C(=O)N(C)C(=O)N(C)C=3N=2)CC=2C(=CC=CC=2)Cl)CC1 GPKKCNOGMPCITH-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- REGXQNJJTYDTNX-UHFFFAOYSA-N C1=NN(C)C=C1C(N(C1=C2)C(=O)OC(C)(C)C)=CC1=CN=C2NC1=CC=C(F)C=C1Cl Chemical compound C1=NN(C)C=C1C(N(C1=C2)C(=O)OC(C)(C)C)=CC1=CN=C2NC1=CC=C(F)C=C1Cl REGXQNJJTYDTNX-UHFFFAOYSA-N 0.000 description 1
- ZGRIIFIEERAZME-UHFFFAOYSA-N CS(=O)(=O)N1C=CC2=CN=C(C=C21)Cl Chemical compound CS(=O)(=O)N1C=CC2=CN=C(C=C21)Cl ZGRIIFIEERAZME-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- BZORFPDSXLZWJF-UHFFFAOYSA-N N,N-dimethyl-1,4-phenylenediamine Chemical compound CN(C)C1=CC=C(N)C=C1 BZORFPDSXLZWJF-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- AEWFHSNRFSJEFK-UHFFFAOYSA-N S1C(C)=NC(C)=C1C(C=C1Cl)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 Chemical compound S1C(C)=NC(C)=C1C(C=C1Cl)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 AEWFHSNRFSJEFK-UHFFFAOYSA-N 0.000 description 1
- QNPBNNMOSUDLRV-UHFFFAOYSA-N [3-chloro-4-[[2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]phenyl]-(4-methoxypiperidin-1-yl)methanone Chemical compound C1CC(OC)CCN1C(=O)C(C=C1Cl)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 QNPBNNMOSUDLRV-UHFFFAOYSA-N 0.000 description 1
- VTXOTUWLUFJYDA-UHFFFAOYSA-N [3-chloro-4-[[2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]phenyl]-pyrrolidin-1-ylmethanone Chemical compound C1=NN(C)C=C1C(NC1=C2)=CC1=CN=C2NC1=CC=C(C(=O)N2CCCC2)C=C1Cl VTXOTUWLUFJYDA-UHFFFAOYSA-N 0.000 description 1
- PYEBQYHPCSDEKK-UHFFFAOYSA-N [3-chloro-4-[[3-chloro-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-yl]amino]phenyl]-(1,1-dioxo-1,4-thiazinan-4-yl)methanone Chemical compound C1=NN(C)C=C1C1=C(Cl)C2=CN=C(NC=3C(=CC(=CC=3)C(=O)N3CCS(=O)(=O)CC3)Cl)C=C2N1 PYEBQYHPCSDEKK-UHFFFAOYSA-N 0.000 description 1
- HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 description 1
- CXOSHIQMCLFUDP-UHFFFAOYSA-N cyclobutyl 6-[2-chloro-4-(dimethylcarbamoyl)anilino]-2-(1-methylpyrazol-4-yl)pyrrolo[3,2-c]pyridine-1-carboxylate Chemical compound ClC1=CC(C(=O)N(C)C)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2C(=O)OC1CCC1 CXOSHIQMCLFUDP-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical compound OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 description 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
- JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 1
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 1
- YQIGZPOCTHORTL-UHFFFAOYSA-N n-(2,4-dimethoxyphenyl)-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2 YQIGZPOCTHORTL-UHFFFAOYSA-N 0.000 description 1
- NEPCERLGWYFASW-UHFFFAOYSA-N n-(2-chloro-4-fluorophenyl)-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=NN(C)C=C1C(NC1=C2)=CC1=CN=C2NC1=CC=C(F)C=C1Cl NEPCERLGWYFASW-UHFFFAOYSA-N 0.000 description 1
- YJIODQXQURPDDG-UHFFFAOYSA-N n-(2-chloro-4-methoxyphenyl)-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound ClC1=CC(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2 YJIODQXQURPDDG-UHFFFAOYSA-N 0.000 description 1
- BEUXYMIIIBPCKC-UHFFFAOYSA-N n-(2-ethoxyphenyl)-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound CCOC1=CC=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2 BEUXYMIIIBPCKC-UHFFFAOYSA-N 0.000 description 1
- SPKPSCQNMQMBEY-UHFFFAOYSA-N n-(2-fluoro-4-methoxyphenyl)-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound FC1=CC(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 SPKPSCQNMQMBEY-UHFFFAOYSA-N 0.000 description 1
- OYEYZLGQJNQHMY-UHFFFAOYSA-N n-(2-methoxyphenyl)-2-(1,3-oxazol-5-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC=CC=C1NC(N=C1)=CC2=C1C=C(C=1OC=NC=1)N2 OYEYZLGQJNQHMY-UHFFFAOYSA-N 0.000 description 1
- VZCBKNMEUYMJGG-UHFFFAOYSA-N n-(2-methoxyphenyl)-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 VZCBKNMEUYMJGG-UHFFFAOYSA-N 0.000 description 1
- PSDOGBDKRWOMIK-UHFFFAOYSA-N n-(2-methoxyphenyl)-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2 PSDOGBDKRWOMIK-UHFFFAOYSA-N 0.000 description 1
- BJHILLFPGOQFKO-UHFFFAOYSA-N n-(2-methoxypyridin-3-yl)-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=NC=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 BJHILLFPGOQFKO-UHFFFAOYSA-N 0.000 description 1
- MWTFPFBKDCXYPU-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-1-methyl-2-(1h-pyrazol-4-yl)pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2C MWTFPFBKDCXYPU-UHFFFAOYSA-N 0.000 description 1
- UIEXDKQSWATHMD-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=C(OC)C(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2 UIEXDKQSWATHMD-UHFFFAOYSA-N 0.000 description 1
- XHZDIKRDUXDGSW-UHFFFAOYSA-N n-(4-fluoro-2-methoxyphenyl)-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC(F)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 XHZDIKRDUXDGSW-UHFFFAOYSA-N 0.000 description 1
- SXJKXTZFHYHUNX-UHFFFAOYSA-N n-(4-methoxyphenyl)-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=CC(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2 SXJKXTZFHYHUNX-UHFFFAOYSA-N 0.000 description 1
- WXPINDLJTJBTJE-UHFFFAOYSA-N n-[1-[6-(2-chlorophenyl)pyridazin-3-yl]piperidin-4-yl]-4,5,6,7-tetrahydro-1h-indazole-3-carboxamide Chemical compound ClC1=CC=CC=C1C1=CC=C(N2CCC(CC2)NC(=O)C=2C=3CCCCC=3NN=2)N=N1 WXPINDLJTJBTJE-UHFFFAOYSA-N 0.000 description 1
- PGVKHBALYLYJRS-UHFFFAOYSA-N n-[2-chloro-4-(2,3-dimethylimidazol-4-yl)phenyl]-1-(cyclopropylmethyl)-2-(1-methylpyrazol-4-yl)pyrrolo[3,2-c]pyridin-6-amine Chemical compound CN1C(C)=NC=C1C(C=C1Cl)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2CC1CC1 PGVKHBALYLYJRS-UHFFFAOYSA-N 0.000 description 1
- ZXLRVBUXRLELRB-UHFFFAOYSA-N n-[2-chloro-4-(2,3-dimethylimidazol-4-yl)phenyl]-2-(1,3-oxazol-5-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound CN1C(C)=NC=C1C(C=C1Cl)=CC=C1NC(N=C1)=CC2=C1C=C(C=1OC=NC=1)N2 ZXLRVBUXRLELRB-UHFFFAOYSA-N 0.000 description 1
- LGIMGHLHIYQOFE-UHFFFAOYSA-N n-[2-chloro-4-(2,3-dimethylimidazol-4-yl)phenyl]-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound CN1C(C)=NC=C1C(C=C1Cl)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 LGIMGHLHIYQOFE-UHFFFAOYSA-N 0.000 description 1
- PZEFPWHXNCBBQI-UHFFFAOYSA-N n-[2-chloro-4-(2-methoxypyridin-4-yl)phenyl]-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=NC(OC)=CC(C=2C=C(Cl)C(NC=3N=CC=4C=C(NC=4C=3)C3=CN(C)N=C3)=CC=2)=C1 PZEFPWHXNCBBQI-UHFFFAOYSA-N 0.000 description 1
- GOTSIPJTAQGKCT-UHFFFAOYSA-N n-[2-chloro-4-(3-methylimidazol-4-yl)phenyl]-2-(1,3-oxazol-5-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound CN1C=NC=C1C(C=C1Cl)=CC=C1NC(N=C1)=CC2=C1C=C(C=1OC=NC=1)N2 GOTSIPJTAQGKCT-UHFFFAOYSA-N 0.000 description 1
- MAIVDGVLZFCZKN-UHFFFAOYSA-N n-[4-(2-methoxyethoxy)phenyl]-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C1=CC(OCCOC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CNN=C1)N2 MAIVDGVLZFCZKN-UHFFFAOYSA-N 0.000 description 1
- XSLQRBBJXSFSGV-UHFFFAOYSA-N n-[4-(2-morpholin-4-ylethoxy)phenyl]-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C=1C=C(NC=2N=CC=3C=C(NC=3C=2)C2=CNN=C2)C=CC=1OCCN1CCOCC1 XSLQRBBJXSFSGV-UHFFFAOYSA-N 0.000 description 1
- ACEFTEPESWDUIC-UHFFFAOYSA-N n-[4-(aminomethyl)-2-methoxyphenyl]-2-(1-methylpyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound COC1=CC(CN)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2 ACEFTEPESWDUIC-UHFFFAOYSA-N 0.000 description 1
- WDLRYVZIXPTZDV-UHFFFAOYSA-N n-[4-(morpholin-4-ylmethyl)phenyl]-2-(1h-pyrazol-4-yl)-1h-pyrrolo[3,2-c]pyridin-6-amine Chemical compound C=1C=C(NC=2N=CC=3C=C(NC=3C=2)C2=CNN=C2)C=CC=1CN1CCOCC1 WDLRYVZIXPTZDV-UHFFFAOYSA-N 0.000 description 1
- FTNFEHXDETWERN-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-2,6-dimethyl-5-[(4-propan-2-yloxyphenyl)methyl]pyrimidin-4-amine Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 FTNFEHXDETWERN-UHFFFAOYSA-N 0.000 description 1
- XHXVAJHZTIXQQD-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]-5-[(4-butoxyphenyl)methyl]-2,6-dimethylpyrimidin-4-amine Chemical compound C1=CC(OCCCC)=CC=C1CC1=C(C)N=C(C)N=C1NP(=O)(N1CC1)N1CC1 XHXVAJHZTIXQQD-UHFFFAOYSA-N 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- XTDXZSGSIMLARD-UHFFFAOYSA-N tert-butyl 2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC=CC=C1 XTDXZSGSIMLARD-UHFFFAOYSA-N 0.000 description 1
- GJFCCTYFMRCIIG-UHFFFAOYSA-N tert-butyl 6-(2,4-dimethoxyanilino)-2-[1-[2-(dimethylamino)-2-oxoethyl]pyrazol-4-yl]pyrrolo[3,2-c]pyridine-1-carboxylate Chemical compound COC1=CC(OC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(CC(=O)N(C)C)N=C1)N2C(=O)OC(C)(C)C GJFCCTYFMRCIIG-UHFFFAOYSA-N 0.000 description 1
- QBTYWQNEBNSMRM-UHFFFAOYSA-N tert-butyl 6-[2-chloro-4-(difluoromethoxy)anilino]-2-(1-methylpyrazol-4-yl)pyrrolo[3,2-c]pyridine-1-carboxylate Chemical compound C1=NN(C)C=C1C(N(C1=C2)C(=O)OC(C)(C)C)=CC1=CN=C2NC1=CC=C(OC(F)F)C=C1Cl QBTYWQNEBNSMRM-UHFFFAOYSA-N 0.000 description 1
- APYFOQGGPLLXSS-UHFFFAOYSA-N tert-butyl 6-[2-chloro-4-(methylcarbamoyl)anilino]-2-(1-methylpyrazol-4-yl)pyrrolo[3,2-c]pyridine-1-carboxylate Chemical compound ClC1=CC(C(=O)NC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2C(=O)OC(C)(C)C APYFOQGGPLLXSS-UHFFFAOYSA-N 0.000 description 1
- GFPRBAVXMBNNMO-UHFFFAOYSA-N tert-butyl 6-[2-methoxy-4-(methylcarbamoyl)anilino]-2-(1-methylpyrazol-4-yl)pyrrolo[3,2-c]pyridine-1-carboxylate Chemical compound COC1=CC(C(=O)NC)=CC=C1NC(N=C1)=CC2=C1C=C(C1=CN(C)N=C1)N2C(=O)OC(C)(C)C GFPRBAVXMBNNMO-UHFFFAOYSA-N 0.000 description 1
- CRYHJOFLWGDFBT-UHFFFAOYSA-N tert-butyl n-[(4-amino-3-methoxyphenyl)methyl]-n-methylcarbamate Chemical compound COC1=CC(CN(C)C(=O)OC(C)(C)C)=CC=C1N CRYHJOFLWGDFBT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de fórmula I **Fórmula** en donde: R1 es hidrógeno, (1-5C)alquilo, (1-5C)fluoroalquilo, (3-8C)cicloalquilo, (3-8C)cicloalquil-(1-4C)alquilo, 5 arilo, aril-(1- 4C)alquilo, heteroarilo, heteroaril-(1-4C)alquilo, -S(O)2-Ra, -C(O)-Ra, o -C(O)-O-Ra, en donde Ra es (1- 5C)alquilo, (3-8C)cicloalquilo, (3-8C)cicloalquil-(1-4C)alquilo, arilo, aril-(1-4C)alquilo, heteroarilo o heteroaril-(1- 4C)alquilo, y en donde cualquier grupo (1-5C)alquilo, (3-8C)cicloalquilo, (3-8C)cicloalquil-(1-4C)alquilo, arilo, aril- (1-4C)alquilo, heteroarilo, heteroaril-(1-4C)alquilo presente en un grupo sustituyente R1 es opcionalmente sustituido por metilo, trifluorometilo, metoxi, trifluorometoxi, halo, ciano, nitro, hidroxi, mercapto, amino, carboxi, carbamoilo, o sulfamoilo; R2 es un arilo, aril(1-2C)alquilo, heteroarilo de 5 o 6 miembros o un heteroaril(1-2C)alquilo de 5 o 6 miembros, en donde R2 es opcionalmente sustituido por uno o más sustituyentes seleccionados de halógeno, trifluorometilo, trifluorometoxi, ciano, nitro, hidroxi, mercapto, amino, carboxi, carbamoilo, sulfamoilo, o un grupo de la fórmula: L-L0-Rb en donde L está ausente o es un grupo enlazante de la fórmula -[CRgRh]n- en la que n es un entero seleccionado de 1, 2, 3 o 4, y Rg y Rh son cada uno seleccionados independientemente de hidrógeno o (1-2C)alquilo; L0 está ausente o se selecciona de O, S, SO, SO2, N(Rc), C(O), C(O)O, OC(O), CH(ORc), C(O)N(Rc), N(Rc)C(O), N(Rc)C(O)N(Rd), SO2N(Rc), o N(Rc)SO2, en donde Rc y Rd se seleccionan cada uno independientemente de hidrógeno o (1-2C)alquilo; y Rb es (1-4C)alquilo, arilo, aril-(1-4C)alquilo, (3-6C)cicloalquilo, (3-6C)cicloalquil-(1-4C)alquilo, heteroarilo, heteroaril-(1-4C)alquilo, heterociclilo, o heterociclil-(1-4C)alquilo; y en donde Rb es opcionalmente sustituido además por uno o más sustituyentes seleccionados independientemente de oxo, halógeno, ciano, nitro, hidroxi, NReRf25 , (1-5C)alquilo, (1-5C)alcoxi, (1-5C)alcanoilo, (1-5C)sulfonilo o arilo; y en donde Re y Rf son cada uno seleccionados independientemente de hidrógeno o (1-4C)alquilo o (3- 6C)cicloalquil-(1-4C)alquilo; o Re y Rf puede estar enlazados de tal manera que, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico, heteroarilo o carbocíclico de 4-7 miembros; R3 es H, (1-3C)alquilo, halógeno o CF3; R4 es ciano, (1-3C)alquilo, (1-3C)fluoroalquilo, (1-3C)alcoxi, (1-3C)perfluoroalcoxi, halo, (1-3C)alcanoilo, C(O)NRiRj, o S(O)2NRiRj; en donde Ri y Rj son cada uno seleccionados independientemente de H o (1-3C)alquilo; X es CH o CR5; W, Y y Z son cada uno seleccionados independientemente de N, CH, o CR5; R5 es Halógeno, trifluorometilo, trifluorometoxi, ciano, nitro, hidroxi, mercapto, amino, carboxi, carbamoilo, sulfamoilo, ureido, (1-6C)alquilo, (2-6C)alquenilo, (2-6C)alquinilo, o R5 es un grupo de la fórmula: -L1-L2-R7 en donde L1 está ausente o es un grupo enlazante de la fórmula -[CR8R9]n- en la que n es un entero seleccionado de 1, 2, 3 o 4, y R8 y R9 son cada uno seleccionados independientemente de hidrógeno o (1-2C)alquilo; L2 está ausente o se selecciona de O, S, SO, SO2, N(R10), C(O), C(O)O, OC(O), CH(OR10), C(O)N(R10), N(R10)C(O), N(R10)C(O)N(R11), S(O)2N(R10), o N(R13)SO2, en donde R10 y R11 son cada uno seleccionados independientemente de hidrógeno o (1-2C)alquilo; y R7 es (1-6C)alquilo, arilo, aril-(1-6C)alquilo, (3-6C)cicloalquilo, (3-6C)cicloalquil-(1-6C)alquilo, heteroarilo, heteroaril-(1-6C)alquilo, heterociclilo, heterociclil-(1-6C)alquilo, y en donde R7 es opcionalmente sustituido además por uno o más sustituyentes seleccionados independientemente de hidrógeno, oxo, halógeno, ciano, nitro, hidroxi, NR12R13, (1-4C)alcoxi, (1-5C)alquilo, (3-8C)cicloalquilo, (3- 8C)cicloalquil-(1-5C)alquilo, arilo, aril-(1-5C)alquilo, (1-5C)alcanoilo, (1-5C)alquilsulfonilo, heterociclilo, heterociclil-(1-5C)alquilo, heteroarilo, heteroaril-(1-5C)alquilo, CONR12R13 y SO2NR12R13; R12 y R13 son cada uno seleccionados independientemente de hidrógeno o (1-2C)alquilo; o R12 y R13 pueden estar enlazados de tal manera que, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico o heteroarilo de 4-7 miembros; o bien W y Z, W e Y o Z y X son ambos CR5 y los grupos R5 en los átomos de carbono adyacentes están enlazados de tal manera que, junto con los átomos de carbono a los que están unidos, forman un anillo fusionado heterocíclico, heteroarilo o carbocíclico de 4-7 miembros; o una sal o solvato farmacéuticamente aceptable del mismo.
Description
5
10
15
20
25
30
35
En un grupo particular de compuestos, R1 es como se definió en uno cualquiera de los párrafos (1) a (6) anteriores.
De manera adecuada, R1 es como se definió en cualquiera de los párrafos (5) o (6) anteriores. En un grupo particular de compuestos, R2 es como se definió en uno cualquiera de los párrafos (16) a (27) más arriba. De manera adecuada, R2 es como se definió en uno cualquiera de los párrafos (25), (26) o (27) anteriores.
De manera adecuada, R3 es hidrógeno o cloro, especialmente hidrógeno. En un grupo particular de compuestos de la invención, R4 es un grupo sustituyente como se definió aquí anteriormente, diferente de hidrógeno. En particular, R4 es un sustituyente diferente de hidrógeno seleccionado de
aquellos definidos en uno cualquiera de los párrafos (35), (36), (38), (39) o (40) anteriores. De manera adecuada, R4 es cloro o metoxi. De manera adecuada, X es CH. De manera adecuada, solamente uno de W, X, Y y Z es CR5. De manera adecuada, solamente uno de W, X, Y y Z es CR5 y los otros son CH. En un grupo particular de compuestos, W es CR5, y X, Y y Z son todos CH o uno de Y y Z es N y los otros son CH.
En un grupo adicional de compuestos,W es CR5, y X es CH y Y y Z son ambos CH o uno de Y y Z es N y el otro es
CH. En un grupo particular de compuestos, Z es CR5, y W, X y Y son todos CH o uno de W y Y es N y los otros son CH. En un grupo adicional de compuestos, Z es CR5, X es CH, W y Y son ambos CH o uno de W y Y es N y el otro es CH.
En un grupo particular de compuestos, W es CR5 y X, Y y Z son todos CH. En un grupo adicional de compuestos, Z es CR5 y W, X y Y son todos CH. De manera adecuada, R5 tiene una cualquiera de las definiciones establecidas aquí anteriormente. En un grupo
particular de compuestos, R5 tiene una cualquiera de las definiciones establecidas en los párrafos (55) a (71) anteriores. En un grupo particular de compuestos, R5 es como se definió en el párrafo (71) más arriba Un grupo particular de compuestos tiene la fórmula estructural VIII:
en donde: R1 tiene una cualquiera de las definiciones establecidas aquí, y en particular es como se definió en el párrafo (5) o
(6) más arriba;
R2 tiene una cualquiera de las definiciones establecidas aquí, y en particular es como se definió en uno cualquiera de los párrafos (25), (26) o (27) más arriba; R4 tiene una cualquiera de las definiciones establecidas aquí, y en particular es como se definió en los párrafos (35),
(36), (38), (39) o (40) más arriba (y especialmente es cloro o metoxi); uno de W, Y y Z es CR5 y los otros son seleccionados de CH o N; R5 tiene una cualquiera de las definiciones establecidas aquí, y en particular es como se definió en los párrafos (55)
a (71) más arriba, y es especialmente como se definió en el párrafo (71) más arriba;
5
10
15
20
25
30
35
40
45
6–(2–metoxi–4–(1–metil–1H–pirazol–4–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–
carboxilato de isopropilo; 6–((2–cloro–5–(1–metil–1H–pirazol–4–il)fenil)amino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de isopropilo;
N–(2–cloro–4–(1,2–dimetil–1H–imidazol–5–il)fenil)–1–(2–metoxietil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
c]piridin–6–amina; 6–(2–cloro–4–(1,4–dimetil–1H–imidazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de tert–butilo;
N–(2–cloro–4–(1,2–dimetil–1H–imidazol–5–il)fenil)–1–(ciclopropilmetil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–amina;
N–(2–cloro–4–(1–metil–1H–imidazol–5–il)fenil)–2–(oxazol–5–il)–1H–pirrolo[3,2–c]piridin–6–amina; 6–((2–cloro–4–(3,3–difluoroazetidin–1–carbonil)fenil)amino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 1–carboxilato de tert–butilo;
(3–cloro–4–((2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–il)amino)fenil)(3,3–difluoroazetidin–1–
il)metanona; propil–6–(2–cloro–4–(1,2–dimetil–1H–imidazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1–carboxilato;
etil–6–(2–cloro–4–(1,2–dimetil–1H–imidazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1 H–pirrolo[3,2– c]piridin–
1–carboxilato; metil–6–(2–cloro–4–(1,2–dimetil–1H–imidazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1–carboxilato;
6–(4–(1,2–dimetil–1H–imidazol–5–il)–2–metoxifenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–
carboxilato de isopropilo; 6–(2–cloro–4–(oxazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–carboxilato de tert– butilo;
6–(2–cloro–4–(tiazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–carboxilato de tert–
butilo; 6–(2–cloro–4–(5–metilisoxazol–4–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 1–carboxilato de tert–butilo;
6–((2–cloro–4–(pirazin–2–il)fenil)amino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–carboxilato de tert–
butilo; 6–(2–cloro–4–(1,2–dimetil–1H–imidazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1– carboxilato de ciclobutilo;
6–(2–cloro–4–(1,2–dimetil–1H–imidazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–
carboxilato de ciclopentilo; 6–(2–cloro–4–(1,2–dimetil–1H–imidazol–5–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1– carboxilato de isopropilo;
6–(2–cloro–4–(6–metilpiridin–3–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1 H–pirrolo[3,2–c]piridin– 1–carboxilato de tert–butilo; 6–(2–cloro–4–(1–metil–1H–imidazol–2–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 1–
- carboxilato de tert–butilo;
- 6–(2–cloro–4–(1,3–dimetil–1H–pirazol–4–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– carboxilato de tert–butilo;
- c]piridin–1–
- 6–(2–cloro–4–(1,5–dimetil–1H–pirazol–4–il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– carboxilato de tert–butilo;
- c]piridin–1–
- 24
Método C: Cromatografía de columna en sílica gel de Biotage eluyendo con DCM/EtOAc 90/10 seguido por filtración a través de una columna SCX–2. Método D: Cromatografía de columna en sílica gel de Biotage eluyendo con 1 a 10% MeOH/NH3 ac. 10/1 en DCM. Método E: Cromatografía de columna en sílica gel de Biotage eluyendo con DCM/EtOAc 80/20 a 60/40. 5 Método F: Cromatografía de columna en sílica gel de Biotage eluyendo con ciclohexano/EtOAc 50/50 a 0/100
seguido por filtración a través de una columna SCX–2. Método G: Filtración a través de una columna SCX–2 seguido por cromatografía de columna en sílica gel eluyendo con 10% (amoniaco 2 M en MeOH) en cloroformo.
10 Método I: Cromatografía de columna en sílica gel eluyendo con acetato de etilo/diclorometano (1:1), seguido por 1% y 2,5% de metanol en acetato de etilo/diclorometano (1:1).
Método H: Cromatografía de columna en sílica gel eluyendo con etanol entre 3–20% en EtOAc.
- Preparación
- Nombre/Estructura Datos
- 56
- 4–Amino–3–metoxi–N–(1–metilpiperidin–4–il)etanona 1H–RMN (500 MHz, CD3OD):δ 1.69 (qd, J = 12.5, 3.8Hz, 2H), 1.91–1.98 (m, 2H), 2.19 (td, J = 12.1, 2.2Hz, 2H), 2.32 (s, 3H), 2.89–2.96 (m, 2H), 3.84–3.92 (m, 1 H), 3.90 (s, 3H), 6.71 (d, J = 8.2Hz, 1 H), 7.31 (dd, J = 8.2, 1.9Hz, 1 H), 7.35 (d, J = 1.9Hz, 1H). LC (Método B)–MS (ESI, m/z) tR 0.44 min, 264 [M+H]+ Usando ácido 4–amino–3–metoxibenzoico, 1– metilpiperidin–4–amina y el método de purificación A.
- 57
- 4–Amino–N,N–dimetil–3–(trifluorometoxi)etanona 1H–RMN (500 MHz, CDCl3): δ 3.08 (s, 6H), 4.10 (br s, 2H), 6.80 (d, J = 8.2Hz, 1H), 7.25 (dd, J = 8.2, 1.8Hz, 1H), 7.30– 7.32 (m, 1H). LC (Método C)–MS (ESI, m/z) tR 2.16 min, 249 [M+H]+ Usando ácido 4–amino– 3– (trifluorometoxi)benzoico, dimetilamina y el método de purificación B.
- 58
- 3–Amino–4–metoxi–N,N–dimetibenzamida 1H–RMN (500 MHz, CD3OD): δ 3.06 (s, 6H), 3.89 (s, 3H), 6.77 (dd, J = 8.2, 2.1 Hz, 1H), 6.82 (d, J = 2.1 Hz, 1H), 6.88 (d, J = 8.2Hz, 1H). LC (Método C)–MS (ESI, m/z) tR 1.07 min, 195 [M+H]+ Usando ácido 3–amino–4–metoxibenzoico, dimetilamina y el método de purificación C.
- 59
- (4–Amino–3–metoxifenil)(tiomorfolino)metanona– S,S– dióxido 1H–RMN (500 MHz, DMSO d–6): δ 3.19– 3.24 (m, 4H), 3.84–3.89 (m, 4H), 3.87 (s, 3H), 5.19 (br s, 2H), 6.62 (d, J = 8.0Hz, 1H), 6.86 (dd, J = 8.0, 1.7Hz, 1H), 6.92 (d, J = 1.7Hz, 1H); LC (Método B)–MS (ESI, m/z) tR 1.19 min, 285 [M+H]+ Usando ácido 4–amino–3– metoxibenzoico, tiomorfolina 1,1–dióxido y el método de purificación D.
- 60
- (4–Amino–3–metoxifenil)(morfolino)metanona 1H–RMN (500 MHz, CD3OD): δ 3.63– 3.72 (m, 8H), 3.88 (s, 3H), 6.74 (d, J = 8.0Hz, 1H), 6.88 (dd, J = 8.0, 1.8Hz, 1H), 6.94 (d, J = 1.8Hz, 1H) LC (Método C)– MS (ESI, m/z) tR 1.27 min, 237 [M+H]+ Usando ácido 4–amino–3– metoxibenzoico, morfolina y el método de purificación E.
- 61
- 4–Amino–3–metoxi–N–(2–metoxietil)etanona 1H–RMN (500 MHz, CDCl3): δ 3.39 (s, 3H), 3.54–3.57 (m, 2H), 3.61–3.65 (m, 2H), 3.90 (s, 3H), 4.12 (br s, 2H), 6.45 (br s, 1H), 6.66 (d, J = 8.1 Hz, 1H), 7.16 (dd, J = 8.1, 1.8Hz, 1H), 7.37 (d, J = 1.8Hz, 1H). LC (Método C)–MS (ESI, m/z) tR 1.35 min, 225 [M+H]+ Usando ácido 4– amino–3–metoxibenzoico, 2– metoxietilamina y el método de purificación B.
- 62
- (4–Amino–3–metoxifenil)(3–metoxiazetidin–1– il)metanona 1H–RMN (500 MHz, CD3OD): δ 3.32 (s, 3H), 3.88 (s, 3H), 3.92–3.99 (m, 1H), 4.18–4.38 (m, 3H), 4.49–4.61 (m, 1H), 3.63–3.72 (m, 8H), 6.71 (d, J = 8.1 Hz, 1H), 7.09 (dd, J = 8.1, 1.8Hz, 1H), 7.16 (d, J = 1.8Hz, 1H). LC (Método C)–MS (ESI, m/z) tR 1.63 min, 237 [M+H]+ Usando ácido 4–amino–3– metoxibenzoico, clorhidrato de 3– metoxiazetidina y el método de purificación F.
- 63
- 4–Amino–3–metoxi–N–metiletanona 1H–RMN (500 MHz, CDCl3): δ 2.95 (d, J=4.9Hz, 3H), 3.85 (s, 3H), 4.1 (s, br, 2H), 6.38 (s, br, 1H), 6.61 (d, J=8.1 Hz, 1H), 7.14 (dd, J=1.9Hz, 8.1 Hz, 1H), 7.35 (d, J=1.9Hz, 1H). Usando ácido 4– amino–3–metoxibenzoico, metilamina y el método de purificación G.
- 64
- 4–Amino–3–cloro–N–metiletanona 1H–RMN (500 MHz, CDCl3): δ 2.93 (d, J=4.7Hz, 3H), 4.45 (s, br, 2H), 6.58 (s, br, 1H), 6.69 (d, J=8.4Hz, 1H), 7.49 (dd, J=2Hz, 8.4Hz, 1H), 7.72 (d, J=2Hz, 1H). Usando ácido 4–amino–3–clorobenzoico, metilamina y el método de purificación G.
- 65
- (4–Amino–3–clorofenil)(3–metoxiazetidin–1– il)metanona 1H–RMN (500 MHz, d6–acetona): δ 3.28 (s, 3H), 3.95 (s, br, 2H), 4.28 (s, br, 1 H), 4.5 (s, br, 2H), 5.4 (s, br, 2H), 6.86 (d, J=8.4Hz, 1H), 7.42 (dd, J=2Hz, 8.4Hz, 1H), 7.58 (d, J=2Hz, 1H). Usando ácido 4–amino–3–clorobenzoico, 3– metoxiazetidina y cromatografía de Método F.
- 66
- (4–Amino–3–clorofenil)(S,S–dioxo– tiomorfolino)metanona 1H–RMN (500 MHz, d6–DMSO): δ 3.21 (s, br,, 4H), 3.85 (s, br, 4H), 6.77 (d, J=8.3Hz, 1H), 7.18 (dd, J=1.9Hz, 8.3Hz, 1H), 7.37 (d, J=1.9Hz, 1H). Usando ácido 4–amino–3–clorobenzoico, S,S–dioxo– tiomorfolina y cromatografía de Método F.
- 67
- 4–Amino–3–cloro–N–etil–N–metiletanona 1H–RMN (500 MHz, CD3OD): δ 1.2 (t, J=6.8Hz, 3H), 3.03 (s, 3H), 3.47 (s, br, 2H), 6.83 (d, J=8.3Hz, 1H), 7.13 (d, J=8Hz, 1H), 7.32 (s, 1H). Usando ácido 4–amino–3–clorobenzoico, N– etilmetilamina y cromatografía de Método F.
- 68
- (4–Amino–3–clorofenil)(pirrolidin–1–il)metanona 1H–RMN (500 MHz, CD3OD): δ 1.95 (m, 4H), 3.55 (m, 4H), 4.85 (s, 2H), 6.82 (d, J=8.4Hz, 1H), 7.28 (dd, J=2Hz, 8.4Hz, 1H), 7.46 (d, J=2Hz, 1H). Usando ácido 4–amino–3–clorobenzoico, pirrolidina y cromatografía de Método F.
- 69
- (4–Amino–3–clorofenil)(4–metipiperazin–1– il)metanona 1H–RMN (500 MHz, DMSO–d6): δ 2.19 (s, 3H), 2.31 (s, br, 4H), 3.47 (s, br, 4H), 6.77 (d, J=8.4Hz, 1H), 7.1 (dd, J=2Hz, 8.3Hz, 1H), 7.24 (d, J=2Hz, 1H). Usando ácido 4–amino–3–clorobenzoico, 1– metipiperazine y el método de purificación H.
- 70
- (4–Amino–3–clorofenil)(4–metoxipiperidin–1– il)metanona 1H–RMN (500 MHz, DMSO–d6): δ 1.41 (m, 2H), 1.81 (m, 2H), 3.2(m, 5H), 3.41 (m, 1H), 3.6 (s, br, 2H), 6.76 (d, J=8.3Hz, 1H), 7.08 (dd, J=1.9Hz, 8.3Hz, 1H), 7.23 (d, J=1.9Hz, 1H). Usando ácido 4– amino–3–clorobenzoico, 4– metoxipiperidina y el método de purificación H.
- 71
- 1H–RMN (500 MHz, DMSO–d6): δ 1.31
- (4–Amino–3–clorofenil)(4–(dimetilamino)piperidin–1– il)metanona
- (dd, J=3.8Hz, 11.7Hz, 2H), 1.73 (d,J=10.7Hz, 2H), 2.19 (s, 6H), 2.4 (t, J=5.6Hz, 1H), 2.88 (s, br, 2H), 3.45 (s, br,
- imagen55
- 2H), 4.05 (s, br, 2H), 6.76 (d, J=8.3Hz, 1H), 7.08 (dd, J=1.9Hz, 8.3Hz, 1H), 7.23 (d, J=1.9Hz, 1H). Usando ácido 4– amino–3–clorobenzoico, N,N– dimetilpiperidin–4–amina y el método de purificación H.
- 72
- (4–amino–3–clorofenil)(3,3–difluoroazetidin–1– il)metanona 1H–RMN (500 MHz, DMSO–d6): δ 4.60 (br s, 4H), 6.07 (s, 2H), 6.79 (d, J = 8.4, 1H), 7.39 (dd, J = 2.1, 8.4 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H). Usando ácido 4– amino–3–clorobenzoico, clorhidrato de 3,3–difluoroazetidina y el método de purificación H.
- 73
- (4–Amino–3–clorofenil)(azetidin–1–il)metanona 1H–RMN (500 MHz, DMSO–d6): δ 2.23 (m, 2H), 3.98 (bs, 2H), 4.30 (br s, 2H), 5.90 (s, 2H), 6.75 (d, J = 8.5, 1H), 7.32 (dd, J = 2.0, 8.5 Hz, 1H), 7.46 (d, J = 1.9 Hz, 1H). Usando ácido 4–amino–3– clorobenzoico, clorhidrato de azetidina y el método de purificación I.
Preparación 74: 4–(Bromometil)–2–metoxi–1–nitrobenceno
Se agregaron tetrabromuro de carbono (0.543g, 1.638 mmol) y trifenilfosfina (0.430g, 1.638 mmol) a una solución de (3–metoxi–4–nitrofenil)metanol (0.2g, 1.092 mmol) en THF (5.46mL). La mezcla de reacción se agitó a temperatura
5 ambiente durante la noche antes de ser concentrada bajo presión reducida y purificada a través de cromatografía de columna en sílica gel de Biotage eluyendo con (ciclohexano/EtOAc 99/1 a 80/20) para producir el producto del título como un sólido amarillo (220mg, 82%). 1H–RMN (500 MHz, CDCl3): δ 4.00 (s, 3H), 4.48 (s, 2H), 7.06 (dd, J = 8.3, 1.7Hz, 1H), 7.12 (d, J = 1.7Hz, 1H), 7.84 (d, J = 8.3Hz, 1H) LC (Método B) tR 2.62 min.
Preparación 75: 4–(3–Metoxi–4–nitrobencil)tiomorfolin–1,1–dióxido
10 Se agregaron 1,1–dióxido de tiomorfolina (0.242g, 1.788 mmol) y trietilamina (0.19mL, 1.341 mmol) a juna solución de 4–(bromometil)–2–metoxi–1–nitrobenceno (Preparación 74, 0.22g, 0.894 mmol) en THF (2.2mL). La mezcla de reacción se agitó durante la noche a temperatura ambiente antes de ser concentrada bajo presión reducida y
Método G: TLC Preparativa (DCM/EtOAc 80/20).
Método H: Cromatografía de columna en sílica gel de Biotage usando una columna KP–NH Biotage eluyendo con ciclohexano/EtOAc 70/30 a 40/60.
Método I: La reacción se enfrió hasta temperatura ambiente y se diluyó con acetato de etilo. La solución orgánica se
5 lavó con agua, salmuera, se secó sobre sulfato de sodio y se filtró. El solvente se eliminó en vacío y el residuo se purificó por cromatografía de columna en sílica gel, eluyendo con un gradiente de 50–20% de hexano en acetato de etilo a 100% de acetato de etilo.
Método J: La reacción se enfrió hasta temperatura ambiente y se diluyó con acetato de etilo. La solución orgánica se lavó con agua, salmuera, se secó sobre sulfato de sodio y se filtró. El solvente se eliminó en vacío y el residuo se
10 purificó por cromatografía de columna en sílica gel, eluyendo con 20% acetato de etilo en diclorometano.
Método K: Cromatografía de columna en sílica gel eluyendo con 100% de acetato de etilo o 3–5% de MeOH en acetato de etilo.
Método L: Cromatografía de columna en sílica gel eluyendo con 5% trietilamina en acetato de etilo.
Método M: Cromatografía de columna en sílica gel eluyendo con 50% diclorometano en acetato de etilo.
15 Método N: Cromatografía de columna en sílica gel eluyendo con 15% MeOH en acetato de etilo.
Método O: TLC Preparativa (2% metanol en acetato de etilo/DCM) (v/v; 1;1).
Método P: TLC Preparativa (8% acetato de etilo/DCM).
Método Q: La reacción se enfrió hasta temperatura ambiente y se diluyó con acetato de etilo. La solución orgánica se lavó con agua, salmuera, se secó sobre sulfato de sodio y se filtró. El solvente se eliminó en vacío y el residuo se
20 purificó por TLC preparativa eluyendo con 4/1 DCM/EtOAc.
Método R: Después de calentar, el solvente se eliminó in vacuo y se sometió a partición entre EtOAc y agua. La capa orgánica se lavó con salmuera, se secó (Na2SO4) y se concentró in vacuo antes de la purificación usando una TLC preparativa eluyendo con 10/1 EtOAc/Amoniaco 2M en MeOH seguido por TLC preparativa eluyendo con 10:1 acetato de etilo: "A"; donde “A” es10:1 metanol: “880” amoniaco.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 2
- 6–(2–metoxipiridin–3–ilamino)–2–(1– metil–1H– pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1– carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3):δ 1.51 (s, 9H), 3.97 (s, 3H), 4.06 (s, 3H), 6.49 (d, J = 0.7Hz, 1H), 6.90 (dd, J = 7.8, 5.0Hz, 1H), 7.03 (s, 1H), 7.53 (s, 1H), 7.60 (s, 1H), 7.62 (s, 1H), 7.73 (dd, J = 5.0, 1.6Hz, 1H), 8.41 (dd, J = 7.8, 1.6Hz, 1H), 8.48 (d, J = 0.7Hz, 1H). LC (Método B)–MS (ESI, m/z) tR 2.51 min, 421 [M+H]+ Usando 2–metoxipiridin– 3–amina y el método de purificación A. Sin datos
- 3
- 6–(4–(dimetilcarbamoil)–2–(trifluorometoxi) 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 0.006
- fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–
- 3.10 (s, 6H), 3.97 (s, 3H), 6.52 (d, J =
- pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo
- 0.7Hz, 1H), 6.91 (s, 1H), 7.38 (dd, J = 8.5, 1.9Hz, 1H), 7.42–7.44 (m, 1H), 7.55 (s, 1H), 7.60 (s, 1H), 7.71 (s, 1H), 8.22 (d, J = 8.5Hz, 1H), 8.52 (d, J = 0.7Hz, 1H); ESI– HRMS Encontrado 545.2115, calculado para C26H27F3N6O4 [M+H]+: 545.2119. Usando 4–amino–N,N–dimetil–3– (trifluorometoxi)etanona (Preparación 57) y el método de purificación A.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 4
- 6–(5–(dimetilcarbamoil)–2– metoxifenilamino)–2– 1H–RMN (500 MHz, CDCl3): δ 1.48 (s, 9H), Sin datos
- (1–metil–1H–pirazol– 4–il)–1H–pirrolo[3,2–
- 3.10 (s, 6H), 3.94 (s, 3H), 3.96 (s, 3H), 6.48
- c]piridin–1–carboxilato de tert–butilo
- (d, J = 0.7Hz, 1H), 6.91 (d, J = 8.3Hz, 1H), 7.07 (dd, J = 8.3, 2.0Hz, 1H), 7.18 (br s, 1H), 7.53 (s, 1H), 7.58 (s, 1H), 7.64 (s, 1H), 8.17 (d, J = 2.0Hz, 1H), 8.45 (s, 1H). LC (Método B)–MS (ESI, m/z) tR 2.30 min, 491 [M+H]+ Usando 3–amino–4–metoxi–N,N– dimetibenzamida (Preparación 58) y el método de purificación A.
- 5
- 6–(2–metoxi–4–(tiomorfolin–4– carbonil) fenilamino)–2–(1–metil–1H–pirazol– 4–il)–1H– pirrolo[3,2–c]piridin–1– carboxilatoS,S–dióxido de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 3.05–3.13 (m, 4H), 3.95 (s, 6H), 4.14–4.19 (m, 4H), 6.50 (d, J= 0.7Hz, 1H), 7.04 (dd, J = 8.2, 1.8Hz, 1H), 7.07 (d, J = 1.8Hz, 1H), 7.31 (s, 1H), 7.53 (s, 1H), 7.59 (s, 1H), 7.69 (m, 1H), 8.28 (d, J = 8.2Hz, 1H), 8.51 (d, J = 0.7Hz, 1H). LC (Método D)–MS (ESI, m/z) tR 1.52 min, 581 [M+H]+ Usando (4– amino–3– metoxifenil)(tiomorfolino)metanona–S,S– dióxido (Preparación 59) y el método de purificación A. Sin datos
- 6
- 6–(2–metoxi–4–(tiomorfolinometil)fenilamino)–2– 1H–RMN (500 MHz, CDCl3): δ 1.50 (s, 9H), Sin datos
- (1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 2.99–3.03 (m, 4H), 3.06–3.10 (m, 4H), 3.61
- c]piridin–1–carboxilato–S,S–dióxido de tert–butilo
- (s, 2H), 3.92 (s, 3H), 3.97 (s, 3H), 6.48 (d, J = 0.7Hz, 1H), 6.86–6.89 (m, 2H), 7.06 (s, 1H), 7.53 (s, 1H), 7.59 (s, 1H), 7.65 (m, 1H), 7.98 (d, J = 8.5Hz, 1H), 8.46 (d, J = 0.8Hz, 1H). LC (Método D)–MS (ESI, m/z) tR 1.46 min, 567 [M+H]+ Usando 2–metoxi– 4–(tiomorfolinometil)anilina–S,S–dióxido (Preparación 76) y el método de purificación A.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 7
- 6–(2–cloro–4–(dimetilcarbamoil)fenilamino)–2–(1– metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin– 1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 3.10 (s, 6H), 3.98 (s, 3H), 6.53 (s, 1H), 7.08 (s, 1H), 7.34 (dd, J = 8.5, 1.9Hz, 1H), 7.55 (d, J = 1.9Hz, 1H), 7.56 (s, 1H), 7.61 (s, 1H), 7.72 (s, 1H), 8.15 (d, J = 8.5Hz, 1H), 8.53 (s, 1H). ESI–HRMS (Método D) Encontrado 495.1900, calculado para C25H28ClN6O3 [M+H]+: 495.1906. Usando 4–amino–3–cloro–N,N–dimetibenzamida y el método de purificación B. 0.006
- 8
- 6–(2–cloro–4–(N,N– dimetilsulfamoil)fenilamino)– 2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1– carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 2.74 (s, 6H), 3.99 (s, 3H), 6.56 (d, J = 0.6Hz, 1H), 7.28 (s, 1H), 7.57 (s, 1H), 7.62 (s, 1H), 7.63 (dd, J = 8.8, 2.1Hz, 1H), 7.78 (s, 1H), 7.82 (d, J = 2.1Hz, 1H), 8.40 (d, J = 8.8Hz, 1H), 8.57 (s, 1H). ESI–HRMS Encontrado 531.1570, calculado para C24H28ClN6O4S [M+H]+: 531.1576. Usando 4–amino–3–cloro–N,N– dimetibencenosulfonamida (Preparación 77) y el método de purificación A. 0.096
- 9
- 6–(2–acetilfenilamino)–2–(1–metil– 1H–pirazol–4– il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de tert– butilo 1H–RMN (500 MHz, CDCl3): δ 1.59 (s, 9H), 2.70 (s, 3H), 3.99 (s, 3H), 6.54 (d, J = 0.9Hz, 1H), 6.88 (ddd, J = 8.1, 7.0, 1.1Hz, 1H), 7.49 (ddd, J = 8.6, 7.0, 1.6Hz, 1H), 7.58 (s, 1H), 7.64 (s, 1H), 7.68 (t, J = 0.9Hz, 1H), 7.89 (dd, J = 8.1, 1.6Hz, 1H), 8.52–8.54 (m, 1H), 8.55 (d, J = 0.9Hz, 1H), 11.46 (s, 1H). ESI–HRMS Encontrado 432.2025, calculado para C24H26N5O3 [M+H]+: 432.2030. Usando 2– aminoacetofenona y el método de purificación A. 0.077
- 10
- 6–(2–metoxi–4–(morfolina–4– carbonil)fenilamino)–2–(1–metil–1H–pirazol– 4–il)– 1H–pirrolo[3,2–c]piridin–1–carboxilato de tert– butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 3.66–3.76 (m, 8H), 3.96 (s, 3H), 3.97 (s, 3H), 6.50 (s, 1H), 7.02 (dd, J = 8.2, 1.7Hz, 1H), 7.07 (d, J = 1.7Hz, 1H), 7.26 (s, 1H), 7.54 (s, 1H), 7.60 (s, 1H), 7.69 (s, 1H), 8.17 J = 8.50 (d, J = 8.2Hz, 1H), 8.50 (s, 1H). ESI–HRMS Encontrado 533.2508, calculado para C28H33N6O5 [M+H]+: 533.2507. Usando (4–amino–3– metoxifenil)(morfolino)metanona (Preparación 60) y el método de purificación A. 0.005
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 11
- 6–(2–metoxi–4–(2– metoxietilcarbamoil) fenilamino)–2–(1– metil–1H–pirazol–4–il)–1H– pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 3.41 (s, 3H), 3.57–3.60 (m, 2H), 3.65–3.69 (m, 2H), 3.97 (s, 3H), 3.98 (s, 3H), 6.50 (s, 1H), 6.58 (t, J = 5.3Hz, 1H), 7.30–7.34 (m, 2H), 7.48 (d, J = 1.8Hz, 1H), 7.54 (s, 1H), 7.60 (s, 1H), 7.72 (s, 1H), 8.15 (d, J = 8.4Hz, 1H), 8.50 (s, 1H). ESI– HRMS Encontrado 521.2505, calculado para C27H33N6O5 [M+H]+: 521.2507. Usando 4– amino–3–metoxi–N–(2–metoxietil)etanona (Preparación 61) y el método de purificación A. 0.009
- 12
- 6–(2–metoxi–4–(3–metoxiazetidin–1– carbonil) fenilamino)–2–(1–metil–1H–pirazol– 4–il)–1H– pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 3.34 (s, 3H), 3.97 (s, 6H), 4.04–4.13 (m, 1H), 4.20–4.29 (m, 2H), 4.36–4.52 (m, 2H), 6.50 (d, J = 0.6Hz, 1H), 7.20 (dd, J = 8.4, 1.8Hz, 1H), 7.32 (s, 1H), 7.34 (d, J = 1.8Hz, 1H), 7.54 (s, 1H), 7.60 (s, 1H), 7.70 (s, 1H), 8.16 (d, J = 8.4Hz, 1H), 8.51 (s, 1H). ESI– HRMS (Método D) Encontrado 533.2509, calculado para C28H33N6O5 (M+H+): 533.2507. Usando (4–amino–3– metoxifenil)(3–metoxiazetidin–1– il)metanona (Preparación 62) y el método de purificación A. 0.007
- 13
- 6–(2,6–dicloro–4–(dimetilcarbamoil)fenilamino)–2– 1H–RMN (500 MHz, CDCl3): δ 1.44 (s, 9H), 0.020
- (1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 3.08 (br s, 3H), 3.11 (br s, 3H), 3.95 (s, 3H),
- c]piridin–1–carboxilato de tert–butilo
- 6.51 (d, J = 0.9Hz, 1H), 6.75 (s, 1H), 7.03 (t, J = 0.9Hz, 1H), 7.50 (s, 2H), 7.55 (d, J = 0.8Hz, 1H), 7.59 (d, J = 0.8Hz, 1H), 8.44 (d, J = 0.9Hz, 1H). ESI–HRMS (Método D) Encontrado 529.1530, calculado para C25H27Cl2N6O3 [M+H]+: 529.1516. Usando 4–amino–3,5–dicloro–N,N– dimetibenzamida (Preparación 82) y el método de purificación D.
- 14
- 6–(2–clorofenilamino)–2–(1–metil– 1H–pirazol–4– il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de tert– butilo 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 3.97 (s, 3H), 6.51 (d, J = 1.0Hz, 1H), 6.89– 6.95 (m, 2H), 7.34 (ddd, J = 8.2, 7.4, 1.5Hz, 1H), 7.41 (dd, J = 8.0, 1.5Hz, 1H), 7.55 (s, 1H), 7.61 (s, 1H), 7.65 (t, J = 1.0Hz, 1H), 7.97 (dd, J = 8.2, 1.5Hz, 1H), 8.49 (d, J = 1.0Hz, 1H). ESI–HRMS (Método B) Encontrado 424.1529, calculado para C22H23ClN5O2 [M+H]+: 421.1535. Usando 2–cloroanilina y el método de purificación A. 0.079
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 15
- 6–(2–cloro–4–(1–metil–1H–pirazol–4– il) fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H– pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 3.97 (s, 3H), 3.98 (s, 3H), 6.52 (s, 1H), 6.90 (s, 1H), 7.36 (dd, J = 8.5, 2.0Hz, 1H), 7.54 (d, J = 2.0Hz, 1H), 7.56 (s, 1H), 7.59 (s, 1H), 7.62 (s, 1H), 7.65 (s, 1H), 7.74 (s, 1H), 7.98 (d, J = 8.5Hz, 1H), 8.50 (s, 1H). ESI– HRMS (Método B) Encontrado 504.1897, calculado para C26H27ClN7O2 [M+H]+: 504.1909. Usando 2–cloro–4–(1–metil–1H– pirazol–4–il)anilina (Preparación 83) y el método de purificación A. 0.018
- 16
- 6–(2–cloro–4–(1–metil–1H–pirazol–3– il) fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H– pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 3.96 (s, 3H), 3.97 (s, 3H), 6.49 (d, J = 2.2Hz, 1H), 6.51 (d, J = 1.0Hz, 1H), 6.96 (s, 1H), 7.38 (d, J = 2.2Hz, 1H), 7.55 (s, 1H), 7.61 (s, 1H), 7.66 (dd, J = 8.5, 2.0Hz, 1H), 7.69 (t, J = 1.0Hz, 1H), 7.88 (d, J = 2.0Hz, 1H), 7.99 (d, J = 8.5Hz, 1H), 8.50 (d, J = 1.0Hz, 1H). ESI–HRMS (Método B) Encontrado 504.1898, calculado para C26H27ClN7O2 [M+H]+: 504.1909. Usando 2–cloro–4–(1–metil–1H–pirazol–3–il)anilina (Preparación 85) y el método de purificación A. 0.019
- 17
- 6–(2–cloro–4–(1–metil–1H–imidazol–5– il) fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H– pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 3.69 (s, 3H), 3.98 (s, 3H), 6.53 (d, J = 0.9Hz, 1H), 7.04 (s, 1H), 7.09 (br s, 1H), 7.27 (dd, J = 8.5, 2.0Hz, 1H), 7.45 (d, J = 2.0Hz, 1H), 7.53 (br s, 1H), 7.56 (s, 1H), 7.61 (s, 1H), 7.72 (t, J = 0.9Hz, 1H), 8.18 (d, J = 8.5Hz, 1H), 8.52 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 504.1885, calculado para C26H27ClN7O2 [M+H]+: 504.1909. Usando 2–cloro–4–(1– metil–1H–imidazol–5–il)anilina (Preparación 86) y el método de purificación A. 0.004
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 18
- 6–(2–cloro–4–(4–metil–4H–1,2,4–triazol–3– 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 0.001
- il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–
- 3.79 (s, 3H), 3.97 (s, 3H), 6.53 (d, J =
- pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo
- 0.8Hz, 1H), 7.20 (s, 1H), 7.55 (dd, J = 8.6, 2.1Hz, 1H), 7.56 (s, 1H), 7.60 (s, 1H), 7.75 (t, J = 0.9Hz, 1H), 7.77 (d, J = 2.1Hz, 1H), 8.19 (s, 1H), 8.29 (d, J = 8.6Hz, 1H), 8.53 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 505.1855, calculado para C25H26ClN8O2 [M+H]+: 505.1862. Usando 2–cloro–4–(4–metil–4H–1,2,4–triazol–3– il)anilina (Preparación 87) y el método de purificación C.
- 19
- 6–(2–cloro–4–(piridin–3– il)fenilamino)–2–(1– 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 0.007
- metil–1H–pirazol–4–il)– 1H–pirrolo[3,2–c]piridin–
- 3.97 (s, 3H), 6.52 (d, J = 0.9Hz, 1H), 7.06
- 1–carboxilato de tert–butilo
- (s, 1H), 7.37 (ddd, J = 7.9, 4.8, 0.9Hz, 1H), 7.48 (dd, J = 8.5, 2.2Hz, 1H), 7.55 (d, J = 0.8Hz, 1H), 7.61 (d, J = 0.8Hz, 1H), 7.65 (d, J = 2.2Hz, 1H), 7.72 (t, J = 0.9Hz, 1H), 7.85 (ddd, J = 7.9, 2.4, 1.6Hz, 1H), 8.18 (d, J = 8.5Hz, 1H), 8.52 (d, J = 0.9Hz, 1H), 8.58 (dd, J = 4.8, 1.6Hz, 1H), 8.83 (dd, J = 2.4, 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 501.1790, calculado para C27H26ClN6O2 [M+H]+: 501.1800. Usando 2–cloro–4–(piridin–3–il)anilina (Preparación 88) y el método de purificación D.
- 20
- 6–(2–cloro–4–(1,5–dimetil–1H–pirazol– 4– 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 0.007
- il)fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H–
- 2.40 (s, 3H), 3.86 (s, 3H), 3.97 (s, 3H), 6.51
- pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo
- (d, J = 0.9Hz, 1H), 6.94 (s, 1H), 7.23 (dd, J = 8.4, 2.0Hz, 1H), 7.41 (d, J = 2.0Hz, 1H), 7.53 (s, 1H), 7.55 (d, J = 0.8Hz, 1H), 7.61 (d, J = 0.8Hz, 1H), 7.64 (t, J = 0.9Hz, 1H), 8.00 (d, J = 8.4Hz, 1H), 8.49 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 518.2059, calculado para C27H29ClN7O2 [M+H]+: 518.2066. Usando 2–cloro–4– (1,5–dimetil–1H–pirazol–4–il)anilina (Preparación 89) y el método de purificación D.
- 21
- 6–(2–cloro–4–(1,3–dimetil–1H–pirazol– 4– 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 0.007
- il)fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H–
- 2.40 (s, 3H), 3.89 (s, 3H), 3.97 (s, 3H), 6.51
- pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo
- (d, J = 0.9Hz, 1H), 6.93 (s, 1H), 7.26 (dd, J = 8.4, 2.0Hz, 1H), 7.41 (s, 1H), 7.43 (d, J = 2.0Hz, 1H), 7.55 (d, J = 0.8Hz, 1H), 7.61 (d, J = 0.8Hz, 1H), 7.64 (t, J = 0.9Hz, 1H), 7.99 (d, J = 8.4Hz, 1H), 8.49 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 518.2068, calculado para C27H29ClN7O2 [M+H]+: 518.2066. Usando 2–cloro–4– (1,3–dimetil–1H–pirazol–4–il)anilina (Preparación 90) y el método de purificación D.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 22
- 6–(2–cloro–4–(1–metil–1H–imidazol–2– 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 0.003
- il)fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H–
- 3.77 (s, 3H), 3.97 (s, 3H), 6.52 (d, J =
- pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo
- 0.8Hz, 1H), 6.96 (d, J = 1.3Hz, 1H), 7.08 (s, 1H), 7.11 (d, J = 1.3Hz, 1H), 7.50 (dd, J= 8.5, 2.1Hz, 1H), 7.55 (d, J = 0.8Hz, 1H), 7.61 (d, J = 0.8Hz, 1H), 7.72–7.74 (m, 2H), 8.18 (d, J = 8.5Hz, 1H), 8.52 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 504.1900, calculado para C26H27ClN7O2 [M+H]+: 504.1909. Usando 2–cloro–4–(1– metil–1H–imidazol–2–il)anilina (Preparación 91) y el método de ifi ió E.
- 23
- 6–(2–cloro–4–(5–metilisoxazol–4– il)fenilamino)– 2–(1–metil–1H–pirazol–4–il)– 1H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 2.60 (d, J = 0.7Hz, 3H), 3.99 (s, 3H), 6.53 (d, J = 0.9Hz, 1H), 7.03 (s, 1H), 7.26 (dd, J = 8.5, 2.0Hz, 1H), 7.43 (d, J = 2.0Hz, 1H), 7.56 (d, J = 0.8Hz, 1H), 7.62 (d, J = 0.8Hz, 1H), 7.71 (t, J = 0.9Hz, 1H), 8.17 (d, J = 8.5Hz, 1H), 8.35 (d, J = 0.7Hz, 1H), 8.52 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 505.1742, calculado para C26H26ClN6O3 [M+H]+: 505.1749. Usando 2–cloro–4–(5–metilisoxazol–4–il)anilina (Preparación 92) y el método de purificación F. 0.011
- 24
- 6–(2–cloro–4–(tiazol–5– il)fenilamino)–2–(1–metil– 1H–pirazol–4–il)– 1H–pirrolo[3,2–c]piridin–1– carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 3.99 (s, 3H), 6.53 (d, J = 0.9Hz, 1H), 7.07 (s, 1H), 7.46 (dd, J = 8.6, 2.1Hz, 1H), 7.56 (s, 1H), 7.62 (s, 1H), 7.64 (d, J = 2.1Hz, 1H), 7.72 (t, J = 0.9Hz, 1H), 8.03 (d, J = 0.7Hz, 1H), 8.16 (d, J = 8.6Hz, 1H), 8.53 (d, J = 0.9Hz, 1H), 8.74 (d, J = 0.7Hz, 1H). ESI–HRMS (Método B) Encontrado 507.1350, calculado para C25H24ClN6O2S [M+H]+: 507.1364. Usando 2–cloro–4– (tiazol–5–il)anilina (Preparación 93) y el método de purificación G. 0.009
- 25
- 6–(2–cloro–4–(oxazol–5– il)fenilamino)–2–(1– 1H–RMN (500 MHz, CDCl3): δ 1.53 (s, 9H), 0.008
- metil–1H–pirazol–4–il)– 1H–pirrolo[3,2–c]piridin–
- 3.99 (s, 3H), 6.54 (d, J = 0.8Hz, 1H), 7.08
- 1–carboxilato de tert–butilo
- (s, 1H), 7.29 (s, 1H), 7.54 (dd, J = 8.6, 2.1Hz, 1H), 7.57 (s, 1H), 7.62 (s, 1H), 7.72– 7.74 (m, 2H), 7.91 (s, 1H), 8.19 (d, J = 8.6Hz, 1H), 8.54 (d, J = 0.9Hz, 1H). ESI– HRMS (Método B) Encontrado 491.1583, calculado para C25H24ClN6O3 [M+H]+: 491.1593. Usando 2–cloro–4–(oxazol–5– il)anilina (Preparación 94) y el método de purificación H.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 26
- tert–Butil–6–(2–cloro–4–(1 H–1,2,4–triazol–1– 1H–RMN (500 MHz, d6–DMSO): δ 1.52 (s, Sin datos
- il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–
- 9H)), 3.9 (s, 3H), 6.65 (s, 1H), 6.82 (s, 1H),
- pirrolo[3,2–c]piridin–1–carboxilato
- 7.4 (s, 1H), 7.62 (s, 1H), 7.65 (s, 1H), 7.7 (s, 1H), 7.93 (s, 1H), 8.22 (s, 1H), 8.55 (s, 1H), 9.17 (s, 1H), 9.23 (s, 1H). Usando 2– cloro–4–(1H–1,2,4–triazol–1–il)anilina (Preparación 96) in dioxano y el método de purificación I.
- 27
- tert–Butil–6–(2–cloro–4–fluorofenilamino)–2–(1– metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin– 1–carboxilato 1H–RMN (500 MHz, CDCl3): δ 1.56 (s, 9H)), 3.96 (s, 3H), 6.49 (s, 1H), 6.71 (s, 1H), 7 (m, 1H), 7.2 (m, 1H), 7.55 (s, 1H), 7.59 (s, 1H), 7.95 (m, 1H), 8.18 (s, 1H), 8.46 (s, 1H). Usando 2–cloro–4–fluoroanilina en dioxano y el método de purificación I. Sin datos
- 28
- tert–Butil–6–(2–cloro–4–(metisulfonil)fenilamino)– 1H–RMN (500 MHz, CDCl3): δ 1.57 (s, 9H)), Sin datos
- 2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–
- 3.06 (s, 3H), 3.98 (s, 3H), 6.55 (s, 1H), 7.31
- c]piridin–1– carboxilato
- (s, 1H), 7.56 (s, 1H), 7.61 (s, 1H), 7.78 (m, 2H), 7.96 (s, 1H), 8.4 (d, J=8.8, 1H), 8.57 (s, 1H). Usando 2–cloro–4– (metisulfonil)anilina in dioxano y el método de purificación J.
- 29
- tert–Butil–6–(2–cloro–4– (difluorometoxi)fenilamino)–2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato 1H–RMN (500 MHz, CDCl3): δ 1.57 (s, 9H)), 3.98 (s, 3H), 6.3 (t, J=80Hz, 1H), 6.51 (s, 1H), 6.82 (s, 1H), 7.08 (m, 1H), 7.55 (s, 1H), 7.6 (d, J=3.4Hz, 2H), 8.03 (d, J=9, 1H), 8.48 (s, 1H), 8.57 (s, 1H). Usando 2–cloro– 4–(difluorometoxi)anilina (Preparación 97) y el método de purificación J. Sin datos
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 30
- tert–Butil–6–(2–metoxi–4– (metilcarbamoil)fenilamino)–2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 3.02 (d, J=4.8Hz, 3H), 3.96 (s, 3H), 4.02 (s, 3H), 6.2(s, br, 1H), 6.49 (s, 1H), 7.27 (m, 2H), 7.47 (s, 1H), 7.53 (s, 1H), 7.59 (s, 1H), 7.7 (s, 1H), 8.14 (d, J=8.4Hz, 1H), 8.49 (s, 1H). Usando 4–amino–3–metoxi–N– metiletanona (Preparación 63) y el método de purificación K. Sin datos
- 31
- tert–Butil–6–(2–cloro–4– (metilcarbamoil)fenilamino)–2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato 1H–RMN (500 MHz, CDCl3): δ 1.48 (s, 9H), 2.97 (d, J=4.8Hz, 3H), 3.94 (s, 3H), 6.2(s, br, 1H), 6.5 (s, 1H), 6.65 (q, J=4.6Hz, 1H), 7.13 (s, 1H), 7.53 (s, 1H), 7.57 (s, 1H), 7.64 (dd, J= 2Hz, 8.7Hz, 1H), 7.72 (s, 1H), 7.88 (d, J=2.1Hz, 1H), 8.1 (d, J=8.7Hz, 1H), 8.49 (s, 1H). Usando 4–amino–3–cloro–N– metiletanona (Preparación 64) y el método de purificación K. Sin datos
- 32
- tert–Butil–6–(2–cloro–4–(2–oxopirrolidin–1– 1H–RMN (500 MHz, CDCl3): δ 1.5 (s, 9H), Sin
- il)fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H–
- 2.17 (m, 2H), 2.62 (t, J= 8.3Hz, 2H), 3.85 (t, datos.
- pirrolo[3,2–c]piridin–1–carboxilato
- J= 7.1Hz, 2H), 3.96 (s, 3H), 6.5 (s, 1H), 6.85 (s, 1H), 7.54 (s, 1H), 7.6 (s, 1H), 7.62 (d, J=6Hz, 2H), 7.76 (s, 1H), 7.97 (s, 1H), 8.47 (s, 1H). Usando 1–(4–amino–3– clorofenil)pirrolidin–2–ona (Preparación 103) y el método de purificación K.
- 33
- 6–(2–metoxi–4–(pirrolidin–1– ilmetil)fenilamino)– 2–(1–metil–1H–pirazol– 4–il)–1H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 1.8 (t, J=6.6Hz, 4H), 2.52 (t, J=6.6Hz, 4H), 3.59 (s, 2H), 3.91 (s, 3H), 3.95 (s, 3H), 6.47(s, 1H), 6.9 (d, J=8Hz, 1H), 6.94 (s, 1H), 6.98(s, 1H), 7.53 (s, 1H), 7.59 (s, 1H), 7.63 (s, 1H), 7.81 (d, J = 8 Hz, 1H), 8.4 (s, 1H). ESI–HRMS Encontrado 503.277 calculado para C28H34N6O3 [M+H]+: 503.2765 Usando 1–(4–amino–3–clorofenil)pirrolidin– 2–ona (Preparación 106) y el método de purificación L. 0.016
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 34
- 6–(4–((tert–butoxicarbonil(metil)amino)metil)–2– metoxifenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H–pirrolo[3,2–c]piridin–1–carboxilato de tert– butilo 1H–RMN (500 MHz, CDCl3): δ 1.5 (s, 9H), 1.51 (s, 9H), 2.94 (s, br, 3H), 3.89 (s, 3H), 3.95 (s, 3H), 4.38 (s, 2H), 6.47 (s, 1H), 6.85 (s, br,, 2H), 7 (s, 1H), 7.53 (s, 1H), 7.59 (s, 1H), 7.62 (s, 1H), 7.92 (s, br, 1H), 8.44 (s, 1H). ESI–HRMS Encontrado 563.298, calculado para C30H38N6O5 [M+H]+: 563.2976 Usando tert–butil–4–amino–3– metoxibencil(metil)carbamato (Preparación 108) y el método de purificación M. 0.111
- 35
- 6–(4–((dimetilamino)metil)–2–metoxifenilamino)– 1H–RMN (500 MHz, CDCl3): δ 1.5 (s, 9H), 0.008
- 2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 2.26 (s, 6H), 3.4 (s, 2H), 3.92 (s, 3H), 3.95
- c]piridin–1–carboxilato de tert–butilo
- (s, 3H), 6.47 (s, 1H), 6.85 (d, J=8Hz, 1H), 6.92 (s, 1H), 7 (s, 1H), 7.53 (s, 1H), 7.59 (s, 1H), 7.64 (s, 1H), 7.84 (d, J=8Hz, 1H), 8.44 (s, 1H). ESI–HRMS Encontrado 477.2617, calculado para C26H32N6O3 [M+H]+: 477.2609 Usando 4–((dimetilamino) metil)–2– metoxianilina (Preparación 110) y el método de purificación L.
- 36
- 6–(3–(cianometoxi)fenilamino)– 2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1– carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.49 (s, 9H), 3.95 (s, 3H), 4.77 (s, 2H), 6.48 (s, 1H), 6.62 (d, J=8.1Hz, 1H), 7.05 (d, J=8.1Hz, 1H), 7.12 (s, 1H), 7.25 (s, 1H), 7.55 (s, br 2H), 7.6 (s, 1H), 7.67 (s, 1H), 8.4 (s, 1H). ESI– HRMS Encontrado 445.2132, calculado para C24H24N6O3 [M+H]+: 445.2103 Usando 2–(3–aminofenoxi)acetonitrilo (Preparación 113) y el método de purificación H. 0.156
- 37
- 6–(2–cloro–4–(3–metoxiazetidin–1– carbonil)fenilamino)–2–(1–metil–1H–pirazol– 4–il)– 1H–pirrolo[3,2–c]piridin–1–carboxilato de tert– butilo 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 3.32 (s, 3H), 3.96 (s, 3H), 4.05 (m, 1H), 4.25 (m, 1H), 4.36 (m, 2H), 6.52 (s, 1H), 7.17 (s, 1H), 7.52 (d, J = 8.6 Hz, 1H), 7.55 (s, 1H), 7.60 (s, 1H), 7.74 (m, 2H), 8.15 (d, J = 8.6 Hz, 1H), 8.52 (s, 1H). ESI–HRMS Encontrado 537.4879, ESI–HRMS Encontrado 537.4879, calculado para C27H29ClN6O4 [M+H]+: 537.4872 Usando (4–amino–3–clorofenil)(3–metoxiazetidin– 1–il)metanona (Preparación 65) y el método de purificación K. 0.008
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 38
- 6–(2–cloro–4–(S,S–dioxo–tiomorfolin–4– carbonil)fenilamino)–2–(1– metil–1H–pirazol–4–il)– 1 H–pirrolo[3,2– c]piridin–1–carboxilato de tert– butilo 1H–RMN (500 MHz, CDCl3): δ 1.50 (s, 9H), 3.09 (s, br, 4H), 3.97 (s, 3H), 4.14 (s, br, 4H), 6.53 (s, 1H), 7.17 (s, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.55 (m, 2H), 7.6 (s, 1H), 7.74 (s, 1H), 8.27 (d, J = 8.6 Hz, 1H), 8.53 (s, 1H). ESI–HRMS Encontrado 585.2117, calculado para C27H29ClN6O5S [M+H]+: 585.2112 Usando (4–amino–3– clorofenil)(S,S–dioxo– tiomorfolino)metanona (Preparación 66) y el método de purificación K. 0.006
- 39
- 6–(2–cloro–4–(etil(metil)carbamoil)penilamino)–2– 1H–RMN (500 MHz, CDCl3): δ 1.25 (s, br, 0.004
- (1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 3H), 1.51 (s, 9H), 3.04 (s, 3H), 3.45 (s, br,
- c]piridin–1–carboxilato de tert–butilo
- 2H), 3.96 (s, 3H), 6.51 (s, 1H), 7.07 (s, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.55 (s, 1H), 7.6 (s, 1H), 7.7 (s, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.51 (s, 1H). ESI–HRMS Encontrado 509.2298 calculado para C26H29ClN6O3 [M+H]+: 509.2291 Usando 4–amino–3–cloro–N–etil–N– metiletanona (Preparación 67) y el método de purificación K.
- 40
- 6–(2–cloro–4–(pirrolidin–1– carbonil)fenilamino)– 2–(1–metil–1H–pirazol– 4–il)–1 H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.5 (s, 9H), 1.95 (m, 4H), 3.6 (m, 4H), 3.96 (s, 3H), 6.51 (s, 1H), 7.11 (s, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.54 (s, 1H), 7.59 (s, 1H), 7.64 (s, 1H), 7.71 (s, 1H), 8.11 (d, J=8.6 Hz, 1H), 8.5 (s, 1H). ESI–HRMS Encontrado 521.4943 calculado para C27H29ClN6O3 [M+H]+: 521.4939 Usando (4–amino–3–clorofenil)(pirrolidin– 1–il)metanona (Preparación 68) y el método de purificación K. 0.004
- 41
- 6–(2–cloro–4–(4–metipiperazin–1– carbonil)fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H–pirrolo[3,2–c]piridin–1–carboxilato de tert– butilo 1H–RMN (500 MHz, CDCl3): δ 1.5 (s, 9H), 2.31 (s, 3H), 2.42 (s, br, 4H), 3.65 (s, br,, 4H), 3.96 (s, 3H), 6.51 (s, 1H), 7.29 (m, 2H), 7.51 (s, 1H), 7.54 (s, 1H), 7.59 (s, 1H), 7.7 (s, 1H), 8.14 (d, J=8.5 Hz, 1H), 8.5 (s, 1H). ESI–HRMS (Método D) Encontrado 550.2416 calculado para C28H32ClN7O3 [M+H]+: 550.2414 Usando (4–amino–3–clorofenil)(4– metipiperazin–1–il)metanona (Preparación 69) y el método de purificación J. 0.008
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 42
- 6–(2–cloro–4–(4–metoxipiperidin–1– carbonil)fenilamino)–2–(1–metil–1H–pirazol– 4–il)– 1H–pirrolo[3,2–c]piridin–1–carboxilato de tert– butilo 1H–RMN (500 MHz, CDCl3) 1.29 (s,br, 2H), 1.39 (s, 9H), 1.7 (m, 2H), 1.95 (m, 2H), 3.3 (s, br, 1H), 3.39 (s, 3H), 3.5 (m, 1H), 3.6(s, br, 1H), 3.96 (s, 3H), 6.55 (s, 1H), 7.3 (s, 1H), 7.3(s, 1H), 7.35 (dd, J= 1.9Hz, 8.2Hz, 1H), 7.56 (m, 4H), 8.18 (s, 1H). ESI–HRMS Encontrado 565.2233 calculado para C29H33ClN6O4 [M+H]+: 565.2235 Usando), (4–amino–3–clorofenil)(4–metoxipiperidin– 1–il)metanona (Preparación 70) y el método de purificación K. 0.008
- 43
- tert–Butil–6–(2–cloro–4–(4– 1H–RMN (500 MHz, CDCl3): δ 1.42 (s, br, 0.005
- (dimetilamino)piperidin–1–carbonil)fenilamino)–2–
- 2H), 1.5 (s, 9H), 1.9 (s, br, 2H), 2.29 (s,
- (1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 6H), 2.4 (m, 1H), 2.9 (s, br, 2H), 3.96 (s,
- c]piridin–1–carboxilato
- 3H), 4.3 (s, br, 2H), 6.51 (s, 1H), 7.08 (s, 1H), 7.29 (d, J=8.5Hz, 1H), 7.5 (d, J=1.9Hz, 1H), 7.54 (s, 1H), 7.59 (s, 1H), 7.7 (s, 1H), 8.13 (d, J=8.5Hz, 1H), 8.51 (s, 1H). ESI– HRMS Encontrado 578.2623, calculado para C30H36ClN7O3 [M+H]+: 578.2641 Usando (4–amino–3–clorofenil)(4– (dimetilamino)piperidin–1–il)metanona (Preparación 71) y el método de purificación N.
- 44
- 6–(2–cloro–4–(1–metil–1H–pirazol–5– 1H–RMN (500 MHz, CDCl3): δ 1.5 (s, 9H), 0.019
- il)fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H–
- 3.91 (s, 3H), 3.96 (s, 3H), 6.28 (d, J=1.9Hz,
- pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo
- 1H), 6.51 (s, 1H), 7.06 (s, 1H), 7.3 (d, J=8.5Hz, 1H), 7.45(d, J=2Hz, 1H), 7.5 (s, 1H), 7.54 (s, 1H), 7.6 (s, 1H), 7.72 (s, 1H), 8.19 (d, J=8.5Hz, 1H), 8.51 (s, 1H). ESI– HRMS Encontrado 504.2129 calculado para C26H26ClN7O2 [M+H]+: 504.2122 Usando 2–cloro–4–(1–metil–1H–pirazol–5– il)anilina (Preparación 121) y el método de purificación K.
- 45
- 6–(2–cloro–4–(2,4–dimetiltiazol–5– il)fenilamino)– 2–(1–metil–1H–pirazol–4–il)– 1H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 2.46 (s, 3H), 2.68 (s, 3H), 3.96 (s, 3H), 6.5 (s, 1H), 7.02 (s, 1H), 7.26(d, J=6.4Hz, 1H), 7.44 (s, 1H), 7.54 (s, 1H), 7.6 (s, 1H), 7.68 (s, 1H), 8.08(d, J=8.6Hz, 1H), 8.49 (s, 1H). ESI–HRMS Encontrado 535.1668 calculado para C27H27ClN6O2S [M+H]+: 535.1677. Usando 2–Cloro–4–(2,4–dimetiltiazol–5– il)anilina (Preparación 122) y el método de purificación K. 0.052
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 46
- 6–(2–cloro–4–(2–metoxipiridin–4– il)fenilamino)– 2–(1–metil–1H–pirazol–4–il)– 1H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 3.96 (s, 3H), 3.97(s, 3H) 6.52 (s, 1H), 6.92 (s, 1H), 7.08(m, 2H), 7.55 (s, 1H), 7.61 (s, 1H), 7.69 (s, 1H), 7.72 (s, 1H), 8.2(m, 2H), 8.52 (s, 1H). ESI– HRMS Encontrado 531.171 calculado para C28H27ClN6O3 [M+H]+: 531.1725 Usando 2–Cloro–4–(2– metoxipiridin–4–il)anilina (Preparación 123) y el método de purificación K. 0.075
- 47
- 6–(2–cloro–4–(1,2–dimetil H–imidazol– 5– il)fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H– pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.5 (s, 9H), 2.44 (s, 3H), 3.52 (s, 3H), 3.96 (s, 3H), 6.5 (s, 1H), 6.92 (s, 1H), 7.05 (s, br, 1H), 7.2(d, J=8.5 Hz, 1H), 7.38 (d, J=2.1Hz, 1H), 7.54 (s, 1H), 7.59 (s, 1H), 7.68 (s, 1H), 8.1 (d, J=8.5Hz, 1H), 8.49 (s, 1H). ESI–HRMS Encontrado 518.2072 calculado para C27H28ClN7O2 [M+H]+: 518.2066 Usando 2–cloro–4–(1,2–dimetil–1H– imidazol–5–il)anilina (Preparación 124) y el método de purificación E. 0.005
- 48
- tert–Butil–6–(2–cloro–4–(6–metoxipiridin–3– 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 0.016
- il)fenilamino)–2–(1–metil–1H–pirazol–4–il)– 1H–
- 3.96 (s, 3H), 3.98 (s, 3H), 6.51 (s, 1H),
- pirrolo[3,2–c]piridin–1–carboxilato
- 6.8(d, J=8.6 Hz, 1H), 6.98 (s, 1H), 7.41 (s, 1H), 7.55 (s, 1H), 7.57 (d, J=2.2Hz, 1H), 7.6 (s, 1H), 7.68 (s, 1H), 7.74(dd, J=2.5Hz, 8.5Hz, 1H), 8.09 (d, J=8.5Hz, 1H), 8.35 (d, J=2.5Hz, 1H), 8.5 (s, 1H). ESI–HRMS Encontrado 531.1892 calculado para C28H27ClN6O3 [M+H]+: 531.1906 Usando 2–cloro–4–(6–metoxipiridin–3–il)anilina (Preparación 126) y la cromatografía del Método de purificación I.
- 49
- 6–(2–cloro–4–(6–metilpiridin–3– il)fenilamino)–2– 1H–RMN (500 MHz, CDCl3): δ 1.51 (s, 9H), 0.009
- (1–metil–1H–pirazol–4–il)– 1H–pirrolo[3,2–
- 2.61 (s, 3H), 3.97 (s, 3H), 6.51 (s, 1H), 7.02
- c]piridin–1–carboxilato de tert–butilo
- (s, 1H), 7.21 (d, J=8.1Hz, 1H), 7.46 (s, 1H), 7.55 (s, 1H), 7.61 (s, 1H), 7.62 (d, J=2.2Hz, 1H), 7.7 (s, 1H), 7.73 (d, J=8.6Hz, 1H), 8.14 (d, J=8.6Hz, 1H), 8.51 (s, 1H), 8.7 (d, J=2.1Hz, 1H). ESI–HRMS Encontrado 515.1983 calculado para C28H27ClN6O2 [M+H]+: 515.1978 Usando 2–cloro–4–(6– metilpiridin–3–il)anilina (Preparación 127) y el método de purificación K.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 50
- 6–((2–cloro–4–(3,3–difluoroazetidin–1– carbonil)fenil)amino)–2–(1–metil–1H–pirazol– 4– il)–1H–pirrolo[3,2–c]piridin–1–carboxilato de tert– butilo 1H–RMN (500 MHz, DMSO–d6): δ 1.45 (s, 9H), 3.88 (s, 3H), 4.60 (br s, 4H), 6.66 (s, 1H), 7.57 (dd, J = 2.1, 8.6 Hz, 1H), 7.62 (s, 1H), 7.74 (d, J = 2.0 Hz, 1H), 7.82 (s, 1H), 7.94 (s, 1H), 8.17 (d, J = 8.5 Hz, 1H), 8.49 (s, 1H), 8.70 (s, 1H). ESI–HRMS: Encontrado 543.1711; calculado para C26H26ClF2N6O3 [M+H]+: 543.1717. Usando (4–amino–3– clorofenil)(3,3–difluoroazetidin–1– il)metanona(Preparación 72), manipulación del Método I seguido por Método de purificación F. 0.006
- 51
- 6–((2–cloro–4–(pirazin–2– il)fenil)amino)–2–(1– 1H–RMN (500 MHz, DMSO–d6): δ 1.45 (s, 0.028
- metil–1H–pirazol–4–il)– 1H–pirrolo[3,2–c]piridin–
- 9H), 3.88 (s, 3H), 6.65 (s, 1H), 7.62 (s, 1H),
- 1–carboxilato de tert–butilo
- 7.75 (s, 1H), 7.94 (s, 1H), 8.07 (dd, J = 2.1, 8.8 Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 8.24 (d, J = 2.1 Hz, 1H), 8.49 (s, 1H), 8.56 (d, J = 2.4 Hz, 1H), 8.64 (s, 1H), 8.68 (dd, J = 1.6, 2.5 Hz, 1H), 9.27 (d, J = 1.3 Hz, 1H). ESI–HRMS: Encontrado 502.1766; calculado para C26H25ClN7O2 [M+H]+: 502.1753. Usando 2–cloro–4–(pirazin–2– il)anilina (Preparación 133), manipulación del Método I seguido por Método de purificación F y HPLC semipreparativa.
- 52
- 6–((2–cloro–4–(pirimidin–5– il)fenil)amino)–2–(1– 1H–RMN (500 MHz, DMSO–d6): δ 1.45 (s, 0.004
- metil–1H–pirazol–4–il)– 1H–pirrolo[3,2–c]piridin–
- 9H), 3.88 (s, 3H), 6.64 (s, 1H), 7.61 (d, J =
- 1–carboxilato de tert–butilo
- 0.6 Hz, 1H), 7.70 (s, 1H), 7.75 (dd, J = 2.2, 8.6 Hz, 1H), 7.93 (s, 1H), 7.98 (d, J = 2.3 Hz, 1H), 8.16 (d, J = 8.8 Hz, 1H), 8.46 (d, J = 0.6 Hz, 1H), 8.61 (s, 1H)0.9.15and9.17(2xs,3H). ESI–HRMS: Encontrado 502.1768; calculado para C26H25ClN7O2 [M+H]+: 502.1753. Usando 2–cloro–4–(pirimidin–5–il)anilina (Preparación 134), manipulación del Método I seguido por Método de purificación F.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 6–((4–(azetidin–1–carbonil)–2– clorofenil)amino)– 2–(1–metil–1H–pirazol–4– il)–1H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo
- 1H–RMN (500 MHz, DMSO–d6): δ 1.45 (s, 9H), 2.26 (m, 2H), 3.88 (s, 3H), 4.04 (br s, 2H), 4.38 (br s, 2H), 6.66 (s, 1H), 7.52 (dd, J = 2.0, 8.6 Hz, 1H), 7.61 (d, J = 0.9 Hz, 1H), 7.66 (d, J = 2.0 Hz, 1H), 7.76 (s, 1H), 7.94 (s, 1H), 8.12 (d, J = 8.6 Hz, 1H), 8.48 (d, J = 0.9 Hz, 1H), 8.63 (s, 1H). ESI– HRMS: Encontrado 507.1911; calculado para C26H28ClN6O3 [M+H]+: 507.1906. Usando (4–amino–3–clorofenil)(azetidin–1– il)metanona (Preparación 73), manipulación del Método I seguido por Método de purificación O. 0.007
- 54
- 6–((2–cianofenil)amino)–2–(1–metil– 1H–pirazol– 4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de tert–butilo 1H–RMN (500 MHz, DMSO–d6): δ 1.45 (s, 9H), 3.88 (s, 3H), 6.63 (d, J = 0.5 Hz, 1H), 7.10 (td, J = 1.0, 7.6 Hz, 1H), 7.58 (s, 1H), 7.59 (td oscurecido, 1H), 7.60 (d, J = 0.5 Hz, 1H), 7.70 (dd, J = 1.4, 7.9 Hz, 1H), 7.72 (d, J = 8.4 Hz, 1H), 7.93 (s, 1H), 8.41 (d, J = 0.8 Hz, 1H), 9.12 (s, 1H). ESI–HRMS: Encontrado 415.1872; calculado para C23H23N6O2 [M+H]+: 415.1877. Usando 2– cianoanilina, manipulación del Método I seguido por Método de purificación F. 0.032
- 55
- 6–((2–cloro–4–(metisulfonil)fenil)amino)–2–(1– metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– Carboxilato de tert–butilo 1H–RMN (500 MHz, DMSO–d6): δ 1.45 (s, 9H), 3.21 (s, 3H), 3.88 (s, 3H), 6.68 (s, 1H), 7.62 (s, 1H), 7.73 (dd, J = 2.2, 8.9 Hz, 1H), 7.88 (s, 1H), 7.90 (d, J = 2.3 Hz, 1H), 7.95 (s, 1H), 8.28 (d, J = 8.6 Hz, 1H), 8.52 (s, 1H), 8.90 (s, 1H). ESI–HRMS: Encontrado 502.1305; calculado para C23H25ClN5O4S (M+H)+: 502.1310. Usando 2–cloro–4– (metisulfonil)anilina, manipulación del Método I seguido por Método de purificación F. 0.024
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 56
- 6–((2–fluoro–4–metoxifenil)amino)– 2–(1–metil– 1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1– carboxilato de tert–butilo 1H–RMN (500 MHz, DMSO–d6): δ 1.41 (s, 9H), 3.76 (s, 3H), 3.86 (s, 3H), 6.56 (s, 1H), 6.75 (dd, J = 2.2, 8.6 Hz, 1H), 6.90 (dd, J = 2.7, 12.6 Hz, 1H), 7.20 (s, 1H), 7.57 (s, 1H), 7.59 (t oscurecido, J = 9.0 Hz, 1H), 7.88 (s, 1H), 8.31 (s, 2H). Usando 2–fluoro–4– metoxianilina, manipulación del Método I seguido por Método de purificación F. Sin datos
- 57
- 6–((2–metoxi–4–(trifluorometil)fenil)amino)–2–(1– metil– 1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 1– carboxilato de tert–butilo 1H–RMN (500 MHz, DMSO–d6): δ 1.45 (s, 9H), 3.87 (s, 3H), 3.94 (s, 3H), 6.63 (s, 1H), 7.22 (s, 1H), 7.24 (d, J = 9.0 Hz, 1H), 7.60 (s, 1H), 7.76 (s, 1H), 7.92 (s, 1H), 8.45 (d, J = 8.7 Hz, 1H), 8.48 (s, 1H), 8.54 (s, 1H). Usando 2–metoxi–4–trifluorometilanilina, manipulación del Método I seguido por Método P. Sin datos
- 58
- 6–((4–fluoro–2–metoxifenil)amino)– 2–(1–metil– 1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de tert–butilo 1H–RMN (500 MHz, DMSO–d6): δ 1.42 (s, 9H), 3.82 (s, 3H), 3.86 (s, 3H), 6.57 (s, 1H), 6.74 (td, J = 2.9, 8.7 Hz, 1H), 6.96 (dd, J = 2.8, 10.8 Hz, 1H), 7.35 (s, 1H), 7.57 (s, 1H), 7.86 (dd, J = 6.7, 8.9 Hz, 1H), 7.89 (s, 1H), 7.99 (s, 1H), 8.34 (s, 1H). Usando 4–fluoro–2–metoxianilina, manipulación del Método I seguido por Método de purificación F. Sin datos
- 59
- 6–(2–metoxifenilamino)–2–(1– metil–1H–pirazol– 4–il)–1H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.52 (s, 9H), 3.92 (s, 3H), 3.96 (s, 3H), 6.49 (d, J=0.63Hz, 1H), 6.91–6.99 (m, 3H), 7.04 (br s, 1H), 7.54 (s, 1H), 7.60 (s, 1H), 7.66 (s, 1H), 7.93 (m, 1H), 8.46 (d, J=0.95Hz, 1H). Usando 2–metoxianilina y el método de purificación Q. Sin datos
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 60
- 6–(2–cloro–4–(dimetilcarbamoil)fenilamino)–2–(1– metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin– 1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), 3.10 (s, 6H), 3.98 (s, 3H), 6.53 (s, 1H), 7.08 (s, 1H), 7.34 (dd, J = 8.5, 1.9 Hz, 1H), 7.54–7.56 (m, 2H), 7.61 (s, 1H), 7.72 (s, 1H), 8.15 (d, J = 8.5 Hz, 1H), 8.53 (s, 1H). Usando 4–amino–3–cloro–N,N– dimetibenzamida y el método de purificación B. Sin datos
- 61
- 6–(4–(dimetilcarbamoil)–2– metoxifenilamino)–2– 1H–RMN (500 MHz, CDCl3): δ 1.52 (s, 9H), Sin datos
- (1–metil–1H–pirazol– 4–il)–1H–pirrolo[3,2–
- 3.11 (s, 6H), 3.95 (s, 3H), 3.97 (s, 3H), 6.50
- c]piridin–1–carboxilato de tert–butilo
- (s, 1H), 7.05 (dd, J = 8.2, 1.7 Hz, 1H), 7.08 (d, J = 1.7 Hz, 1H), 7.22 (s, 1H), 7.54 (s, 1H), 7.60 (s, 1H), 7.69 (s, 1H), 8.10 (d, J = 8.2 Hz, 1H), 8.49 (s, 1H). Usando 4– amino–3–metoxi–N,N–dimetibenzamida y el método de purificación B.
- 62
- 6–((2–cloro–5–(1–metil–1H–pirazol–4– 1H–RMN (500 MHz, DMSO–d6): δ 1.40 (s, 0.537
- il)fenil)amino)–2–(1–metil–1H–pirazol–4–il)– 1H–
- 9H), 3.84 (s, 3H), 3.87 (s, 3H), 6.62 (d, J =
- pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo
- 0.6 Hz, 1H), 7.23 (dd, J = 2.2, 8.4 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.48 (s, 1H), 7.59 (d, J = 0.7 Hz, 1H), 7.81 (d, J = 0.8 Hz, 1H), 7.91 (s, 1H), 7.96 (d, J = 2.3 Hz, 1H), 8.11 (s, 1H), 8.33 (s, 1H), 8.42 (d, J = 0.8 Hz, 1H). ESI–HRMS: Encontrado 504.1899; calculado para C26H27ClN7O2 (M+H)+: 504.1909. Usando 2–cloro–5–(1–metil–1H– pirazol–4–il)anilina (Preparación 132) y el método de purificación Q.
- 63
- 6–(2–cloro–4–(1,4–dimetil–1H–imidazol–5– il)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H– pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.52 (s, 9H), 2.23 (s, 3H), 3.55 (s, 3H), 3.97 (s, 3H), 6.53 (d, J = 0.63Hz, 1H), 7.04 (s, 1H), 7.17 (dd, J = 1.89, 8.51 Hz, 1H), 7.34 (d, J = 1.89Hz, 1H), 7.43 (s, 1H), 7.56 (s, 1H), 7.61 (s, 1H), 7.72 (s, 1H), 8.17 (d, J = 8.51 Hz, 1H), 8.52 (d, J = 0.95Hz, 1H). HRMS calculado para C27H27 35ClN7O2 (M+H)+ 518.2069, encontrado 518.2053 Usando 2–Cloro–4– (1,4–dimetil–1H–imidazol–5–il)anilina (Preparación 161) y el método de purificación R. 0.005
Ejemplo 64
Método L: columna de SCX–2 seguido por TLC preparativa eluyendo con EtOAc dos veces seguido por HPLC preparativa (Véase Parte Experimental General)
Método M: TLC Preparativa eluyendo dos veces con EtOAc seguido por TLC preparativa eluyendo dos veces con EtOAc/DCM 1/1.
5 Método N: Después de calentar, el solvente se eliminó in vacuo y se sometió a partición entre EtOAc y agua. La capa orgánica se lavó con salmuera, se secó (Na2SO4) y se concentró in vacuo antes de la purificación usando cromatografía de columna en sílica gel eluyendo con EtOAc/hexano/trietilamina 10/10/1.
Método O: Después de calentar, el solvente se eliminó in vacuo y se sometió a partición entre EtOAc y agua. La capa orgánica se lavó con salmuera, se secó (Na2SO4) y se concentró in vacuo antes de la purificación usando una
10 TLC preparativa eluyendo con 10/1 EtOAc/Amoniaco 2M en MeOH.
Método P: TLC Preparativa eluyendo con 10/1 acetato de etilo: "A"; donde “A” es 10/1 metanol:“880” amoniaco.
Método Q: Después de calentar, la reacción se sometió a partición entre EtOAc y agua. La capa orgánica se lavó con salmuera, se secó (Na2SO4) y se concentró in vacuo antes de aplicar a una columna de SCX–2. El residuo se disolvió en EtOAc y se filtró a través de Celita antes de purificación adicional utilizando HPLC preparativa (Véase
15 Parte Experimental General)
Método R: HPLC preparativa (Véase Parte Experimental General) eluyendo con agua/MeOH 75/25 a 40/60.
Método S: Cromatografía de columna en sílica gel de Biotage eluyendo con DCM/EtOH 99/1 a 97/3 seguido por HPLC preparativa eluyendo con agua/MeOH 60/40 a 0/100.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 65
- 3–cloro–6–(2–cloro–4– (dimetilcarbamoil) fenilamino)– 2–(1– metil–1H–pirazol–4–il)–1H– pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3): δ 1.46 (s, 9H), 3.10 (s, 6H), 4.01 (s, 3H), 7.15 (s, 1H), 7.36 (dd, J = 8.5, 1.9Hz, 1H), 7.55 (d, J = 1.9Hz, 1H), 7.60 (s, 1H), 7.62 (s, 1H), 7.72 (d, J = 0.9Hz, 1H), 8.21 (d, J = 8.5Hz, 1H), 8.56 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 529.1510, calculado para C25H27Cl2N6O3 [M+H]+: 529.1516. Usando la Preparación 80 y 4–amino–3–cloro–N,N– dimetibenzamida. 0.127
- 66
- 3–Cloro–4–(1–(ciclopropilmetil)–2–(1– metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–ilamino)–N,N– dimetibenzamida 1H–RMN (500 MHz, CD3OD): δ 0.24–0.27 (m, 2H), 0.47–0.51 (m, 2H), 1.08–1.16 (m, 1H), 3.10 (s, 6H), 4.00 (s, 3H), 4.16 (d, J = 6.3Hz, 2H), 6.62 (d, J = 0.8Hz, 1H), 7.20 (t, J = 0.8Hz, 1H), 7.30 (dd, J = 8.5, 2.0Hz, 1H), 7.53 (d, J = 2.0Hz, 1H), 7.69 (d, J = 8.5Hz, 1H), 7.77 (d, J = 0.8Hz, 1H), 7.97 (d, J = 0.8Hz, 1H), 8.49 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 449.1850, calculado para C24H26ClN6O [M+H]+: 449.1851. Usando la Preparación 81 y 4–amino–3–cloro–N,N– dimetibenzamida. 0.030
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 67
- N–(2–Clorofenil)–1–(ciclohexilmetil)–2– 1H–RMN (500 MHz, CD3OD): δ 0.87–0.97 (m, 2H), 4.879
- (1–metil–1H–pirazol–4–il)–1H–
- 1.06–1.17 (m, 3H), 1.43–1.49 (m, 2H), 1.58–1.67 (m,
- pirrolo[3,2–c]piridin–6–amina
- 3H), 1.68–1.76 (m, 1H), 3.98 (s, 3H), 4.01 (d, J = 7.3Hz, 2H), 6.56 (s, 1H), 6.91 (ddd, J = 8.0, 7.3, 1.5Hz, 1H), 7.01 (s, 1H), 7.20 (ddd, J = 8.2, 7.3, 1.5Hz, 1H), 7.40 (dd, J = 8.0, 1.5Hz, 1H), 7.58 (dd, J = 8.2, 1.5Hz, 1H), 7.72 (s, 1H), 7.90 (s, 1H), 8.41 (s, 1H). ESI–HRMS (Método B) Encontrado 420.1960, calculado para C24H27ClN5 [M+H]+: 420.1950. Usando la Preparación 84, 2–cloroanilina y el método de purificación A.
- 68
- 6–(4–(1,2–dimetil–1H–imidazol–5–il)–2– metoxifenilamino)–2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de isopropilo 1H–RMN (500 MHz, CDCl3): δ 1.35 (d, J = 6.3Hz, 6H), 2.48 (s, 3H), 3.56 (s, 3H), 3.96 (s, 3H), 3.98 (s, 3H), 5.20 (sept, J = 6.3Hz, 1H), 6.54 (d, J = 0.9Hz, 1H), 6.90 (d, J = 1.8Hz, 1H), 6.95 (dd, J = 8.2, 1.8Hz, 1H), 6.96 (s, 1H), 7.21 (s, 1H), 7.58 (d, J = 0.8Hz, 1H), 7.64 (d, J = 0.8Hz, 1H), 7.74 (t, J = 0.9Hz, 1H), 8.07 (d, J = 8.2Hz, 1H), 8.50 (d, J = 0.9Hz, 1H). ESI– HRMS (Método B) Encontrado 500.2408, calculado para C27H30N7O3 [M+H]+: 500.2405. Usando la Preparación 26, Preparación 95 y el método de purificación B. 0.002
- 69
- tert–Butil–6–(2,4–dimetoxifenilamino)– 2–(1–(2–(dimetilamino)–2–oxoetil)–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato 1H–RMN (500 MHz, CDCl3): δ 1.47 (s, 9H), 3.0 (s, 3H), 3.11 (s, 3H), 3.81 (s, 3H), 3.85 (s, 3H), 5 (s, 2H), 6.5 (m, 2H), 6.55 (s, 1H), 6.63 (s, 1H), 7.42 (s, 1H), 7.62 (s, 1H), 7.66 (d, J=8.7Hz, 1H), 7.7 (s, 1H), 8.39 (s, 1H). Usando la Preparación 120, 2,4– dimetoxianilina y el método de purificación C. Sin datos
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 70
- 3–Cloro–4–(1–(4–fluorobencil)–2–(1– metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–ilamino)–N,N– dimetibenzamida 1H–RMN (500 MHz, d6–DMSO): δ 2.97 (s, 6H), 3.86 (s, 3H), 5.42 (s, 2H), 6.66 (s, 1H), 7 (m, 2H), 7.16 (m, 3H), 7.44 (s, 1H), 7.64 (s, 1H), 7.97(s, 1H), 8.08 (d, J=8.4, 2H), 8.52(s, 1H), ESI–HRMS Encontrado 503.175, calculado para C27H24ClFN6O (M+H+): 503.1757 Usando la Preparación 114, 4–amino–3– cloro–N,N– dimetibenzamida y el método de purificación C. 0.038
- 71
- 3–Cloro–4–(1–(ciclohexilmetil)–2–(1– metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–ilamino)–N,N– dimetibenzamida 1H–RMN (500 MHz, d6–DMSO): δ 0.95 (m, 2H), 1.11 (m, 4H), 1.4 (m, 2H), 1.6 (m, 2H), 1.7 (m, 1H), 2.98 6H), 3.92 (s, 3H), 4.02 (d, J = 7.4 Hz, 2H), 6.55 (d, J = 0.8 Hz, 1H), 7.29 (m, 2H), 7.46 (d, J = 2.0 Hz, 1H), 7.78 (s, 1H), 8.09 (s, 1H), 8.11 (d, J = 8.6 Hz, 1H), 8.18 (d, J=8.6Hz, 1H), 8.46 (s, 1H). ESI–HRMS Encontrado 491.2315, calculado para C27H31ClN6O (M+H+): 491.2321 Usando la Preparación 115, 4– amino–3–cloro–N,N– dimetibenzamida y el método de purificación C. 0.067
- 72
- 6–(2–cloro–4– 1H–RMN (500 MHz, CDCl3): δ 1.61 (m, 4H), 1.77 (m, 0.003
- (dimetilcarbamoil)fenilamino)–2–(1–
- 4H), 3.09 (s, 6H), 3.96 (s, 3H), 5.38 (quin, J = 5.6 Hz,
- metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 1H), 6.54 (s, 1H), 7.1 (s, 1H), 7.34 (dd, J = 1.8Hz, 8.5
- c]piridin–1–carboxilato de ciclopentilo
- Hz, 1H), 7.55 (m, 2H), 7.62 (s, 1H), 7.73 (s, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.52 (s, 1H). ESI–HRMS Encontrado 507.1933, calculado para C26H27ClN6O3 (M+H+): 507.1906 Usando la Preparación 116, 4– amino–3–cloro–N,N– dimetibenzamida y el método de purificación C.
- 73
- 3–Cloro–4–(1–ciclopentil–2–(1–metil– 1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–ilamino)–N,N– dimetibenzamida 1H–RMN (500 MHz, d6–DMSO): 1.7 (m, 2H), 1.75 (m, 4H), 2.18 (m, 2H), 2.98 (s, 6H), 3.92 (s, 3H), 4.86 (quin, J = 5.6 Hz, 1H), 6.45 (s, 1H), 7.25 (s, 1H), 7.32 (d, J = 8.3 Hz, 1H), 7.5 (s, 1H), 7.69 (s, 1H), 8.03 (s, 1H), 8.1 (m, 1H), 8.33 (s, br, 1H), 8.49 (s, 1H). ESI– HRMS (Método B) Encontrado 463.2024, calculado para C25H27ClN6O (M+H+): 463.2008 Usando la Preparación 117, 4–amino–3–cloro–N,N– dimetibenzamida y el método de purificación C. 0.007
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 74
- 3–Cloro–4–(1–isopropil–2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6– ilamino)–N,N–dimetibenzamida 1H–RMN (500 MHz, d6–DMSO): δ 1.55 (d, J=7Hz, 6H), 2.98 (s, 6H), 3.92 (s, 3H), 4.7 (sep, J = 7 Hz, 1H), 6.42 (s, 1H), 7.3 (d, J = 8.6 Hz, 1H), 7.46 (d, J=2Hz, 1H), 7.53 (s, 1H), 7.66 (s, 1H), 8 (s, 1H), 8.2 (s, 1H), 8.27 (d, J=8.6Hz, 1H), 8.48 (s, 1H). ESI– HRMS Encontrado 437.2252, calculado para C23H25ClN6O (M+H+): 437.2248 Usando la Preparación 118, 4–amino–3–cloro–N,N– dimetibenzamida y el método de purificación C. 0.050
- 75
- 6–(2–cloro–4–(1–metil–1H–pirazol–4– il)fenilamino)–2–(1–metil–1H–pirazol–4– il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de ciclopentilo 1H–RMN (500 MHz, CDCl3): δ 1.56 (m, 4H), 1.73 (m, 2H), 1.87 (m, 2H), 3.94 (s, 3H), 3.95 (s, 3H), 5.35 (quin, J = 3.2 Hz, 1H), 6.5 (s, 1H), 6.91 (s, 1H), 7.33 (dd, J = 2.1 Hz, 8.5 Hz, 1H), 7.52 (s, 1H), 7.56 (s, 1H), 7.61 (d, J=6.6Hz, 1H), 7.71 (s, 1H), 7.91 (d, J = 8.5 Hz, 1H), 8.47 (s, 1H). ESI–HRMS Encontrado 516.1897, calculado para C27H26ClN7O2 (M+H+): 516.1909 Usando la Preparación 116, Preparación 83 y el método de purificación C. 0.012
- 76
- 6–(2–cloro–4–(1–metil–1H– pirazol–4– il)fenilamino)–2–(1– metil–1H–pirazol– 4–il)–1H– pirrolo[3,2–c]piridin–1– carboxilato de isopropilo 1H–RMN (500 MHz, CDCl3): δ 1.3 (d, J=6.7Hz, 6H), 3.94 (s, 3H), 3.95 (s, 3H), 5.16 (sep, J = 6.3 Hz, 1H), 6.51 (s, 1H), 6.93 (s, 1H), 7.34 (d, J = 8.5Hz, 1H), 7.51 (s, 1H), 7.56 (s, 2H), 7.62 (s, 1H), 7.66 (s, 1H), 7.71 (s, 1H), 7.91 (d, J=8.5Hz, 1H), 8.47 (s, 1H). ESI–HRMS Encontrado 490.1767, calculado para C25H24ClN7O2 (M+H+): 490.175 Usando la Preparación 26, Preparación 83 y el método de purificación C. 0.017
- 77
- 6–(2–cloro– 4– (dimetilcarbamoil)fenilamino)– 2–(1– metil–1H–pirazol–4–il)–1H– pirrolo[3,2– c]piridin–1–carboxilato de isopropilo 1H–RMN (500 MHz, CDCl3): δ 1.35 (d, J=6.3Hz, 6H), 3.09 (s, 6H), 3.98 (s, 3H), 5.2 (sep, J = 6.2 Hz, 1H), 6.55 (s, 1H), 7.11 (s, 1H), 7.34 (dd, J =2Hz, 8.5Hz, 1H), 7.55 (s, 1H), 7.58 (s, 1H), 7.63 (s, 1H), 7.74 (s, 1H), 8.09 (d, J=8.5Hz, 1H), 8.52 (s, 1H). ESI–HRMS Encontrado 481.1737, calculado para C24H25ClN6O3 (M+H+): 481.1749 Usando la Preparación 26, 4– amino–3–cloro–N,N– dimetibenzamida y el método de purificación D. 0.006
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 78
- 6–((2–cloro–4–(1–metil– 1H–imidazol– 1H–RMN (500 MHz, CDCl3): δ 1.58(m, 4H), 1.76 (m, 0.011
- 5–il)fenil)amino)–2–(1– metil–1H–
- 2H), 1.91 (m, 2H), 3.65 (s, 3H), 3.95 (s, 3H), 5.35
- pirazol–4–il)–1H– pirrolo[3,2–c]piridin–
- (quin, J = 3 Hz, 1H), 6.51 (s, 1H), 7.04 (s, 1H), 7.06
- 1–carboxilato de cilcopentilo
- (s, 1H), 7.24 (dd, J=2.1 Hz, 8.5Hz, 1H), 7.42 (s, 1H), 7.5 (s, 1H), 7.54 (s, 1H), 7.6 (s, 1H), 7.7 (s, 1H), 8.1 (d, J = 8.5 Hz, 1H), 8.49 (s, 1H); ESI–HRMS (Método B) Encontrado 516.1895, calculado para C27H26CIN7O2 (M+H+): 516.1909 Usando la Preparación 116, Preparación 86 y el método de purificación E.
- 79
- 6–(2–cloro–4–(1–metil–1H– imidazol–5– il)fenilamino)–2–(1– metil–1H–pirazol– 4–il)–1H– pirrolo[3,2–c]piridin–1– carboxilato de isopropilo 1H–RMN (500 MHz, CDCl3): δ 1.33 (d, J=6.3Hz, 6H), 3.69 (s, 3H), 3.96 (s, 3H), 5.19 (sep, J = 6.3 Hz, 1H), 6.55 (s, 1H), 7.04 (s, 1H), 7.09 (s, 1H), 7.26 (dd, J = 2Hz, 8.5Hz, 2H), 7.45 (s, 1H), 7.52 (s, 1H), 7.63 (s, 1H), 7.74 (s, 1H), 8.12 (d, J=8.5Hz, 1H), 8.52 (s, 1H); ESI–HRMS Encontrado 490.1736, calculado para C25H24ClN7O2 (M+H+): 490.1753 Usando la Preparación 26, Preparación 86 y el método de purificación E. 0.003
- 80
- N–(2–cloro–4–(1–metil–1H–imidazol– 1H–RMN (500 MHz, CDCl3): δ 1.73(m, 2H), 2.02 (m, 0.003
- 5–il)fenil)–1–ciclopentil–2–(1– metil–1H–
- 4H), 2.34 (m, 2H), 3.68 (s, 3H), 4.02 (s, 3H), 4.84
- pirazol–4–il)–1H– pirrolo[3,2–c]piridin–
- (quin, J = 3 Hz, 1H), 6.42 (s, 1H), 6.92 (s, 1H), 7.02
- 6–amina
- (s, 1H), 7.08 (s, 1H), 7.21 (dd, J=2Hz, 8.5Hz, 1H), 7.43 (s, 1H), 7.51 (s, 1H), 7.52 (s, 1H), 7.61 (s, 1H), 7.91 (d, J = 8.5 Hz, 1H), 8.61 (s, 1H); ESI–HRMS (Método B) Encontrado 472.2002, calculado para C26H26ClN7 (M+H+): 472.2011 Usando la Preparación 117, Preparación 86 y el método de purificación F.
- 81
- Ciclobutil–6–(2–cloro–4– (dimetilcarbamoil) fenilamino)– 2–(1– metil–1H–pirazol–4–il)–1H– pirrolo[3,2– c]piridin–1–carboxilato 1H–RMN (500 MHz, CDCl3): δ 1.71 (m, 1H), 1.88 (m, 1H), 2.13 (m, 2H), 2.44 (m, 2H), 3.1 (s, 6H), 3.98 (s, 3H), 5.19 (quin, J = 5.6 Hz, 1H), 6.56 (s, 1H), 7.12 (s, 1H), 7.34 (dd, J = 2Hz, 8.5 Hz, 1H), 7.55 (d, J= 2Hz, 1H), 7.59 (s, 1H), 7.65 (s, 1H), 7.76 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.53(s, 1H); ESI–HRMS Encontrado 493.1734, calculado para C25H25ClN6O3 (M+H+): 493.1749 Usando la Preparación 125, 4–amino–3– cloro–N,N– dimetibenzamida y el método de purificación F. 0.003
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 82
- Ciclobutil–6–(2–cloro–4–(1–metil– 1H–RMN (500 MHz, CDCl3): δ 1.68 (m, 1H), 1.86 (m, 1H), 2.12 (m, 2H), 2.44 (m, 2H), 3.68 (s, 3H), 3.97 (s, 0.005
- 1H–imidazol–5–il)fenilamino)–2–(1–
- 3H), 5.18 (quin, J = 7.3 Hz, 1H), 6.55 (s, 1H), 7.06 (s,
- metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 1H), 7.08 (s, 1H), 7.26 (d, J = 8.5 Hz, 1H), 7.44 (d,
- c]piridin–1–carboxilato
- J=2.1Hz, 1H), 7.52 (s, 1H), 7.58 (s, 1H), 7.64 (s, 1H), 7.75 (s, 1H), 8.14 (d, J = 8.5 Hz, 1H), 8.51 (s, 1H); ESI–HRMS (Método B) Encontrado 502.1744, calculado para C26H24ClN7O2 (M+H+): 502.1753 Usando la Preparación 125, Preparación 86 y el método de purificación F.
- 83
- 6–(2–cloro–4–(1,2–dimetil–1H– 1H–RMN (500 MHz, CDCl3): δ 1.32 (d, J=6.3Hz, 6H), 0.002
- imidazol–5–il)fenilamino)–2–(1–metil–
- 2.44 (s, 3H), 3.53 (s, 3H), 3.96 (s, 3H), 5.19 (sep, J =
- 1H–pirazol–4–il)–1H–pirrolo[3,2–
- 6.3 Hz, 1H), 6.53 (s, 1H), 6.93 (s, 1H), 7.04 (s, 1H),
- c]piridin–1–carboxilato de isopropilo
- 7.21 (dd, J = 2Hz, 8.5Hz, 1H), 7.4 (d, J=2Hz, 1H), 7.57 (s, 1H), 7.62 (s, 1H), 7.72 (s, 1H), 8.08 (d, J=8.5Hz, 1H), 8.5 (s, 1H); ESI–HRMS Encontrado 504.1903, calculado para C26H26ClN7O2 (M+H+): 504.1909 Usando la Preparación 26, Preparación 124 y el método de purificación F.
- 84
- 6–(2–cloro–4–(1,2–dimetil–1H– 1H–RMN (500 MHz, CDCl3): δ 1.59 (m, 4H), 1.75 (m, 0.002
- imidazol–5–il)fenilamino)–2–(1–metil–
- 2H), 1.89 (m, 2H), 2.45 (s, 3H), 3.53 (s, 3H), 3.96 (s,
- 1H–pirazol–4–il)–1H–pirrolo[3,2–
- 3H), 5.36 (quin, J = 3Hz, 1H), 6.52 (s, 1H), 6.93 (s,
- c]piridin–1–carboxilato de ciclopentilo
- 1H), 7.01 (s, 1H), 7.21 (dd, J=2Hz, 8.5Hz, 1H), 7.4 (d, J=2Hz, 1H), 7.55 (s, 1H), 7.61 (s, 1H), 7.7 (s, 1H), 8.08 (d, J = 8.5 Hz, 1H), 8.5 (s, 1H); ESI–HRMS Encontrado 530.206, calculado para C28H28ClN7O2 (M+H+): 530.2066 Usando la Preparación 116, Preparación 124 y el método de purificación F.
- 85
- 6–(2–cloro–4–(1,2–dimetil–1H– 1H–RMN (500 MHz, CDCl3): δ 1.67 (m, 1H), 2.09 (m, 0.004
- imidazol–5–il)fenilamino)–2–(1–metil–
- 1H), 2.11 (m, 2H), 2.39 (m, 2H), 2.44 (s, 3H), 3.6 (s,
- 1H–pirazol–4–il)–1H–pirrolo[3,2–
- 3H), 3.96 (s, 3H), 5.17 (q, J = 7.4 Hz, 1H), 6.54 (s,
- c]piridin–1–carboxilato de ciclobutilo
- 1H), 6.93 (s, 1H), 7.04 (s, 1H), 7.21 (dd, J = 2Hz, 8.5 Hz, 1H), 7.4 (d, J=2Hz, 1H), 7.58 (s, 1H), 7.64 (s, 1H), 7.73 (s, 1H), 8.11 (d, J = 8.5 Hz, 1H), 8.5 (s, 1H); ESI–HRMS Encontrado 516.2109 calculado para C27H26ClN7O2 (M+H+): 516.2067 Usando la Preparación 125, Preparación 124 y el método de purificación F.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 86
- Metil–6–(2–cloro–4–(1,2–dimetil–1H– 1H–RMN (500 MHz, CDCl3): δ 2.45 (s, 3H), 3.49 (s, 0.007
- imidazol–5–il)fenilamino)–2–(1–metil–
- 3H), 3.94 (s, 3H), 3.97 (s, 3H), 6.55 (s, 1H), 6.94 (s,
- 1H–pirazol–4–il)–1H–pirrolo[3,2–
- 1H), 7.04 (s, 1H), 7.22 (dd, J = 2Hz, 8.5 Hz, 1H), 7.4
- c]piridin–1–carboxilato
- (d, J=2Hz, 1H), 7.59 (s, 1H), 7.63 (s, 1H), 7.67 (s, 1H), 8.21 (d, J = 8.5 Hz, 1H), 8.51 (s, 1H); ESI– HRMS (Método B) Encontrado 476.1584 calculado para C24H22ClN7O2 (M+H+): 476.1596 Usando la Preparación 128, Preparación 124 y el método de purificación F.
- 87
- Etil–6–(2–cloro–4–(1,2–dimetil–1H– 1H–RMN (500 MHz, CDCl3): δ 1.34 (t, J=7.2Hz, 3H), 0.002
- imidazol–5–il)fenilamino)–2–(1–metil–
- 2.45 (s, 3H), 3.53 (s, 3H), 3.96 (s, 3H), 4.42 (q, J=
- 1H–pirazol–4–il)–1H–pirrolo[3,2–
- 7.2Hz, 2H), 6.54 (s, 1H), 6.93 (s, 1H), 7.04 (s, 1H),
- c]piridin–1–carboxilato
- 7.22 (dd, J = 2.1Hz, 8.5 Hz, 1H), 7.4 (d, J=2Hz, 1H), 7.58 (s, 1H), 7.63 (s, 1H), 7.7 (s, 1H), 8.13 (d, J = 8.5 Hz, 1H), 8.5 (s, 1H); ESI–HRMS Encontrado 490.1741 calculado para C25H24ClN7O2 (M+H+): 490.1753 Usando la Preparación 129, Preparación 124 y el método de purificación F.
- 88
- Propil–6–(2–cloro–4–(1,2–dimetil–1H– 1H–RMN (500 MHz, CDCl3): δ 0.89 (t, J=7.4Hz, 3H), 0.002
- imidazol–5–il)fenilamino)–2–(1–metil–
- 1.69 (m, 2H), 2.45 (s, 3H), 3.53 (s, 3H), 3.95 (s, 3H),
- 1H–pirazol–4–il)–1H–pirrolo[3,2–
- 4.3 (t, J= 6.7Hz, 2H), 6.53 (s, 1H), 6.93 (s, 1H), 7.03
- c]piridin–1–carboxilato
- (s, 1H), 7.21 (dd, J = 2Hz, 8.5 Hz, 1H), 7.39 (d, J=2Hz, 1H), 7.57 (s, 1H), 7.62 (s, 1H), 7.7 (s, 1H), 8.12 (d, J = 8.5 Hz, 1H), 8.5 (s, 1H); ESI–HRMS Encontrado 504.1899 calculado para C26H26ClN7O2 (M+H+): 504.1909 Usando la Preparación 130, Preparación 124 y el método de purificación F.
- 89
- 6–((2–cloro–5–(1–metil–1H–pirazol–4– il)fenil)amino)–2–(1–metil–1H–pirazol– 4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de isopropilo 1H–RMN (500 MHz, DMSO–d6): δ 1.20 (d, J = 6.5 Hz, 6H), 3.84 (s, 3H), 3.87 (s, 3H), 5.05 (septet, J = 6.1 Hz, 1H), 6.66 (s, 1H), 7.24 (dd, J = 2.2, 8.2 Hz, 1H), 7.44 (d, J = 8.4 Hz, 1H), 7.48 (s, 1H), 7.63 (s, 1H), 7.81 (d, J = 0.6 Hz, 1H), 7.94 (s, 1H), 7.94 (d oscurecido, 1H), 8.11 (s, 1H), 8.36 (s, 1H), 8.42 (d, J = 0.6 Hz, 1H); ESI–HRMS: Encontrado 490.1746; calculado para C25H25ClN7O2 (M+H)+: 490.1753 Usando la Preparación 26, Preparación 132 y el método de purificación G. 0.287
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 90
- 3–Cloro–N,N–dimetil–4–((2–(1–metil– 1H–pirazol–4–il)–1–((5–metilisoxazol– 3–il)metil)–1H–pirrolo[3,2–c]piridin–6– il)amino)etanona 1H–RMN (500 MHz, DMSO–d6): δ 2.32 (s, 3H), 2.97 (s, 6H), 3.90 (s, 3H), 5.39 (s, 2H), 5.94 (s, 1H), 6.62 (s, 1H), 7.24 (s, 1H), 7.29 (dd, J = 2.1, 8.7 Hz, 1H), 7.45 (d, J = 2.1 Hz, 1H), 7.76 (s, 1H), 8.08 (s, 1H), 8.12 (d, J = 8.7 Hz, 1H), 8.20 (s, 1H), 8.49 (s, 1H). ESI–HRMS: Encontrado 490.1752; calculado para C25H25ClN7O2 (M+H)+: 490.1753. Usando la Preparación 135, 4–amino–3–cloro–N,N– dimetibenzamida y el método de purificación H. 0.343
- 91
- 6–(2–cloro–4–(1–metil–1H– imidazol–5– il)fenilamino)–2–(oxazol– 5–il)–1H– pirrolo[3,2–c]piridin–1– carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.50 (s, 9H), 3.70 (s, 3H), 6.84 (d, J = 0.95Hz, 1H), 7.11 (br s, 2H), 7.30 (dd, J = 2.21, 8.51 Hz, 1H), 7.32 (s, 1H), 7.46 (d, J = 2.21 Hz, 1H), 7.55 (br s, 1H), 7.77 (m, 1H), 8.01 (s, 1H), 8.24 (d, J = 8.51 Hz, 1H), 8.61 (d, J = 0.95Hz, 1H). HRMS calculado para C25H24 35ClN6O3 (M+H)+ 491.1593, encontrado 491.1580 Usando la Preparación 140, Preparación 86 y el método de purificación I. 0.006
- 92
- 3–Cloro–N,N–dimetil–4–(2–(1–metil– 1H–pirazol–4–il)–1–(5–metilpiridin–2– il)–1H–pirrolo[3,2–c]piridin–6– ilamino)etanona 1H–RMN (CDCl3, 500MHz): δ 2.46 (s, 3H), 3.08 (s, 6H,), 3.88 (s, 3H), 6.68 (d, J = 0.95Hz, 1H), 6.93 (br s, 1H, NH), 6.97 (t, J = 0.95Hz, 1H), 7.06 (d, J = 8.51 Hz, 1H), 7.22 (s, 1H), 7.25 (d, J = 0.63Hz, 1H), 7.29 (dd, J = 1.58, 8.51 Hz, 1H), 7.49 (d, J = 1.89Hz, 1H), 7.63 (ddd, J = 0.63, 2.21, 8.20Hz, 1H), 7.97 (d, J = 8.51 Hz, 1H), 8.52 (m, 1H), 8.64 (d, J = 0.95Hz, 1H). HRMS calculado para C26H25 35ClN7O (M+H)+ 486.1804, encontrado 486.1787 Usando la Preparación 141, 4–amino–3–cloro–N,N– dimetibenzamida y manipulación del Método H seguido por Método J. 0.043
- 93
- 3–Cloro–N,N–dimetil–4–(2–(1–metil– 1H–RMN (CDCl3, 500MHz): δ 3.09 (s, 6H), 3.93 (s, 0.094
- 1H–pirazol–4–il)–1–(pirimidin–2–il)–1H–
- 3H), 6.70 (d, J = 0.63Hz, 1H), 7.03 (s, 1H, NH), 7.27
- pirrolo[3,2–c]piridin–6–ilamino)etanona
- (t, J = 4.73Hz, 1H), 7.32 (dd, J = 1.89, 8.51 Hz, 1H), 7.33 (d, J = 0.63Hz, 1H), 7.50 (s, 1H), 7.52 (d, J = 1.89Hz, 1H), 7.64 (m, 1H), 8.11 (d, J = 8.51 Hz, 1H), 8.63 (d, J = 0.95Hz, 1H), 8.81 (d, J = 4.73Hz, 2H). HRMS calculado para C24H22 35ClN8O (M+H)+ 473.1600, encontrado 473.1584 Usando la Preparación 142, 4–amino–3–cloro–N,N– dimetibenzamida y el método de purificación J.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 94
- 3–Cloro–N,N–dimetil–4–(2–(1–metil– 1H–RMN (CDCl3, 500MHz): δ 3.08 (s, 6H), 3.88 (s, 0.078
- 1H–pirazol–4–il)–1–(piridin–2–il)–1H–
- 3H), 6.70 (d, J = 0.63Hz, 1H), 6.94 (s, 1H), 7.05 (t, J
- pirrolo[3,2–c]piridin–6–ilamino)etanona
- = 0.95Hz, 1H), 7.15 (d of t, J = 0.95, 7.88Hz, 1H), 7.21 (s, 1H), 7.27 (d, J = 0.63Hz, 1H), 7.29 (dd, J = 1.57, 8.51 Hz, 1H), 7.40 (m, 1H), 7.50 (d, J = 1.89Hz, 1H), 7.82 (t of d, J = 1.89, 7.56Hz), 8.01 (d, J = 8.51 Hz, 1H), 8.65 (d, J = 0.95Hz, 1H), 8.71 (ddd, J = 0.95, 1.89, 4.73Hz, 1H). HRMS calculado para C25H 35ClN O (M+H)+ 472.1647, encontrado 472.1634 Usando la Preparación 143, 4–amino–3–cloro–N,N– dimetibenzamida y el método de purificación J.
- 95
- 3–cloro–6–(2–cloro–4– (dimetilcarbamoil)fenilamino)– 2– (oxazol–5–il)–1H–pirrolo[3,2–c]piridin– 1–carboxilat de tert–butilo o HRMS calculado para C24H24 35Cl2N5O4 (M+H)+ requiere 516.1200, encontrado 516.1198 (tiempo de ret = 3.22min). Producto contaminado con 3–Cloro– 4–(3–cloro– 2–(oxazol–5–il)–1H–pirrolo[3,2– c]piridin–6– ilamino)–N,N–dimetibenzamida. HRMS calculado para C19H 35Cl N O (M+H)+ requiere 416.0676, encontrado 16 2 5 4 416.0676 (tiempo de ret = 2.48min). Usando la Preparación 145 y tomada en crudo. Sin datos
- 96
- 6–(2–metoxifenilamino)– 2–(oxazol–5– il)–1H–pirrolo[3,2– c]piridin–1– carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.50 (s, 9H), 3.92 (s, 3H), 6.80 (d, J = 0.63Hz, 1H), 6.92–7.02 (m, 3H), 7.14 (br s, 1H), 7.30 (s, 1H), 7.70 (t, J = 0.95Hz, 1H), 7.99 (m, 2H), 8.55 (d, J = 0.95Hz, 1H). HRMS calculado para C22H23N4O4 (M+H)+ 407.1714, encontrado 407.1707 Usando la Preparación 140.2– metoxianilina y el método de purificación H. 0.254
- 97
- 6–(2–metoxi–4–(3– metoxiazetidin–1– carbonil)fenilo amino)–2–(oxazol–5–il)– 1H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.50 (s0.9H), 3.34 (s, 3H), 3.98 (s, 3H), 4.15 (s, v br, 2H), 4.27 (m, 1H), 4.45 (s, v br, 2H), 6.82 (d, J = 0.95Hz), 7.22 (dd, J = 1.89, 8.51 Hz, 1H), 7.30 (s, 1H), 7.35 (d, J = 1.89Hz, 1H), 7.40 (br s, 1H, NH), 7.75 (m, 1H), 8.00 (s, 1H), 8.23 (d, J = 8.51 Hz, 1H), 8.60 (d, J = 0.63Hz, 1H). HRMS calculado para C27H30N5O6 (M+H)+ 520.2191, encontrado 520.2186 Usando la Preparación 140, Preparación 62 y el método de purificación L. 0.010
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 98
- 6–(2–cloro–4– (dimetilcarbamoil)fenilamino)– 2– (oxazol–5–il)–1H–pirrolo[3,2–c]piridin– 1–carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.50 (s, 9H), 3.10 (s, 6H), 6.84 (d, J = 0.63Hz, 1H), 7.17 (brs, 1H, NH), 7.37 (dd, J = 1.89, 8.51 Hz, 1H), 7.56 (d, J = 1.89Hz, 1H), 7.77 (s, 1H), 8.01 (s, 1H), 8.21 (d, J = 8.51 Hz, 1H), 8.61 (d, J = 0.95Hz, 1H). HRMS calculado para C24H25ClN5O4 (M+H)+ 482.1590, encontrado 482.1586 Usando la Preparación 140, 4–amino–3– cloro–N,N– dimetibenzamida y el método de purificación M. 0.023
- 99
- 6–(2–metoxifenilamino)– 2–(1– (2,2,2–trifluoroetil)–1H–pirazol– 4– il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.50 (s, 9H), 3.92 (s, 3H), 4.76 (q, J = 8.51 Hz, 2H), 6.53 (d, J = 0.63Hz, 1H), 6.91–7.01 (m, 3H), 7.07 (br s, 1H), 7.68 (s, 1H), 7.69 (s, 1H), 7.70 (d, J = 0.63Hz, 1H), 7.96 (dd, J = 1.89, 7.25Hz, 1H), 8.48 (s, 1H). 19F – RMN (CDCl3, 470.385MHz):–71.61 Usando la Preparación 150, 2–metoxianilina y el método de purificación G. Sin dat os
- 100
- 2–(1–(difluorometil)–1H– pirazol– 4–il)–6–(2–metoxifenilamino)– 1H– pirrolo[3,2–c]piridin–1– carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.50 (s, 9H), 3.92 (s, 3H), 6.57 (d, J = 0.63Hz, 1H), 6.91– 7.01 (m, 3H), 7.09 (s, 1H, NH), 7.24 (t, J = 60.5Hz, 1H), 7.69 (s, 1H), 7.77 (s, 1H), 7.95–8.01 (m, 2H), 8.49 (s, 1H). 19F – RMN (CDCl3, 470.385MHz): δ –93.22 Usando la Preparación 154, 2–metoxianilina y el método de purificación G. Sin dat os
- 101
- 6–(2,4– dimetoxifenilamino)– 2–(1–((5– metilisoxazol–3– il)metil)–1H– pirazol–4–il)–1H– pirrolo[3,2– c]piridin–1– carboxilato de tert–butilo 1H–RMN (500 MHz, CDCl3) 1.45 (s, 9H), 2.41 (s, 3H), 3.82 (s, 3H), 3.85 (s, 3H), 5.36 (s, 2H), 6.01 (s, 1H), 6.46 (s, 1H), 6.50 (m, 2H), 6.55 (s, 1H), 6.62 (s, 1H), 7.41 (s, 1H), 7.62 (s, 1H), 7.69 (s, 1H), 8.39 (s, 1H). Usando la Preparación 34 y el método de purificación N. Sin dat os
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 102
- 6–(2–metoxi–4–(1–metil– 1H–pirazol–4– il)fenilamino)–2–(1– metil–1H–pirazol– 4–il)–1H– pirrolo[3,2–c]piridin–1– carboxilato de isopropilo 1H–RMN (500 MHz, CDCl3): δ 1.33 (d, J=6.3Hz, 6H), 3.95 (s, 3H), 3.96 (s, 3H), 5.18 (sep, J = 6.3 Hz, 1H), 6.51 (s, 1H), 7.01 (d, J = 1.9Hz, 1H), 7.05 (s, 1H), 7.07 (dd, J= 1.9Hz, 8.2Hz, 1H), 7.56 (s, 1H), 7.58 (s, 1H), 7.62 (s, 1H), 7.69 (s, 1H), 7.74 (s, 1H), 7.87 (d, J=8.2Hz, 1H), 8.46 (s, 1H). ESI–HRMS Encontrado 486.226, calculado para C26H28N7O3 (M+H+): 486.2248 Usando la Preparación 155, Preparación 26 y el método de purificación F. 0.007
- 103
- 6–(4–(1,3–dimetil–1H– pirazol–4–il)–2– metoxifenilamino)–2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2– c]piridin– 1–carboxilato de isopropilo 1H–RMN (500 MHz, CDCl3): δ 1.34 (d, J=6.3Hz, 6H), 2.42 (s, 3H), 3.89 (s, 3H), 3.94 (s, 3H), 3.96 (s, 3H), 5.18 (sep, J = 6.3 Hz, 1H), 6.51 (s, 1H), 6.93 (d, J = 1.8Hz, 1H), 6.98 (dd, J= 1.9Hz, 8.2Hz, 1H), 7.05 (s, 1H), 7.42 (s, 1H), 7.57 (s, 1H), 7.63 (s, 1H), 7.71 (s, 1H), 7.9 (d, J=8.2Hz, 1H), 8.46 (s, 1H). ESI–HRMS Encontrado 500.2389, calculado para C27H30N7O3 (M+H+): 500.2405 Usando la Preparación 156, Preparación 26 y el método de purificación F. 0.002
- 104
- N–(2–Cloro–4–(1,2–dimetil–1H– 1H–RMN (CDCl3, 500MHz): δ 2.46 (s, 3H), 3.32 (s, 0.083
- imidazol–5–il)fenil)–1–(2–metoxietil)–2–
- 3H), 3.54 (s, 3H), 3.71 (t, J = 5.68Hz, 2H), 4.02 (s,
- (1–metil–1H–pirazol–4–il)–1H–
- 3H), 4.27 (t, J = 5.68Hz, 2H), 6.52 (d, J = 0.63Hz,
- pirrolo[3,2–c]piridin–6–amina
- 1H), 6.94 (s, 1H), 6.98 (s, 1H), 6.99 (br s, 1H, NH), 7.20 (dd, J = 2.21, 8.51 Hz, 1H), 7.39 (d, J = 2.21 Hz, 1H), 7.68 (s, 1H), 7.73 (d, J = 0.95Hz, 1H), 7.97 (d, J = 8.51 Hz, 1H), 8.59 (d, J = 0.95Hz, 1H). HRMS calculado para C25H27 35ClN7O (M+H)+ 476.1960, encontrado 476.1949 Usando la Preparación 157, Preparación 124 y el método de purificación O.
- 105
- N–(2–Cloro–4–(1,2–dimetil–1H– 1H–RMN (d6–DMSO, 500MHz): δ 0.29 (m, 2H), 0.43 0.029
- imidazol–5–il)fenil)–1–(ciclopropilmetil)–
- (m, 2H), 1.10 (m, 1H), 2.34 (s, 3H), 3.52 (s, 3H), 3.93
- 2–(1–metil–1H–pirazol–4–il)–1H–
- (s, 3H), 4.08 (d, J = 6.62Hz, 2H), 6.54 (s, 1H), 6.84
- pirrolo[3,2–c]piridin–6–amina
- (s, 1H), 7.24 (s, 1H), 7.27 (dd, J = 1.89, 8.51 Hz, 1H), 7.44 (d, J = 1.89Hz, 1H), 7.79 (s, 1H), 8.04 (s, 1H), 8.12 (s, 1H), 8.20 (d, J = 8.51 Hz, 1H), 8.46 (s, 1H). HRMS calculado para C26H27 35ClN7 (M+H)+ 472.2011, encontrado 472.2001 Usando la Preparación 158, Preparación 124 y el método de purificación O seguido por Método P.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 106
- 6–(2–cloro–4–(1,2–dimetil–1 H– imidazol–5–il)fenilamino)–2–(oxazol–5– il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de isopropilo 1H–RMN (CDCl3, 500MHz): δ 1.30 (d, J = 6.31 Hz, 6H), 2.47 (s, 3H), 3.56 (s, 3H), 5.19 (sept, J = 6.31 Hz, 1H), 6.88 (d, J = 0.63Hz, 1H), 6.96 (s, 1H), 7.12 (s, 1H), 7.26 (dd, J = 1.89, 8.51 Hz, 1H), 7.34 (s, 1H), 7.43 (d, J = 2.21 Hz, 1H), 7.79 (s, 1H), 8.01 (s, 1H), 8.16 (d, J = 8.51 Hz, 1H), 8.61 (d, J = 0.95Hz, 1H). HRMS calculado para C25H24 35ClN6O3 (M+H)+ 491.1593, encontrado 491.1587 Usando la Preparación 162, Preparación 124 y el método de purificación Q. 0.002
- 107
- 6–(2–cloro–4–(1,2–dimetil–1H– imidazol–5–il)fenilamino)–2–(oxazol–5– il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de tert–butilo 1H–RMN (CDCl3, 500MHz): δ 1.50 (s, 9H), 2.47 (s, 3H), 3.56 (s, 3H), 6.84 (d, J = 0.63Hz, 1H), 6.96 (s, 1H), 7.11 (s, 1H), 7.26 (dd, J = 1.89, 8.20Hz, 1H), 7.32 (s, 1H), 7.42 (d, J = 1.89Hz, 1H), 7.75 (s, 1H), 8.01 (s, 1H), 8.20 (d, J = 8.83Hz, 1H), 8.60 (d, J = 0.95Hz, 1H). HRMS calculado para C26H26 35ClN6O3 (M+H)+ 505.1750, encontrado 505.1739 Usando la Preparación 140, Preparación 124 y el método de purificación Q. 0.002
- 108
- 6–(4–(1,2–dimetil–1H–imidazol–5– il)fenilamino)–2–(1–metil–1H–pirazol–4– il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de isopropilo 1H–RMN (500MHz, CDCl3): δ 1.32 (d, J = 6.3 Hz, 6H), 2.46 (s, 3H), 3.54 (s, 3H), 3.97 (s, 3H), 5.18 (sept, J = 6.3 Hz, 1H), 6.53 (d, J = 0.9 Hz, 1H), 6.90 (s, 1H), 6.93 (s, 1H), 7.30–7.34 (m, 2H), 7.41–7.45 (m, 2H), 7.58 (d, J = 0.8 Hz, 1H), 7.63 (d, J = 0.8 Hz, 1H), 7.72 (t, J = 0.9 Hz, 1H), 8.46 (d, J = 0.9 Hz, 1H); ESI–HRMS (Método B) Encontrado 470.2294, calculado para C26H28N7O2 (M+H+): 470.2299. Usando la Preparación 26, Preparación 162 y el método de purificación F seguido por Método R. 0.002
- 109
- 6–(4–metoxi–2–(1–metil–1H–pirazol–4– il)pirimidin–5–ilamino)–2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1– carboxilato de isopropilo 1H–RMN (500MHz, CDCl3) d 1.33 (d, J = 6.3 Hz, 6H), 3.97 (s, 3H), 3.97 (s, 3H), 4.14 (s, 3H), 5.17 (sept, J = 6.3 Hz, 1H), 6.51 (d, J = 0.8 Hz, 1H), 6.73 (s, 1H), 7.55 (d, J = 0.8 Hz, 1H), 7.59 (t, J = 0.8 Hz, 1H), 7.61 (d, J = 0.8 Hz, 1H), 8.01 (s, 1H), 8.12 (s, 1H), 8.47 (d, J = 0.9 Hz, 1H), 9.34 (s, 1H); ESI– HRMS (Método B) Encontrado 488.2165, calculado para C24H26N9O3 (M+H+): 488.2153. Usando la Preparación 26, Preparación 119 y el método de purificación S. 0.014
Ejemplo 110
3–Cloro–4–(1–(ciclopentilsulfonil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N– dimetibenzamida
106
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 112
- N–(2–Metoxipiridin–3–il)–2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6– amina 1H–RMN (500 MHz, CD3OD): δ 3.94 (s, 3H), 4.03 (s, 3H), 6.56 (d, J = 0.8Hz, 1H), 6.88 (dd, J = 7.8, 5.0Hz, 1H), 6.99 (s, 1H), 7.62 (dd, J = 5.0, 1.6Hz, 1H), 7.85 (s, 1H), 7.93 (s, 1H), 7.97 (dd, J = 7.8, 1.6Hz, 1H), 8.39 (d, J = 0.8Hz, 1H). ESI–HRMS Encontrado 321.1452, calculado para C17H17N6O [M+H]+: 321.1458. Usando el Ejemplo 2. 0.021
- 113
- N,N–Dimetil–4–(2–(1–metil–1H– pirazol– 4–il)–1H–pirrolo[3,2–c]piridin–6– ilamino)– 3–(trifluorometoxi)etanona 1H–RMN (500 MHz, CD3OD): δ 3.09 (s, 6H), 3.94 (s, 3H), 6.61 (d, J = 0.9Hz, 1H), 7.10 (t, J = 0.9Hz, 1H), 7.32 (dd, J = 8.6, 2.0Hz, 1H), 7.40–7.42 (m, 1H), 7.74 (d, J = 8.6Hz, 1H), 7.87 (s, 1H), 7.97 (s, 1H), 8.44 (d, J = 0.9Hz, 1H). ESI–HRMS Encontrado 445.1604, calculado para C21H20F3N6O2 [M+H]+: 445.1594. Usando el Ejemplo 3. 0.068
- 114
- 4–Metoxi–N,N–dimetil–3–(2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6– ilamino)etanona 1H–RMN (500 MHz, CD3OD): δ 3.06 (s, 6H), 3.92 (s, 3H), 3.94 (s, 3H), 6.54 (d, J = 0.9Hz, 1H), 6.96 (dd, J = 8.3, 2.0Hz, 1H), 7.00 (d, J = 8.3Hz, 1H), 7.02 (d, J = 0.9Hz, 1H), 7.72 (d, J = 2.0Hz, 1H), 7.83 (s, 1H), 7.91 (s, 1H), 8.36 (d, J = 0.9Hz, 1H). ESI–HRMS Encontrado 391.1884, calculado para C21H23N6O2 [M+H]+: 391.1877. Usando el Ejemplo 4. 0.497
- 115
- (3–Metoxi–4–(2–(1–metil–1H–pirazol–4– il)–1H–pirrolo[3,2–c]piridin–6– ilamino)fenil)(tiomorfolino)metanona–S,S– dióxido 1H–RMN (500 MHz, CD3OD): δ 3.21–3.26 (m, 4H), 3.96 (s, 3H), 3.99 (s, 3H), 4.09–4.15 (m, 4H), 6.61 (d, J = 0.9Hz, 1H), 7.08 (dd, J = 8.2, 1.9Hz, 1H), 7.10 (m, 1H), 7.16 (d, J = 1.9Hz, 1H), 7.71 (d, J = 8.2Hz, 1H), 7.87 (s, 1H), 7.99 (s, 1H), 8.42 (d, J = 0.9Hz, 1H). ESI–HRMS Encontrado 481.01639, calculado para C23H25N6O4S [M+H]+: 481.1653. Usando el Ejemplo 5 y el método de purificación A. 0.007
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 116
- N–(2–Metoxi–4–(tiomorfolinometil)fenil)–2– 1H–RMN (500 MHz, CD3OD): δ 2.98–3.02 (m, 0.010
- (1– metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 4H), 3.11–3.15 (m, 4H), 3.66 (s, 2H), 3.93 (s, 3H),
- c]piridin–6–amina–S,S–dióxido
- 3.95 (s, 3H), 6.57 (d, J = 0.9Hz, 1H), 6.89 (dd, J = 8.1, 1.8Hz, 1H), 7.00 (m, 1H), 7.03 (d, J = 1.8Hz, 1H), 7.50 (d, J = 8.1Hz, 1H), 7.84 (s, 1H), 7.96 (s, 1H), 8.34 (d, J = 0.9Hz, 1H). ESI–HRMS Encontrado 467.1852, calculado para C23H27N6O3S [M+H]+: 467.1860. Usando el Ejemplo 6 y el método de purificación A.
- 117
- 3–Cloro–N,N–dimetil–4–(2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6– ilamino)bencenosulfonamida 1H–RMN (500 MHz, CD3OD): δ 2.68 (s, 6H), 3.96 (s, 3H), 6.67 (d, J = 0.9Hz, 1H), 7.19 (t, J = 0.9Hz, 1H), 7.53 (dd, J = 8.8, 2.2Hz, 1H), 7.68 (d, J = 8.8Hz, 1H), 7.75 (d, J = 2.2Hz, 1H), 7.88 (s, 1H), 8.01 (s, 1H), 8.50 (d, J = 0.9Hz, 1H). ESI–HRMS Encontrado 431.1042, calculado para C19H20ClN6O2S [M+H]+: 431.1051. Usando el Ejemplo 8. 0.026
- 118
- (3–Metoxi–4–(2–(1–metil–1H–pirazol–4– il)–1H–pirrolo[3,2–c]piridin–6– ilamino)fenil)(morfolino)m etanona 1H–RMN (500 MHz, CD3OD): δ 3.66–3.76 (m, 8H), 3.94 (s, 3H), 3.95 (s, 3H), 6.58 (d, J = 0.8Hz, 1H), 6.99 (dd, J = 8.2, 1.8Hz, 1H), 7.06 (s, 1H), 7.07 (d, J = 1.8Hz, 1H), 7.67 (d, J = 8.2Hz, 1H), 7.86 (s, 1H), 7.95 (s, 1H), 8.40 (d, J = 0.8Hz, 1H). ESI– HRMS Encontrado 433.1975, calculado para C23H25N6O3 [M+H]+: 433.1983. Usando el Ejemplo 10. 0.012
- 119
- 3–Metoxi–N–(2–metoxietil)–4–(2–(1– 1H–RMN (500 MHz, CD3OD): δ 3.40 (s, 3H), 3.57– 0.019
- metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 3.59 (m, 4H), 3.94 (s, 3H), 3.98 (s, 3H), 6.58 (d, J
- c]piridin–6–ilamino)etanona
- = 0.8Hz, 1H), 7.06 (t, J = 0.8Hz, 1H), 7.43 (dd, J = 8.4, 1.9Hz, 1H), 7.48 (d, J = 1.9Hz, 1H), 7.66 (d, J = 8.4Hz, 1H), 7.85 (s, 1H), 7.94 (s, 1H), 8.41 (d, J = 0.9Hz, 1H). ESI–HRMS Encontrado 421.1985, calculado para C22H25N6O3 [M+H]+: 421.1983. Usando el Ejemplo 11.
- 120
- (3–Metoxi–4–(2–(1–metil–1H–pirazol–4– il)–1H–pirrolo[3,2–c]piridin–6– ilamino)fenil)(3–metoxiazetidin–1– il)metanona 1H–RMN (500 MHz, CD3OD): δ 3.35 (s, 3H), 3.97 (s, 3H), 4.00 (s, 3H), 3.95–4.03 (m, 1H), 4.25–4.40 (m, 3H), 4.58–4.65 (m, 1H), 6.63 (s, 1H), 7.12 (s, 1H), 7.24 (dd, J = 8.4, 1.8Hz, 1H), 7.31 (d, J = 1.8Hz, 1H), 7.68 (d, J = 8.4Hz, 1H), 7.88 (s, 1H), 8.00 (s, 1H), 8.44 (s, 1H). ESI–HRMS Encontrado 433.1980, calculado para C23H25N6O3 [M+H]+: 433.1983. Usando el Ejemplo 12. 0.007
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 121
- 3,5–Dicloro–N,N–dimetil–4–(2–(1– metil– 1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin– 6–ilamino)etanona 1H–RMN (500 MHz, CD3OD): δ 3.10 (br s, 3H), 3.12 (br s, 3H), 3.95 (s, 3H), 6.57 (d, J = 0.9Hz, 1H), 6.60 (t, J = 0.9Hz, 1H), 7.54 (s, 2H), 7.85 (d, J = 0.8Hz, 1H), 7.96 (d, J = 0.8Hz, 1H), 8.27 (d, J = 0.9Hz, 1H). ESI–HRMS Encontrado 429.0986, calculado para C20H19Cl2N6O [M+H]+: 429.0992. Usando el Ejemplo 13. 0.091
- 122
- N–(2–Clorofenil)–2–(1–metil–1H– pirazol– 4–il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (500 MHz, CD3OD): δ 3.95 (s, 3H), 6.60 (d, J = 0.9Hz, 1H), 6.90 (ddd, J = 8.0, 7.4, 1.5Hz, 1H), 7.00 (t, J = 0.9Hz, 1H), 7.18–7.23 (m, 1H), 7.40 (dd, J = 8.0, 1.5Hz, 1H), 7.54 (dd, J = 8.2, 1.5Hz, 1H), 7.85 (s, 1H), 7.96 (s, 1H), 8.39 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 324.1007, calculado para C17H15ClN5 [M+H]+: 324.1010. Usando el Ejemplo 14. 0.078
- 123
- N–(2–Clorofenil)–2–(1–metil–1H– pirazol– 4–il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (500 MHz, CD3OD): δ 3.90 (s, 3H), 3.93 (s, 3H), 6.57 (s, 1H), 6.97 (s, 1H), 7.35 (dd, J = 8.5, 1.9Hz, 1H), 7.53 (d, J = 8.5Hz, 1H), 7.58 (d, J = 1.9Hz, 1H), 7.75 (s, 1H), 7.84 (s, 1H), 7.86 (s, 1H), 7.93 (s, 1H), 8.37 (s, 1H). ESI–HRMS (Método B) Encontrado 404.1377, calculado para C21H19ClN7 [M+H]+: 404.1385. Usando el Ejemplo 15. 0.018
- 124
- N–(2–Cloro–4–(1–metil–1H–pirazol–3– 1H–RMN (500 MHz, CD3OD): δ 3.93 (s, 3H), 3.96 0.052
- il)fenil)–2–(1–metil–1H–pirazol–4–il)– 1H–
- (s, 3H), 6.57 (d, J = 2.3Hz, 1H), 6.61 (d, J = 0.9Hz,
- pirrolo[3,2–c]piridin–6–amina
- 1H), 7.05 (t, J = 0.9Hz, 1H), 7.59 (d, J = 2.3Hz, 1H), 7.59–7.60 (m, 2H), 7.83 (dd, J = 1.5, 0.9Hz, 1H), 7.87 (s, 1H), 7.97 (s, 1H), 8.42 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 404.1376, calculado para C21H19ClN7 [M+H]+: 404.1385. Usando el Ejemplo 16.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50 (µM)
- 125
- N–(2–Cloro–4–(1–metil–1H–imidazol–5– 1H–RMN (500 MHz, CD3OD): δ 3.71 (s, 3H), 3.96 0.004
- il)fenil)–2–(1–metil–1H–pirazol–4–il)– 1H–
- (s, 3H), 6.62 (d, J = 0.9Hz, 1H), 7.01 (br s, 1H),
- pirrolo[3,2–c]piridin–6–amina
- 7.09 (t, J = 0.9Hz, 1H), 7.27 (dd, J = 8.5, 2.0Hz, 1H), 7.49 (d, J = 2.0Hz, 1H), 7.66 (d, J = 8.5Hz, 1H), 7.68 (br s, 1H), 7.87 (s, 1H), 7.98 (s, 1H), 8.43 (d, J = 0.9Hz, 1H). ESI–HRMS (Método B) Encontrado 404.1373, calculado para C21H19ClN7 [M+H]+: 404.1385. Usando el Ejemplo 17.
- 126
- N–(3,4–dimetoxifenil)–1–metil– 2–(1H– pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6– amina 1H–RMN (500 MHz, CD3OD): δ 3.68 (s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 6.54 (d, J = 0.9 Hz, 1H), 6.79 (s, 1H), 6.88 (dd, J = 8.6, 2.4 Hz, 1H), 6.92 (d, J = 8.6 Hz, 1H), 7.02 (d, J = 2.4 Hz, 1H), 7.92 (br s, 2H), 8.34 (d, J = 0.9 Hz, 1H). ESI–HRMS Encontrado 350.1620, calculado para C19H20N5O2 [M+H]+: 350.1612. Usando la Preparación 55. 0.026
- 127
- 3–cloro–N,N–dimetil–4–(2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6– ilamino)etanona 1H–RMN (500 MHz, CD3OD): δ 3.08 (s, 6H), 3.95 (s, 3H), 6.62 (s, 1H), 7.10 (s, 1H), 7.27 (dd, J = 8.5, 2.0 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.86 (s, 1H), 7.97 (s, 1H), 8.44 (s, 1H). ESI–HRMS Encontrado 395.1370, calculado para C20H20ClN6O [M+H]+: 395.1382. Usando el Ejemplo 7. 0.014
- 128
- 3–metoxi–N,N–dimetil–4–(2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6– ilamino)etanona 1H–RMN (500 MHz, CD3OD): δ 3.11 (s, 6H), 3.95 (s, 3H), 3.96 (s, 3H), 6.59 (d, J = 0.8 Hz, 1H), 7.01 (dd, J = 8.2, 1.8 Hz, 1H), 7.06–7.09 (m, 2H), 7.65 (d, J = 8.2 Hz, 1H), 7.85 (s, 1H), 7.95 (s, 1H), 8.40 (d, J = 0.8 Hz, 1H). ESI–HRMS Encontrado 391.1873, calculado para C21H23N6O2 [M+H]+: 391.1877. Usando el Ejemplo 61. 0.024
Método N: Columna de Si–carbonato Isolute eluyendo con metanol seguido por TLC preparativa eluyendo con 7% MeOH en EtOAc.
Método O: Manipular usando EtOAc seguido por TLC preparativa eluyendo con 10/1 EtOAc/amoniaco 2M en MeOH a 20/1 EtOH/amoniaco 2M en MeOH.
Método P: Columna Isolute Flash NH2 SPE eluyendo con MeOH.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 130
- N–(2–Cloro–4–fluorofenil)–2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–amina 1H–RMN (500 MHz, d6–DMSO): δ 3.88 (s, 3H), 6.5 (s, 1H), 6.97 (s, 1H), 7.16 (m, 1H), 7.42 (m, 1H), 7.86 (m, 2H), 7.95 (m, 1H), 8.07 (s, 1H), 8.36 (s, 1H), 11.3 (s, 1H). ESI–HRMS Encontrado 342.0958 calculado para C19H15ClN8 [M+H]+: 342.0916 Usando el Ejemplo 27 y el método de purificación A. 0.51
- 131
- N–(2–Cloro–4–(metisulfonil)fenil)–2–(1– metil– 1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6– amina 1H–RMN (500 MHz, d6–DMSO): δ 3.18 (s, 3H), 3.9 (s, 3H), 6.6 (s, 1H), 7.23 (s, 1H), 7.67 (d, J=8.9Hz, 1H), 7.86 (s, 1H), 7.91 (s, 1H), 8.13 (s, 1H), 8.22 (d, J=8.9Hz, 1H), 8.48 (s, 1H), 8.51 (s, 1H), 11.58 (s, 1H); ESI–HRMS Encontrado 402.0729, calculado para C18H16ClN5O2S[M+H]+: 342.0786 Usando el Ejemplo 28 y el método de purificación A. 0.024
- 132
- N–(2–Cloro–4–(difluorometoxi)fenil)–2–(1– 1H–RMN (500 MHz, CDCl3): δ 3.94 (s, 3H), 0.288
- metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 6.44 (t, J=74Hz, 1H), 6.52 (s, 1H), 6.58 (s,
- c]piridin–6–amina
- 1H), 6.9 (s, 1H), 6.95 (dd, J=2.7Hz, 9Hz, 1H), 7.2 (d, J= 2.7Hz, 1H), 7.78 (m, 3H), 8.53 (s, 1H), 9.49 (s, 1H). ESI–HRMS Encontrado 390.0935, calculado para C18H15ClF2N5O [M+H]+: 390.0928 Usando el Ejemplo 29 y el método de purificación A.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 133
- 3–Metoxi–N–metil–4–(2–(1–metil–1H– pirazol– 4–il)–1H–pirrolo[3,2–c]piridin–6– ilamino)etanona 1H–RMN (500 MHz, d6–DMSO): δ 2.78 (d, J=4.5Hz, 3H), 3.89 (s, 3H), 3.98 (s, 3H), 6.54 (s, 1H), 7.09 (s, 1H), 7.39 (s, 1H), 7.41 (s, 1H), 7.45 (m, 1H), 7.89 (s, 1H), 8.1 (s, 1H), 8.15 (s, br, 1H), 8.26 (s, br, 1H), 8.42 (s, 1H), 11.4 (s, 1H). ESI–HRMS Encontrado 377.1232 calculado para C20H20N6O2 [M+H]+: 377.1235 Usando el Ejemplo 30 y el método de purificación B. 0.027
- 134
- 3–Cloro–N–metil–4–(2–(1–metil–1H– pirazol– 4–il)–1H–pirrolo[3,2–c]piridin–6– ilamino)etanona 1H–RMN (500 MHz, d6–DMSO): δ 3.16 (d, J=5Hz, 3H), 3.89 (s, 3H), 4.1 (q, br, 1H), 6.57 (s, 1H), 7.14 (s, 1H), 7.7 (dd, J= 2Hz, 8.1Hz, 1H), 7.88 (m, 2H), 8.08 (m, 1H), 8.15 (s, 1H), 8.3 (s, br, 1H), 8.44 (s, 1H), 11.5 (s, 1H). ESI–HRMS Encontrado 381.0713 calculado para C19H17ClN6O [M+H]+: 381.0711. Usando el Ejemplo 31 y el método de purificación C. 0.020
- 135
- 2–(4–(6–(2,4–Dimetoxifenilamino)–1H– pirrolo[3,2–c]piridin–2–il)–1H–pirazol–1– il)– N,N–dimetilacetamida 1H–RMN (500 MHz, d6–DMSO): δ 2.86 (s, 1H), 2.94 (s, 3H), 3.74 (s, 3H), 3.81 (s, 3H), 5.15 (s, 2H), 6.48 (s, 1H), 6.5 (s, 1H), 6.62 (d, J= 2.7Hz, 1H), 6.66 (s, 1H), 7.22 (s, 1H), 7.72 (d, J= 8.7Hz, 1H), 7.84 (s, 1H), 8 (s, 1H), 8.28 (s, 1H), 11.2 (s, 1H). ESI– HRMS Encontrado 421.1959 calculado para C22H24N6O3 [M+H]+: 421.1983 Usando el Ejemplo 69 y el método de purificación C. 0.821
- 136
- 1–(3–cloro–4–((2–(1–metil–1H–pirazol–4–il)– 1H–RMN (500 MHz, d5–DMSO): δ 2.04 (m, 0.018
- 1H–pirrolo[3,2–c]piridin–6–
- 2H), 2.47 (t, J= 8.3Hz, 2H), 3.82 (t, J= 7Hz,
- il)amino)fenil)pirrolidin–2–ona
- 2H), 3.88 (s, 3H), 6.52 (s, 1H), 6.89 (s, 1H), 7.1 (m, 1H), 7.42 (d, J=9Hz, 1H), 7.86 (m, 2H), 7.9 (d, J=9Hz, 1H), 8.08 (s, 1H), 8.35(s, 1H), 11.35 (s, 1H). ESI–HRMS Encontrado 407.1371 calculado para C21H19ClN6O [M+H]+: 407.1382 Usando el Ejemplo 32 y el método de purificación C.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 137
- N–(2–metoxi–4–(pirrolidin–1– ilmetil)fenil)–2– 1H–RMN (500 MHz, d6–DMSO): δ 1.68 (t, 0.025
- (1–metil–1H–pirazol–4– il)–1H–pirrolo[3,2–
- J=3.3Hz, 4H), 2.43 (s, br, 4H), 3.5 (s, 2H),
- c]piridin–6–amina
- 3.84 (s, 3H), 3.88 (s, 3H), 6.48 (s, 1H), 6.8 (d, J=8.1 Hz, 1H), 6.9 (m, 2H), 7.46 (s, 1H), 7.85 (s, 1H), 7.94 (d, J = 8.1 Hz, 1H), 8.06 (s, 1H), 8.34 (s, 1H), 11.25 (s, 1H). ESI– HRMS Encontrado 403.2236 calculado para C28H34N6O3 [M+H]+: 403.2241 Usando el Ejemplo 33 y el método de purificación C
- 138
- N–(2–metoxi–4–((metilamino)metil)fenil)–2–(1– 1H–RMN (500 MHz, d6–DMSO): δ 2.15 (s, 0.031
- metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- br, 1H), 2.27 (s, 3H), 3.57 (s, 2H), 3.84 (s,
- c]piridin–6–amina
- 3H), 3.88 (s, 3H), 6.48 (s, 1H), 6.8 (d, J=8Hz, 1H), 6.88 (s, 1H), 6.95 (d, J=1.4Hz, 1H), 7.43 (s, 1H), 7.85 (s, 1H), 7.92 (d, J = 8 Hz, 1H), 8.06 (s, 1H), 8.33 (s, 1H), 11.2 (s, 1H). ESI–HRMS Encontrado 363.1924, calculado para C20H22N6O [M+H]+: 363.1928. Usando el Ejemplo 34 y el método de purificación C.
- 139
- N–(4–((dimetilamino)metil)–2–metoxifenil)–2– 1H–RMN (500 MHz, d6–DMSO): δ 2.35 (s, 0.055
- (1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- br, 6H), 3.6 (s, br, 2H), 3.86 (s, 3H), 3.88
- c]piridin–6–amina
- (s, 3H), 6.47 (s, 1H), 6.55 (s, 1H), 6.82 (s, 1H), 6.95 (m, 2H), 7.64 (s, 1H), 7.85 (s, 1H), 8.1 (m, 2H), 8.36 (s, 1H), 11.25 (s, 1H). ESI–HRMS Encontrado 377.2078, calculado para C21H24N6O [M+H]+: 377.2084 Usando el Ejemplo 35 y el método de purificación D.
- 140
- N–(4–(Aminometil)–2–metoxifenil)–2–(1–metil– 1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (500 MHz, d6–DMSO): δ 3.66 (s, 2H), 3.85 (s, 3H), 3.88 (s, 3H), 6.48 (s, 1H), 6.8 (d, J=8.2Hz, 1H), 6.87 (s, 1H), 7 (s, 1H), 7.41 (s, 1H), 7.85 (s, 1H), 7.9 (d, J=8.1Hz, 1H), 8.06 (s, 1H), 8.33 (s, 1H), 11.25 (s, 1H). ESI–HRMS Encontrado 371.1594, calculado para C19H20N6O [M+H]+: 371.1591 Usando la Preparación 131 y el método de purificación C. 0.043
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 141
- 2–(3–(2–(1–Metil–1H–pirazol–4–il)–1H– pirrolo[3,2–c]piridin–6–ilamino)fenoxi) acetonitrilo 1H–RMN (500 MHz, d6–DMSO): δ 3.89 (s, 3H), 5.1 (s, 2H), 6.51 (m, 2H), 6.8 (s, 1H), 7.17 (m, 2H), 7.48 (s, 1H), 7.86 (s, 1H), 8.07(s, 1H), 8.39 (s, 1H), 8.73 (s, 1H), 11.3 (s, 1H). ESI–HRMS Encontrado 345.1984, calculado para C19H16N6O [M+H]+: 345.1983 Usando el Ejemplo 36 y el método de purificación C. 0.132
- 142
- (3–Cloro–4–(2–(1–metil–1H–pirazol–4–il)–1H– 1H–RMN (500 MHz, d6–DMSO): δ 3.22 (s, 0.010
- pirrolo[3,2–c]piridin–6–ilamino)fenil)(3–
- 3H), 3.89 (s, 3H), 4.23 (m, 4H), 4.5 (s, br,,
- metoxiazetidin–1–il)metanona
- 1H), 6.57(s, 1H), 7.16 (s, 1H), 7.49 (dd, J =2.1Hz, 8.4 Hz, 1H), 7.65 (d, J=2.1Hz, 1H), 7.9 (s, 1H), 8.11 (s, 1H), 8.13 (d, J=2.1Hz, 1H), 8.21 (s, 1H), 8.44 (s, 1H), 11.55 (s, 1H). ESI–HRMS Encontrado 437.1757, calculado para C22H21ClN6O2 [M+H]+: 437.1772 Usando el Ejemplo 37 y el método de purificación C.
- 143
- (3–Cloro–4–(2–(1–metil–1H–pirazol–4–il)–1H– pirrolo[3,2–c]piridin–6–ilamino)fenil)(S,S– dioxo–tiomorfolino)metanona 1H–RMN (500 MHz, d6–DMSO): δ 3.22 (s, 3H), 3.89 (s, 3H), 4.23 (m, 4H), 4.5 (s, br,, 1H), 6.57(s, 1H), 7.16 (s, 1H), 7.49 (dd, J =2.1Hz, 8.4 Hz, 1H), 7.65 (d, J=2.1Hz, 1H), 7.9 (s, 1H), 8.11 (s, 1H), 8.13 (d, J=2.1Hz, 1H), 8.21 (s, 1H), 8.44 (s, 1H), 11.55 (s, 1H). ESI–HRMS Encontrado 437.1757, calculado para C22H21ClN6O2 [M+H]+: 437.1772 Usando el Ejemplo 38 y el método de purificación C. 0.006
- 144
- 3–Cloro–N–etil–N–metil–4–(2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6– ilamino)etanona 1H–RMN (500 MHz, d6–DMSO): δ 1.1 (t, J=7.1Hz, 3H), 2.94 (s, 3H), 3.37 (q, J=7.1Hz, 2H), 3.89 (s, 3H), 6.56 (s, 1H), 7.1 (s, 1H), 7.24 (d, J = 8.3 Hz, 1H), 7.42 (s, 1H), 7.89 (s, 1H), 8.08 (m, 3H), 8.42 (s, 1H), 11.45 (s, 1H). ESI–HRMS Encontrado 409.1537 calculado para C21H21ClN6O [M+H]+: 409.1538 Usando el Ejemplo 39 y el método de purificación C. 0.011
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 145
- (3–Cloro–4–(2–(1–metil–1H–pirazol–4–il)– 1H– 1H–RMN (500 MHz, d6–DMSO): δ 1.83(s, 0.012
- pirrolo[3,2–c]piridin–6– ilamino)fenil)(pirrolidin–
- br, 4H), 3.45 (s, br, 4H), 3.89(s, 3H), 6.56
- 1–il)metanona
- (s, 1H), 7.12 (s, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.56 (s, 1H), 7.89 (s, 1H), 8.1 (m, 3H), 8.43 (s, 1H), 11.5 (s, 1H). ESI–HRMS Encontrado 421.1535 calculado para C22H21ClN6O [M+H]+: 421.1538 Usando el Ejemplo 40 y el método de purificación C.
- 146
- (3–Cloro–4–(2–(1–metil–1H–pirazol–4–il)– 1H– 1H–RMN (500 MHz, d6–DMSO): δ 2.16 (s, 0.020
- pirrolo[3,2–c]piridin–6– ilamino)fenil)(4–
- 3H), 2.31 (s, br, 4H), 3.5 (s, br,, 4H), 3.89
- metipiperazin–1–il) metanona
- (s, 3H), 6.56 (s, 1H), 7.11 (s, 1H), 7.23 (m, 2H), 7.43 (s, 1H), 7.89 (s, 1H), 8.09 (m, 2H), 8.42(s, 1H), 8.5 (s, 1H), 11.5 (s, 1H); ESI–HRMS Encontrado 450.1888 calculado para C23H24ClN7O [M+H]+: 450.1881 Usando el Ejemplo 41 y el método de purificación C.
- 147
- (3–Cloro–4–(2–(1–metil–1H–pirazol–4–il)– 1H– 1H–RMN (500 MHz, d6–DMSO): δ 1.46 0.012
- pirrolo[3,2–c]piridin–6– ilamino)fenil)(4–
- (s,br, 2H), 1.85 (s, br,, 2H), 3.26 (s, br, 4H),
- metoxipiperidin–1– il)metanona
- 3.29 (s, 3H), 3.46 (s, br,1H), 3.9 (s, 3H), 6.57 (s, 1H), 7.11 (s, 1H), 7.43 (d, J= 1.9Hz, 1H), 7.89 (s, 1H), 8.1 (m, 3H), 8.42 (s, 1H), 11.5 (s, 1H).ESI–HRMS (Método D) Encontrado 465.1789 calculado para C24H25ClN6O2 [M+H]+: 465.18 Usando el Ejemplo 42 y el método de purificación C.
- 148
- (3–Cloro–4–(2–(1–metil–1H–pirazol–4–il)– 1H– 1H–RMN (500 MHz, d6–DMSO): δ 1.35 (m, 0.020
- pirrolo[3,2–c]piridin–6–ilamino)fenil)(4–
- 2H), 1.75 (s, br, 2H), 2.16 (s, 6H), 2.32 (t,
- (dimetilamino)piperidin– 1–il)metanona
- J=7Hz, 1H), 2.9 (s, br, 2H), 3.9 (s, 3H), 4.05 (s, br, 2H), 6.57 (s, 1H), 7.11 (s, 1H), 7.28 (d, J=8.2Hz, 1H), 7.43 (d, J=2Hz,1H), 7.89 (s, 1H), 8.09 (m, 3H), 8.42 (s, 1H), 11.45 (s, 1H). ESI–HRMS Encontrado 478.2099, calculado para C25H28ClN7O [M+H]+: 478.2117 Usando el Ejemplo 43 y el método de purificación C.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 149
- N–(2–Cloro–4–(1–metil–1H–pirazol–5– 1H–RMN (500 MHz, d6–DMSO): δ 3.87 (s, 0.022
- il)fenil)–2–(1–metil–1H–pirazol–4–il)–1H–
- 3H), 3.9 (s, 3H), 6.39 (d, J=1.8Hz, 1H),
- pirrolo[3,2–c]piridin–6–amina
- 6.56 (s, 1H), 7.44(d, J=1.9Hz, 1H), 7.56 (s, 1H), 7.89 (s, 1H), 8.09 (s, 1H), 8.11 (s, 1H), 8.16 (d, J=8.6Hz, 1H), 8.42 (s, 1H), 11.45 (s, 1H).ESI–HRMS Encontrado 404.1375 calculado para C21H18ClN7 [M+H]+: 404.1385 Usando el Ejemplo 44 y el método de purificación C.
- 150
- N–(2–Cloro–4–(2,4–dimetiltiazol–5– il)fenil)–2– 1H–RMN (500 MHz, d6–DMSO): δ 2.38 (s, 0.114
- (1–metil–1H–pirazol–4–il)–1H– pirrolo[3,2–
- 3H), 2.61 (s, 3H), 3.89 (s, 3H), 6.55 (s, 1H),
- c]piridin–6–amina
- 7.08 (s, 1H), 7.32 (d, J=8.5Hz, 1H), 7.44 (d, J=2.2Hz, 1H), 7.89 (s, 1H), 8.06 (s, 1H), 8.11 (s, 1H), 8.12 (s, 1H), 8.41 (s, 1H), 11.45 (s, 1H). ESI–HRMS Encontrado 435.1159 calculado para C22H19ClN6S [M+H]+: 435.1153 Usando el Ejemplo 45 y el método de purificación C.
- 151
- N–(2–Cloro–4–(2–metoxipiridin–4– il)fenil)–2– 1H–RMN (500 MHz, d6–DMSO): δ 3.89 (s, 0.182
- (1–metil–1H–pirazol–4–il)–1H– pirrolo[3,2–
- 3H), 3.9 (s, 3H), 6.57 (s, 1H), 7.11 (s, 1H),
- c]piridin–6–amina
- 7.13 (s, 1H), 7.32 (d, J=2.2Hz, 1H), 7.7 (d, J=2.2Hz 1H), 7.9 (s, 1H), 8.12 (d, J= 10Hz, 1H), 8.17 (s, 1H), 8.2(s, 1H), 8.44 (s, 1H), 11.46 (s, 1H). ESI–HRMS Encontrado 431.1315 calculado para C23H19ClN6O [M+H]+: 431.1312 Usando el Ejemplo 46 y el método de purificación C.
- 152
- N–(2–Cloro–4–(1,2–dimetil–1H–imidazol–5– 1H–RMN (500 MHz, d6–DMSO): δ 2.34 (s, 0.005
- il)fenil)–2–(1–metil–1H–pirazol–4–il)–1H–
- 3H), 3.53 (s, 3H), 3.89 (s, 3H), 6.55 (s, 1H),
- pirrolo[3,2–c]piridin–6–amina
- 6.85(s, 1H), 7.05(s, 1H), 7.26 (d, J=8.6Hz, 1H), 7.44 (s, 1H), 7.88 (s, 1H), 8 (s, 1H), 8.09(d, J=8.6Hz, 1H), 8.1 (s, 1H), 8.4 (s, 1H), 11.4 (s, 1H). ESI–HRMS Encontrado 418.1531 calculado para C22H20ClN7 [M+H]+: 418.1541 Usando el Ejemplo 47 y el método de purificación C.
- 153
- (3–Cloro–4–((2–(1–metil–1H–pirazol–4–il)– 1H–RMN (500 MHz, DMSO–d6): δ 3.90 (s, 0.021
- 1H–pirrolo[3,2–c]piridin–6–il)amino)fenil)(3,3–
- 3H), 4.60 (br s, 4H), 6.59 (s, 1H), 7.19 (s,
- difluoroazetidin–1–il)metanona
- 1H), 7.54 (dd, J = 2.2, 8.8 Hz, 1H), 7.71 (d, J = 2.0 Hz, 1H), 7.90 (s, 1H), 8.12 (s, 1H), 8.16 (d, J = 8.5 Hz, 1H), 8.28 (s, 1H), 8.46 (s, 1H), 11.52 (s, 1H). ESI–HRMS: Encontrado 465.1006; calculado para C21H17ClF2N6ONa [M+Na]+: 465.1013. Usando el Ejemplo 50 y el método de purificación E.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 154
- N–(2–cloro–4–(metisulfonil)fenil)–2–(1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (500 MHz, DMSO–d6): δ 3.18 (s, 3H), 6.63 (s, 1H), 7.22 (s, 1H), 7.67 (dd, J = 2.2, 8.9 Hz, 1H), 7.85 (d, J = 2.2 Hz, 1H), 8.09 (br s, 2H), 8.22 (d, J = 9.0 Hz, 1H), 8.47 (s, 1H), 8.50 (br s, 1H). ESI– HRMS: Encontrado 388.0620, calculado para C17H15ClN5O2S [M+H]+: 388.0629. Usando la Preparación 164 y el método de purificación F. 0.002
- 155
- N–(2–Fluoro–4–metoxifenil)–2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3.2–c]piridin–6– amina 1H–RMN (500 MHz, DMSO–d6): δ 3.74 (s, 3H), 3.87 (s, 3H), 6.46 (d, J = 1.0 Hz, 1H), 6.62 (s, 1H), 6.73 (dd, J = 2.5, 8.9 Hz, 1H), 6.86 (dd, J = 2.8, 10.1 Hz, 1H), 7.76 (t, J = 9.4 Hz, 1H), 7.83 (s, 1H), 7.87 (s, 1H), 8.04 (s, 1H), 8.28 (s, 1H), 11.14 (s, 1H). ESI– HRMS: Encontrado 338.1407, calculado para C18H17FN5O [M+H]+: 338.1412. Usando el Ejemplo 56 y el método de purificación C. 0.053
- 156
- N–(2–Metoxi–4–(trifluorometil)fenil)–2–(1– 1H–RMN (500 MHz, DMSO–d6): δ 3.88 (s, 0.164
- metil–1H–pirazol–4–il)–1H–pirrolo[3,2–
- 3H), 3.96 (s, 3H), 6.54 (s, 1H), 7.13 (s, 1H),
- c]piridin–6–amina
- 7.18 (s, 1H), 7.20 (d, J = 9.2 Hz, 1H), 7.89 (s, 1H), 8.10 (s, 1H), 8.11 (s, 1H), 8.43 (s, 1H), 8.47 (d, J = 8.6 Hz, 1H), 11.41 (s, 1H). ESI–HRMS: Encontrado 388.1387, calculado para C19H17F3N5O [M+H]+: 388.1380. Usando el Ejemplo 57 y el método de purificación G.
- 157
- N–(4–Fluoro–2–metoxifenil)–2–(1–metil– 1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (500 MHz, DMSO–d6): δ 3.86 (s, 3H), 3.88 (s, 3H), 6.48 (s, 1H), 6.70 (td, J = 2.6, 8.6 Hz, 1H), 6.84 (s, 1H), 6.92 (dd, J = 3.2, 11.2 Hz, 1H), 7.51 (s, 1H), 7.85 (d, J = 0.6 Hz, 1H), 8.04 (dd, J = 6.5, 8.6 Hz, 1H), 8.06 (s, 1H), 8.32 (s, 1H), 11.22 (s, 1H). ESI–HRMS: Encontrado 338.1408. calculado para C18H17FN5O [M+H]+: 338.1412. Usando el Ejemplo 58 y el método de purificación H. 0.119
- 158
- N–(4–Metoxifenil)–2–(1H–pirazol–4–il)– 1H– pirrolo[3,2–c]piridin–6–amina 1H–RMN (d4–MeOH, 500MHz): δ 3.80 (s, 3H), 6.57 (d, J=0.95Hz, 1H), 6.75 (m, 1H), 6.91 (d, J=8.83Hz, 1H), 7.22 (d, J=8.83Hz, 2H), 7.97 (br s, 2H), 8.28 (d, J=0.95Hz, 1H). ESI–HRMS Encontrado 306.1375, calculado para C17H16N5O [M+H]+: 306.1349. Usando la Preparación 35 y el método de purificación I. 0.035
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 159
- N–(2–Metoxifenil)–2–(1H–pirazol–4–il)– 1H– pirrolo[3,2–c]piridin–6–amina 1H–RMN (d4–MeOH, 500MHz): δ 3.92 (s, 3H), 6.61 (d, J=0.95Hz, 1H), 6.91–6.97 (m, 2H), 7.00–7.03 (m, 2H), 7.51 (dd, J–1.89, 7.57Hz, 1H), 8.00 (br s, 2H), 8.35 (d, J=0.95Hz, 1H). ESI–HRMS Encontrado 307.1384, calculado para C17H17N5O [M+2H]2+: 307.1422 Usando la Preparación 40 y el método de purificación I. 0.017
- 160
- N–(2,4–Dimetoxifenil)–2–(1H–pirazol–4– il)– 1H–pirrolo[3,2–c]piridin–6–amina 1H–RMN (d6–DMSO, 500MHz): δ 3.75 (s, 3H), 3.81 (s, 3H), 6.47–6.51 (m, 2H), 6.62 (d, J=2.52Hz, 1H), 6.66 (s, 1H), 7.18 (s, 1H), 7.72 (d, J=8.83Hz, 1H), 7.90 (br s, 1H), 8.10 (br s, 1H), 8.28 (s, 1H), 11.08 (br s, 1H, NH), 12.95 (br s, 1H, NH). ESI– HRMS Encontrado 336.1456, calculado para C18H18N5O2 [M+H]+: 336.1455 Usando la Preparación 41 y el método de purificación I. 0.019
- 161
- 2–(1H–Pirazol–4–il)–N–(4–(trifluorometil)fenil)– 1H– pirrolo[3,2–c]piridin–6–amina 1H–RMN (d6–DMSO, 500MHz): δ 6.57 (d, J=0.95Hz, 1H), 6.87 (s, 1H), 7.52 (d, J=8.51Hz, 2H), 7.76 (d, J=8.51Hz, 2H), 7.95 (br s, 1H), 8.16 (br s, 1H), 8.44 (s, 1H), 9.10 (s, 1H), 11.32 (br s, 1H, NH), 13.00 (br s, 1H, NH). 19F – RMN (CDCl3): δ – 59.34. ESI–HRMS Encontrado 344.1112, calculado para C17H13F3N5 [M+H]+: 344.1118 Usando la Preparación 42 y el método de purificación I. 1.065
- 162
- N–(3,4–Dimetoxifenil)–2–(1H–pirazol–4– il)– 1H–pirrolo[3,2–c]piridin–6–amina 1H–RMN (d6–DMSO, 500MHz): δ 3.74 (s, 3H), 3.74 (s, 3H), 6.50 (s, 1H), 6.72 (s, 1H), 6.84 (d, J=8.83Hz, 1H), 7.06 (dd, J=2.21, 8.51 Hz, 1H), 7.21 (d, J=2.52Hz, 1H), 8.01 (s, 1H), 8.25 (s, 1H), 8.33 (s, 1H), 11.11 (br s, 1H, NH), 12.96 (br s, 1H, NH). ESI– HRMS Encontrado 336.1468, calculado para C18H18N5O2 [M+H]+: 336.1455 Usando la Preparación 43 y el método de purificación I. 0.024
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 163
- N–(2–Cloro–4–metoxifenil)–2–(1H– pirazol–4– il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (d6–DMSO, 500MHz): δ 3.76 (s, 3H), 6.51 (m, 1H), 6.65 (m, 1H), 6.89 (dd, J=2.84, 8.83Hz, 1H), 7.05 (d, J=2.84Hz, 1H), 7.60 (s, 1H), 7.69 (d, J=8.83Hz, 1H), 7.91 (br s, 1H), 8.12 (brs, 1H), 8.29 (s, 1H), 11.15 (br s, 1H, NH), 12.96 (br s, 1H, NH). ESI–HRMS Encontrado 340.0971, calculado para C17H15ClN5O [M+H]+: 340.0960. Usando la Preparación 44 y el método de purificación I. 0.012
- 164
- 2–(1H–Pirazol–4–il)–N–(2–(trifluorometil)fenil)– 1H–pirrolo[3,2–c]piridin–6–amina 1H–RMN (d6–DMSO, 500MHz): δ 6.56 (m, 1H), 6.92 (s, 1H), 7.09 (t, J=7.88Hz, 1H), 7.51 (t, J=7.57Hz, 1H), 7.55 (s, 1H), 7.62 (dd, J=1.58, 7.88Hz, 1H), 7.70 (d, J=8.20Hz, 1H), 7.94 (br s, 1H), 8.15 (br s, 1H), 8.35 (s, 1H), 11.32 (br s, 1H, NH), 12.99 (br s, 1H, NH). 19F – RMN (d6– DMSO): δ –59.50. ESI–HRMS Encontrado 344.1124, calculado para C17H13F3N5 [M+H]+: 344.1118 Usando la Preparación 45 y el método de purificación I. 0.512
- 165
- N–(2–Etoxifenil)–2–(1H–pirazol–4–il)–1H– pirrolo[3,2–c]piridin–6–amina 1H–RMN (d6–DMSO, 500MHz): δ 1.40 (t, J=6.94Hz, 3H), 4.11 (q, J=6.94Hz, 2H), 6.54 (m, 1H), 6.79–6.89 (m, 2H), 6.94 (m, 1H), 6.97 (dd, J=1.58, 7.88Hz, 1H), 7.35 (s, 1H), 7.95 (dd, J=1.89, 7.88Hz, 1H) sobre 7.93 (br s, 1H), 8.14 (br s, 1H), 8.36 (s, 1H), 11.23 (br s, 1H, NH), 12.98 (br s, 1H, NH). ESI–HRMS Encontrado 321.1541, calculado para C18H18N5O [M+H]+: 321.1579 Usando la Preparación 46 y el método de purificación I. 0.017
- 166
- N–(2–Metoxi–4–(1–metilpiperidin–4– 1H–RMN (d6–DMSO, 500MHz): δ 1.64 (m, 0.007
- iloxi)fenil)–2–(1H–pirazol–4–il)–1H–
- 2H), 1.93 (m, 2H), 2.20 (s, 3H sobre m,
- pirrolo[3,2–c]piridin–6–amina
- 2H), 2.64 (m, 2H), 3.80 (s, 3H), 4.29 (m, 1H), 6.48 (s, 1H), 6.51 (dd, J=2.52, 8.83Hz, 1H), 6.62 (d, J=2.52Hz, 1H), 6.68 (s, 1H), 7.19 (s, 1H), 7.72 (d, J=8.51 Hz, 1H), 7.90 (br s, 1H), 8.10 (br s, 1H), 8.28 (s, 1H), 11.08 (br s, 1H, NH), 12.95 (br s, 1H, NH). ESI–HRMS Encontrado 419.2194, calculado para C23H27N6O [M+H]+: 419.2190 Usando la Preparación 48 y el método de purificación I.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 167
- 4–(2–(1H–Pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–ilamino)–N,N– dimetibencenosulfonamida 1H–RMN (d6–DMSO, 500MHz): δ 2.57 (s, 6H), 6.59 (d, J=0.95Hz, 1H), 6.90 (s, 1H), 7.56 (d, J=8.83Hz, 2H), 7.79 (d, J=8.83Hz, 2H), 7.95 (br s, 1H), 8.16 (br s, 1H), 8.45 (s, 1H), 9.27 (s, 1H), 11.37 (s, 1H, NH), 13.01 (br s, 1H, NH). ESI–HRMS Encontrado 383.1293, calculado para C18H19N6O2S [M+H]+: 383.1285 Usando la Preparación 47 y el método de purificación I. 0.017
- 168
- 4–(2–(1H–Pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–ilamino)–N,N–dimetibenzamida 1H–RMN (500 MHz, CD3OD): δ 3.11 (s, 6H), 6.63 (d, J = 0.8 Hz, 1H), 7.00 (s, 1H), 7.36 (m, 4H), 7.96 (br s, 1H), 8.06 (br s, 1H), 8.42 (d, J = 0.6 Hz, 1H). ESI–HRMS: Encontrado 347.1631, calculado para C19H19N6O [M+H]+: 347.1615. Usando la Preparación 49 y el método de purificación J. 0.011
- 169
- 1–(4–(4–(2–(1H–Pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–ilamino) fenil)piperazin–1– il)etanona 1H–RMN (500 MHz, CD3OD): δ 2.16 (s, 3H), 3.10 (t, J= 5.5 Hz, 2H), 3.15 (t, J = 5.2 Hz, 2H), 3.71 (t, J = 5.1 Hz, 2H), 3.76 (t, J = 5.1 Hz, 2H), 6.56 (d, J = 0.9 Hz, 1H), 6.80 (s, 1H), 7.00 (d, J = 8.9 Hz, 2H), 7.23 (d, J = 8.8 Hz, 2H), 7.97 (br s, 2H), 8.29 (d, J = 0.9 Hz, 1H). ESI–HRMS: Encontrado 402.2026; calculado para C22H24N7O [M+H]+: 402.2037. Usando la Preparación 50 y el método de purificación J. 0.080
- 170
- N–(4–(2–Metoxietoxi)fenil)–2–(1H– pirazol–4– il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (500 MHz, DMSO–d6): δ 3.31 (s, 3H), 3.65 (t, J = 4.6 Hz, 2H), 4.03 (t, J = 4.6 Hz, 2H), 6.49 (s, 1H), 6.68 (s, 1H), 6.84 (d, J = 9.0 Hz, 2H), 7.43 (d, J = 9.0 Hz, 2H), 7.90 (br s, 1H), 8.10 (br s, 1H), 8.24 (s, 1H), 8.31 (s, 1H), 11.08 (s, 1H), 12.97 (s, 1H). ESI–HRMS: Encontrado 350.1615; calculado para C19H20N5O2 [M+H]+: 350.1612. Usando la Preparación 51 y el método de purificación J. 0.009
- 171
- N–(4–(Morfolinometil)fenil)–2–(1H–pirazol–4– il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (500 MHz, DMSO–d6): δ 2.34 (m, 4H), 3.36 (s, 2H), 3.57 (t, J = 4.7 Hz, 4H), 6.52 (m, 1H), 6.78 (s, 1H), 7.12 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.92 (s, 1H), 8.12 (s, 1H), 8.35 (s, 1H), 8.49 (s, 1H), 11.16 (s, 1H), 12.97 (s, 1H). ESI– HRMS: Encontrado 375.1942; calculado para C21H23N6O [M+H]+: 375.1928. Usando la Preparación 52 y el método de purificación J. 0.009
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 172
- N–(2–Metoxifenil)–2–(1–metil–1H– pirazol–4– il)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (d6–DMSO, 500MHz): δ 3.86 (s, 3H), 3.89 (s, 3H), 6.49 (d, J=0.95Hz, 1H), 6.81–6.89 (m, 2H), 6.93 (dd, J=7.88, 1.58Hz, 1H), 7.50 (s, 1H), 7.86 (s, 1H), 8.04–8.08 (s sobre dd, 2H), 8.36 (s, 1H), 11.23 (br s, 1H). ESI–HRMS Encontrado 320.1522, calculado para C18H18N5O [M+H]+: 320.1506 Usando el Ejemplo 59 y el método de purificación I. 0.085
- 173
- N–(2,4–Dimetoxifenil)–2–(1–((5– metilisoxazol–3–il)metil)–1H–pirazol–4– il)– 1H–pirrolo[3,2–c]piridin–6–amina 1H–RMN (500 MHz, CDCl3): δ 2.36 (s, 3H), 3.76 (s, 6H), 5.3 (s, 2H), 5.92 (s, 1H), 6.41 (m, 1H), 6.46 (s, 2H), 6.50 (s, 1H), 6.70 (s, 1H), 7.47 (d, J = 8.7 Hz, 1H), 7.66 (s, 1H), 7.79 (s, 1H), 8.46 (s, 1H), 9.01 (s, 1H). ESI–HRMS: Encontrado 430.1769, calculado para C23H23N6O3 [M+H]+: 430.1754 Usando el Ejemplo 101 y el método de purificación K. 0.207
- 174
- N–(4–((1H–Pirazol–1–il)metil)fenil)–2–(1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 6–amina 1H–RMN (500 MHz, CDCl3): δ 5.22 (s, 2H), 6.25 (d, J = 2Hz, 1H), 6.57 (s, 1H), 6.82 (s, 1H), 7.14 (d, J = 8.5 Hz, 2H), 7.44 (s, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.75 (d, J = 2 Hz, 1H), 8.38 (s, 1H), 8.69 (s, 1H), 11.3 (s, 1H), 13 (s, 1H). ESI–HRMS: Encontrado 355.1548, calculado para C20H18N7 [M+H]+: 355.1545 Usando la Preparación 36 y el método de purificación J. 0.012
- 175
- 2–(1H–Pirazol–4–il)–N–(4– 1H–RMN (500 MHz, DMSO–d6):δ 2.81 0.004
- (tiomorfolinometil)fenil)–1H–pirrolo[3,2–
- (m,br, 4H), 3.04 (m, br, 4H), 3.57 (s, 2H),
- c]piridin–6–amina–S,S–dióxido
- 6.51 (s, 1H), 6.57 (s, 1H), 6.83 (s, 1H), 7.18 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 8.3 Hz, 1H), 7.95 (br, s, 1H), 8.15 (br, s, 1H), 8.39 (s, 1H), 8.68 (s, 1H), 11.3 (s, 1H), 13 (s, 1H). ESI–HRMS: Encontrado 422.1535, calculado para C21H23N6O2S [M+H]+: 422.1525 Usando la Preparación 37 y el método de purificación J.
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 176
- N–(4–(2–Morfolinoetoxi)fenil)–2–(1H–pirazol– 4–il)–1H–pirrolo[3,2–c]piridin–6–amina 1H–RMN (500 MHz, DMSO–d6):δ 2.49 (br, s, 4H), 2.68 (t, J = 5.7 Hz, 2H), 3.58 (m, 4H), 4.02 (t, J = 5.7 Hz, 2H), 6.5 (s, 1H), 6.69 (s, 1H), 6.84 (d, J = 9 Hz, 2H), 7.42 (d, J = 9 Hz, 2H), 8.1 (br s, 1H), 8.15 (br s, 1H), 8.25 (s, 1H), 8.32 (s, 1H), 11.1 (s, 1H), 12.96 (s, 1H). ESI–HRMS: Encontrado 404.1976, calculado para C22H25N6O2 [M+H]+: 404.1961 Usando la Preparación 38 y el método de purificación J. 0.030
- 177
- 4–(2–(1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–6–ilamino) benzonitrilo 1H–RMN (500 MHz, DMSO–d6): δ 6.6 (s, 1H), 6.9 (s, 1H), 7.59 (d, J = 8.9 Hz, 2H), 7.73 (d, J = 8.9 Hz, 2H), 7.95 (s, 1H), 8.69 (s, 1H), 11.3 (brs, 1H), 8.15 (br s, 1H), 8.46 (s, 1H), 9.31 (s, 1H), 11.4 (s, 1H), 13 (s, 1H). ESI–HRMS: Encontrado 300.1121, calculado para C17H12N6 [M+H]+: 300.1123 Usando la Preparación 39 y el método de purificación J. 0.150
- 178
- 3–Cloro–4–(3–cloro–2–(oxazol–5–il)–1H– pirrolo[3,2–c]piridin–6–ilamino)–N,N– dimetibenzamida 1H–RMN (d6–DMSO, 500MHz): δ 2.97 (s, 6H), 7.14 (d, J = 0.95Hz, 1H), 7.31 (dd, J = 1.89, 8.51Hz, 1H), 7.49 (d, J = 1.89Hz, 1H), 7.75 (s, 1H), 8.07 (d, J = 8.51 Hz, 1H), 8.52 (s, 1H), 8.64 (s, 1H), 12.16 (br s, 1H, NH). HRMS calculado para C19H16Cl2N5O4(M+H)+ 416.0676, encontrado 416.0668 Usando el Ejemplo 95 y el método de purificación L. 0.003
- 179
- (3–Metoxi–4–(2–(oxazol–5–il)–1H–pirrolo[3,2– c]piridin–6–ilamino)fenil)(3–metoxiazetidin–1– il)metanona 1H–RMN (d6–DMSO, 500MHz): δ 3.22 (s, 3H), 3.83 (s, v br, 1H), 3.92 (s, 3H), 4.19 (s, v br, 2H), 4.23 (m, 1H), 4.50 (s, v br, 2H), 6.82 d, J = 0.95Hz, 1H), 7.16 (t, J = 0.95Hz, 1H), 7.20 (dd, J = 1.89, 8.51 Hz, 1H), 7.22 (d, J = 1.89Hz, 1H), 7.57 (s, 1H), 8.16 (s, 1H, NH), 8.33 (d, J = 8.51 Hz, 1H), 8.49 (s, 1H), 8.56 (s, 1H), 11.80 (s, 1H, NH). HRMS calculado para C22H22N5O4(M+H)+ 420.1666, encontrado 420.1663 Usando el Ejemplo 97 y el método de purificación I. 0.003
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 180
- 3–Cloro–N, N–d im etil–4–(2–(oxazol–5–il)– 1H–pirrolo[3,2–c]piridin–6–ilamino)etanona 1H–RMN (d6–DMSO, 500MHz): δ 2.98 (s, 6H), 6.84 (s, 1H), 7.14 (s, 1H), 7.30 (dd, J = 1.89, 8.51Hz, 1H), 7.47 (d, J = 1.89Hz, 1H), 7.58 (s, 1H), 8.09 (d, J = 8.51 Hz, 1H), 8.25 (s, 1H), 8.50 (s, 1H), 8.55 (s, 1H), 11.86 (br s, 1H, NH). HRMS calculado para C19H17ClN5O2 (M+H)+ 382.1065, encontrado 382.1063 Usando el Ejemplo 98 y el método de purificación M. 0.005
- 181
- N–(2–Metoxifenil)–2–(oxazol–5–il)–1H– pirrolo[3,2–c]piridin–6–amina 1H–RMN (d6–DMSO, 500MHz): δ 3.86 (s, 3H), 6.78 (d, J = 0.95Hz, 1H), 6.84–6.91 (m, 2H), 6.96 (t, J = 0.95Hz, 1H), 6.98–7.01 (m, 1H), 7.53 (s, 1H), 7.70 (br s, 1H, NH), 8.04–8.07 (m, 1H), 8.47 (s, 1H), 8.49 (s, 1H), 11.65 (br s, 1H, NH). HRMS calculado para C17H15N4O2 (M+H)+ 307.1190, encontrado 307.1186 Usando el Ejemplo 96 y el método de purificación A. 0.025
- 182
- N–(2–Metoxifenil)–2–(1–(2,2,2– trifluoroetil)– 1H–pirazol–4–il)–1H– pirrolo[3,2–c]piridin–6– amina 1H–RMN (d6–acetona, 500MHz): δ 3.90 (s, 3H), 5.11 (q, J = 8.83Hz, 2H), 6.67 (m, 1H), 6.81–6.93 (m, 2H), 6.96–7.00 (m, 2H), 7.21 (br s, 0.4H, NH), 8.02 (d, J = 0.63Hz, 1H), 8.14 (t of d, J = 1.89, 7.88Hz,1H), 8.25 (s, 1H), 8.47 (s, 1H), 10.53 (br s, 0.4H, NH). Las señales de NH parciales se deben al intercambio con la d6–acetona 19F – RMN (d6–acetona, 470.385MHz): –72.25. ESI– HRMS Encontrado 388.1369, calculado para C19H16F3N5O (M+H+): 388.1380. Usando el Ejemplo 99 y el método de purificación A. 0.049
- 183
- 2–(1–(Difluorometil)–1H–pirazol–4–il)–N–(2– metoxifenil)–1H–pirrolo[3,2–c]piridin–6– amina 1H–RMN (d6–acetona, 500MHz): δ 3–90 (s, 3H), 6.79 (s, 1H), 6.83–6.93 (m, 2H), 6.98 (d, J = 7.88Hz, 1H), 7.01 (s, 1H), 7.25 (br s, 0.5H, NH), 7.68 (t, J = 59.9Hz, 1H), 8.15, (t of d, J = 1.58, 7.88Hz, 1H), 8.20 (s, 1H), 8.50 (s, 1H), 8.54 (s, 1H), 10.58 (br s, 0.5H, NH). Las señlaes de NH parciales surgen del intercambio con la d6–acetona. 19F – RMN (d6–acetona, 470.385MHz): – 95.39. ESI– HRMS Encontrado 356.1322, calculado para C18H16F2N5O (M+H+): 356.1318. Usando el Ejemplo 100 y el método de purificación A. 0.482
- Ejemplo No.
- Nombre/Estructura Datos MPS1 IC50(µM)
- 184
- N–(2–Cloro–5–(1–metil–1H–pirazol–4– 1H–RMN (500 MHz, DMSO–d6):δ 3.84 (s, 0.548
- il)fenil)–2–(1–metil–1H–pirazol–4–il)– 1H–
- 3H), 3.89 (s, 3H), 6.55 (s, 1H), 6.97 (s, 1H),
- pirrolo[3,2–c]piridin–6–amina
- 7.10 (dd, J = 1.6, 8.0 Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.76 (s, 1H), 7.83 (s, 1H), 7.88 (s, 1H), 8.06 (s, 1H), 8.08 (d, J = 1.9 Hz, 1H), 8.09 (s, 1H), 8.41 (s, 1H), 11.35 (s, 1H). ESI–HRMS: Encontrado 404.1375; calculado para C21H19ClN7 (M+H)+: 404.1385. Usando el Ejemplo 62 y el método de purificación N.
- 185
- N–(2–Cloro–4–(1–metil–1H–imidazol–5– 1H–RMN (CD3OD, 500MHz): δ 3.74 (s, 0.005
- il)fenil)–2–(oxazol–5–il)–1H–pirrolo[3,2–
- 3H), 6.92 (d, J = 0.95Hz, 1H), 7.04 (br s,
- c]piridin–6–amina
- 1H), 7.11 (s, 1H), 7.33 (dd, J = 1.89, 8.51Hz, 1H), 7.49 (s, 1H), 7.53 (d, J = 1.89Hz, 1H)), 7.71 (br s, 1H), 7.77 (d, J = 8.51 Hz, 1H), 8.30 (s, 1H), 8.55 (s, 1H). ESI–HRMS calculado para C20H 35ClN O 16 6 (M+H)+ 391.1069, encontrado 391.1060 Usando el Ejemplo 91 y el método de purificación O
- 186
- N–(2–Cloro–4–(1,2–dimetil–1H–imidazol–5– 1H–RMN (d6–DMSO, 500MHz): δ 2.34 (s, 0.001
- il)fenil)–2–(oxazol–5–il)–1H–pirrolo[3,2–
- 3H), 3.53 (s, 3H), 6.81 (d J = 0.95Hz, 1H),
- c]piridin–6–amina
- 6.85 (s, 1H), 7.07 (t, J = 0.95Hz, 1H), 7.28 (dd, J = 2.21, 8.51Hz, 1H), 7.45 (d, J = 1.89Hz, 1H), 7.55 (s, 1H), 8.07 (d, J = 8.51Hz, 1H), 8.13 (br s, 1H, NH), 8.48 (s, 1H), 8.53 (d, J = 0.95Hz, 1H), 11.9 (v br s, 1H, NH). HRMS calculado para C21H18 35ClN6O (M+H)+ 405.1225, encontrado 405.1214 Usando el Ejemplo 107 y el método de purificación P.
Ejemplo 187 N–(4–fluorofenil)–1–(metisulfonil)–2–(1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–amina
Se agregó hidróxido de sodio acuoso (127 µL, 1 M, 0.127 mmol) a una solución de 4–(6–(4–fluorofenilamino)– 1– (metisulfonil)–1H–pirrolo[3,2–c]piridin–2–il)–1H–pirazol–1–carboxilato de tert–butilo (Preparación 53, 20 mg, 0.042 mmol) (mezclada con un poco de 4–(6–cloro–1–(metisulfonil)–1H–pirrolo[3,2–c]piridin–2–il)–1H–pirazol–1–
- 192
- 3–Cloro–4–(3–cloro–1– 1H–RMN (500 MHz, CDCl3): δ 0.18–0.22 (m, 2H), 0.053
- (ciclopropilmetil)–2–(1–metil–1H–
- 0.52–0.56 (m, 2H), 1.03–1.11 (m, 1H), 3.11 (s, 6H),
- pirazol–4–il)–1H–pirrolo[3,2–c]piridin–
- 4.01 (d, J = 6.3Hz, 2H), 4.06 (s, 3H), 6.90 (s, 1H), 7.36
- 6–ilamino)–N,N–dimetibenzamida
- (dd, J = 8.5, 2.0Hz, 1H), 7.56 (d, J = 2.0Hz, 1H), 7.75 (s, 1H), 7.76 (s, 1H), 7.92 (d, J = 8.5Hz, 1H), 8.61 (s, 1H); ESI–HRMS (Método B) Encontrado 483.1459, calculado para C24H25Cl2N6O (M+H+): 483.1461. Usando el Ejemplo 66.
- 193
- 3–Cloro–N–(2–clorofenil)–2–(1–metil– 1H–RMN (500 MHz, CD3OD): δ 4.01 (s, 3H), 6.96 (s, 0.421
- 1H–pirazol–4–il)–1H–pirrolo[3,2–
- 1H), 6.95–7.00 (m, 1H), 7.26 (m, 1H), 7.44 (dd, J = 8.0,
- c]piridin–6–amina
- 1.5Hz, 1H), 7.64 (dd, J = 8.2, 1.5Hz, 1H), 8.02 (s, 1H), 8.24 (s, 1H), 8.38 (br s, 1H); ESI–HRMS (Método B) Encontrado 358.0615, calculado para C17H14Cl2N5 (M+H+): 358.0621. Usando el Ejemplo 122.
- 194
- 3–Cloro–N–(2–cloro–4–(1–metil–1H– 1H–RMN (500 MHz, CD3OD): δ 3.93 (s, 3H), 3.99 (s, 0.128
- pirazol–4–il)fenil)–2–(1–metil–1H–
- 3H), 6.91 (s, 1H), 7.41 (dd, J = 8.5, 2.1Hz, 1H), 7.62 (d,
- pirazol–4–il)–1H–pirrolo[3,2–c]piridin–
- J = 2.1Hz, 1H), 7.62 (d, J = 8.5Hz, 1H), 7.78 (s, 1H),
- 6–amina
- 7.91 (s, 1H), 8.00 (s, 1H), 8.19 (s, 1H), 8.35 (s, 1H); ESI–HRMS (Método B) Encontrado 438.0986, calculado para C21H18Cl2N7 (M+H+): 438.0995. Usando el Ejemplo 123.
- 195
- (3–cloro–4–(3–cloro–2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 6–ilamino)fenil)(3–metoxiazetidin–1– il)metanona 1H–RMN (500 MHz, CD3OD): δ 3.32 (m, 5H), 3.99 (s, 3H), 4.31 (s, 3H), 7.2(s, 1H), 7.61 (m, 2H), 7.84 (d, J=1.9 Hz, 1H), 8.08 (s, 1H), 8.33 (s, 1H), 8.51 (s, 1H); ESI–HRMS (Método D) Encontrado 471.1092, calculado para C22H20Cl2N6O2 (M+H+): 471.1098 Usando el Ejemplo 142 y el método de purificación A. 0.021
- 196
- (3–Cloro–4–(3–cloro–2–(1–metil–1H– pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 6–ilamino)fenil)(S,S–dioxo– tiomorfolino)metanona 1H–RMN (500 MHz, CD3OD): δ 3.24 (s, br, 4H), 4.01 (s, 3H), 4.1 (s, br, 4H), 7.13 (s, 1H), 7.41(dd, J =2.1Hz, 8.5 Hz, 1H), 7.67 (s, 1H), 7.73 (d, J=8.5Hz, 1H), 8.05 (s, 1H), 8.27 (s, 1H), 8.45 (s, 1H); ESI–HRMS Encontrado 519.0761, calculado para C22H20Cl2N6O3S (M+H+): 519.0767 Usando el Ejemplo 143 y el método de purificación A. 0.009
- 197
- 3–Cloro–N–(2–cloro– 1H–RMN (500 MHz, DMSO–d6): δ 3.20 (s, 3H), 3.95 0.069
- 4–(metisulfonil)fenil)–2–(1–
- (s, 3H), 7.25 (s, 1H), 7.70 (dd, J = 1.8, 8.8 Hz, 1H),
- metil–1H–pirazol–4–il)–1H–
- 7.87 (d, J = 2.2 Hz,. 1H), 8.03 (s, 1H), 8.24 (d, J =
- pirrolo[3,2–c]piridin–6–amina
- 9.4 Hz, 1H), 8.34 (s, 1H), 8.45 (s, 1H), 8.66 (s, 1H), 11.86 (s, 1H). ESI– HRMS: Encontrado 436.0395; calculado para C18H16Cl2N5O2S (M+H)+: 436.0396. Usando el Ejemplo 131 y el método de purificación B.
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7 6–(2–cloro–4–(S,S–dioxo–tiomorfolin–4–carbonil)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1Hpirrolo[3,2–c]piridin–1– carboxilato de tert–butilo;N–(2–clorofenil)–1–(ciclohexilmetil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–amina; 3–cloro–N–(2–cloro–4–(1–metil–1H–pirazol–4–il)fenil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 6– amina;3–cloro–N–(2–clorofenil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–amina; N–(2–clorofenil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–amina; N–(2–clorofenil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–amina; (3–cloro–4–(2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)fenil)(3–metoxiazetidin–1– il)metanona; 6–(2–cloro–4–(3–metoxiazetidin–1–carbonil)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo;6–(2–cloro–4–(1–metil–1H–pirazol–4–il) fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1– carboxilato; 6–(2–clorofenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo; 3–cloro–4–(1–isopropil–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N–dimetibenzamida; 3–cloro–4–(1–ciclopentil–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N–dimetilbenzamida; 3–cloro–4–(3–cloro–1–(ciclopentilmetilo)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N–dimetibenzamida;3–cloro–4–(3–cloro–1–(ciclopropilmetil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N– dimetibenzamida; 3,5–dicloro–N,N–dimetil–4–(2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)etanona; 6–(4–(dimetilcarbamoil)–2–(trifluorometoxi) fenilamino)–2–(l –metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo;6–(2,6–dicloro–4–(dimetilcarbamoil)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2– c]piridin–1–carboxilato de tert–butilo; 3–cloro–4–(1–(ciclopropilmetil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N–dimetibenzamida;6–(2–cloro–4–(dimetilcarbamoil)fenilamino)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin– 1–carboxilato de cilcopentilo; 3–cloro–4–(1–(ciclohexilmetil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N–dimetibenzamida;3–cloro–4–(1–(4–fluorobencil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N– dimetibenzamida; 3–cloro–4–(1–(ciclopentilsulfonil)–2–(1–metil–1H–pirazol–4–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N–dimetibenzamida; 3–cloro–4–(3–cloro–2–(oxazol–5–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)–N,N–dimetibenzamida; 6–(2–metoxifenilamino)–2–(oxazol–5–il)–1H–pirrolo[3,2–c]piridin–1–carboxilato de tert–butilo; 3–cloro–N,N–dimetil–4–((2–(l –metil–1H–pirazol–4–il)–1–((5–metilisoxazol–3–il)metil)–1H–pirrolo[3,2–c]piridin–6–il)amino)etanona; (3–metoxi–4–(2–(oxazol–5–il)–1H–pirrolo[3,2–c]piridin–6–ilamino)fenil)(3–metoxiazetidin–1–il)metanona; 6–(2–metoxi–4–(3–metoxiazetidin–1–carbonil)fenilamino)–2–(oxazol–5–il)–1H–pirrolo[3,2–c]piridin– 1–carboxilato detert–butilo;138imagen8 imagen9 imagen10 imagen11
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1104267.8A GB201104267D0 (en) | 2011-03-14 | 2011-03-14 | Pyrrolopyridineamino derivatives |
| GB201104267 | 2011-03-14 | ||
| PCT/GB2012/050564 WO2012123745A1 (en) | 2011-03-14 | 2012-03-14 | Pyrrolopyridineamino derivatives as mps1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2573778T3 true ES2573778T3 (es) | 2016-06-10 |
Family
ID=43980940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12711433.8T Active ES2573778T3 (es) | 2011-03-14 | 2012-03-14 | Derivados de pirrolopiridinamino como inhibidores de MPS1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9371319B2 (es) |
| EP (1) | EP2686318B1 (es) |
| JP (1) | JP6027989B2 (es) |
| CN (1) | CN103517903B (es) |
| AU (1) | AU2012228090B2 (es) |
| CA (1) | CA2830143C (es) |
| ES (1) | ES2573778T3 (es) |
| GB (1) | GB201104267D0 (es) |
| WO (1) | WO2012123745A1 (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| CN105102448B (zh) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
| EP2818472A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators |
| GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
| GB201403536D0 (en) * | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
| ES2966392T3 (es) | 2015-04-17 | 2024-04-22 | Crossfire Oncology Holding B V | Biomarcadores pronósticos para quimioterapia inhibidora de TTK |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017007756A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc | Hetero-halo inhibitors of histone deacetylase |
| GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| WO2018125983A1 (en) | 2016-12-30 | 2018-07-05 | Mitobridge, Inc. | Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors |
| HUE057849T2 (hu) | 2017-01-11 | 2022-06-28 | Alkermes Inc | Hiszton deacetiláz biciklusos gátlói |
| TWI674260B (zh) * | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| PT3624796T (pt) | 2017-05-19 | 2025-06-02 | Nflection Therapeutics Inc | Compostos de pirrolopiridina-anilina para tratamento de distúrbios dérmicos |
| EP3641745A1 (en) * | 2017-06-20 | 2020-04-29 | The Institute of Cancer Research : The Royal Cancer Hospital | Methods and medical uses |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| LT3664802T (lt) | 2017-08-07 | 2022-06-27 | Alkermes, Inc. | Bicikliniai histonų deacetilazės inhibitoriai |
| CN107550905B (zh) * | 2017-09-11 | 2020-07-17 | 浙江永宁药业股份有限公司 | 多取代吡咯并吡啶类化合物的药物用途及其制备方法 |
| WO2020106305A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| WO2020106306A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Cyanoaryl-aniline compounds for treatment of dermal disorders |
| WO2020106308A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| CA3130478A1 (en) * | 2019-03-13 | 2020-09-17 | Voronoi Co., Ltd. | Heteroaryl derivatives, and pharmaceutical composition comprising the same as active ingredient |
| US12473262B2 (en) | 2019-07-30 | 2025-11-18 | Oregon State University | Aryl hydrocarbon receptor activators |
| US20240124444A1 (en) * | 2020-12-28 | 2024-04-18 | Celgene Corporation | Heterocyclic Compounds and Their Use for Parasitic Diseases |
| CN113248496B (zh) * | 2021-05-06 | 2022-02-11 | 东南大学 | 吡咯并吡啶类化合物及其盐及其用途 |
| WO2024054749A2 (en) * | 2022-09-08 | 2024-03-14 | Bridge Medicines | Inhibitors of enl/af9 yeats and flt3 |
| KR20250105461A (ko) * | 2022-11-17 | 2025-07-08 | (주) 팜캐드 | 피페리딘 유도체, 이의 염 및 이를 유효성분으로 포함하는 약학적 조성물 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2697710A (en) | 1953-01-02 | 1954-12-21 | Burroughs Wellcome Co | Pyrido (2,3-d) pyrimidines and method of preparing same |
| US3021332A (en) | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
| PL181893B1 (pl) | 1994-11-14 | 2001-10-31 | Warner Lambert Co | Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO2000025780A1 (en) | 1998-10-29 | 2000-05-11 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of impdh enzyme |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PT1154774E (pt) | 1999-02-10 | 2005-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de angiogenese |
| AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
| ES2316383T3 (es) | 1999-09-17 | 2009-04-16 | Millennium Pharmaceuticals, Inc. | Benzamidas e inhibidores relacionados del factor xa. |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| CA2397961C (en) | 2000-01-25 | 2008-08-26 | Richard John Booth | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| US20090124690A1 (en) | 2000-04-03 | 2009-05-14 | Alberte Randall S | Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| WO2003000011A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidines and uses thereof |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| US20040235867A1 (en) * | 2001-07-24 | 2004-11-25 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| ES2314224T3 (es) | 2002-03-07 | 2009-03-16 | F. Hoffmann-La Roche Ag | Inhibidores pirimidina y piridina biciclicos de p38 quinasa. |
| AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
| US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
| AU2003291329A1 (en) | 2002-11-12 | 2004-06-03 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| ES2387780T3 (es) * | 2003-10-06 | 2012-10-01 | Glaxosmithkline Llc | Preparación de azabencimidazoles 1,6-disustituidos como inhibidores de quinasas |
| US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | S1p受容体結合能を有する化合物およびその用途 |
| CN101213187B (zh) | 2005-06-28 | 2012-06-06 | 塞诺菲-安万特股份有限公司 | 作为rho-激酶抑制剂的异喹啉衍生物 |
| WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
| UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
| CA2651072A1 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| EA017405B9 (ru) * | 2006-12-08 | 2014-05-30 | АйАрЭм ЭлЭлСи | Соединения и композиции в качестве ингибиторов протеинкиназы |
| KR101472765B1 (ko) | 2006-12-08 | 2014-12-15 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 경구용 Xa 인자 억제제를 포함하는 단위 용량 제형 및 경구용 Xa 인자 억제제를 사용하는 혈전증의 치료 방법 |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| JP2010533147A (ja) | 2007-07-13 | 2010-10-21 | アデックス ファルマ エス.エイ. | 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体 |
| WO2009010871A2 (en) | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Pyrazole derivatives as antagonists of adenosine a3 receptor |
| JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| PL2183254T3 (pl) | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitory aktywności białkowej kinazy tyrozynowej |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
| SG178106A1 (en) | 2009-08-05 | 2012-03-29 | Versitech Ltd | Antiviral compounds and methods of making and using thereof |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| ES2526124T3 (es) | 2010-06-16 | 2015-01-07 | Cymabay Therapeutics, Inc. | Agonistas del receptor GPR120 y sus usos |
| ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
| US9458463B2 (en) * | 2010-09-03 | 2016-10-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for treatment of diabetes by a small molecule inhibitor for GRK5 |
| JP2013545749A (ja) | 2010-11-10 | 2013-12-26 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 複素環化合物及びその使用 |
| WO2012079032A2 (en) | 2010-12-09 | 2012-06-14 | Trana Discovery, Inc. | Compositions and methods of treating drug-resistant retroviral infections |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| EA026115B1 (ru) | 2010-12-17 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение |
| US8987271B2 (en) | 2010-12-22 | 2015-03-24 | Eutropics Pharmaceuticals, Inc. | 2,2′-biphenazine compounds and methods useful for treating disease |
| WO2012092471A2 (en) | 2010-12-29 | 2012-07-05 | Development Center For Biotechnology | Novel tubulin inhibitors and methods of using the same |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
-
2011
- 2011-03-14 GB GBGB1104267.8A patent/GB201104267D0/en not_active Ceased
-
2012
- 2012-03-14 ES ES12711433.8T patent/ES2573778T3/es active Active
- 2012-03-14 EP EP12711433.8A patent/EP2686318B1/en active Active
- 2012-03-14 US US14/004,515 patent/US9371319B2/en not_active Expired - Fee Related
- 2012-03-14 CA CA2830143A patent/CA2830143C/en active Active
- 2012-03-14 CN CN201280023272.2A patent/CN103517903B/zh not_active Expired - Fee Related
- 2012-03-14 JP JP2013558506A patent/JP6027989B2/ja not_active Expired - Fee Related
- 2012-03-14 AU AU2012228090A patent/AU2012228090B2/en not_active Ceased
- 2012-03-14 WO PCT/GB2012/050564 patent/WO2012123745A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2830143A1 (en) | 2012-09-20 |
| CN103517903A (zh) | 2014-01-15 |
| CA2830143C (en) | 2019-10-01 |
| CN103517903B (zh) | 2017-03-01 |
| AU2012228090B2 (en) | 2017-03-30 |
| AU2012228090A1 (en) | 2013-10-03 |
| GB201104267D0 (en) | 2011-04-27 |
| EP2686318B1 (en) | 2016-03-09 |
| US20130345181A1 (en) | 2013-12-26 |
| JP2014508185A (ja) | 2014-04-03 |
| WO2012123745A1 (en) | 2012-09-20 |
| US9371319B2 (en) | 2016-06-21 |
| JP6027989B2 (ja) | 2016-11-16 |
| EP2686318A1 (en) | 2014-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2573778T3 (es) | Derivados de pirrolopiridinamino como inhibidores de MPS1 | |
| AU2017323584C1 (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| AU2022229380B2 (en) | Fgfr3 inhibitor compounds | |
| TWI598351B (zh) | Rsv抗病毒化合物 | |
| US9289419B2 (en) | Substituted heterocyclic compounds as tropomyosin receptor kinase a (TrkA) inhibitors | |
| ES2655194T3 (es) | Compuestos inhibidores | |
| AU2018379321B2 (en) | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors | |
| ES2400619T3 (es) | Inhibidores de imidazopiridina quinasa | |
| US9714248B2 (en) | Therapeutically active pyrazolo-pyrimidine derivatives | |
| CA2961984C (en) | Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines | |
| US11214563B2 (en) | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | |
| ES3062921T3 (en) | Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method | |
| AU2009212338A1 (en) | Furo-and Thieno[3,2-c] Pyridines | |
| WO2006025567A1 (ja) | 新規置換イミダゾール誘導体 | |
| ES2903528T3 (es) | Compuestos de heteroarilo y su uso como inhibidores de MER | |
| KR20190016106A (ko) | 새로운 피페리디닐 유도체, 이의 제조를 위한 방법 및 이를 함유하는 약학적 조성물 | |
| AU2020256720B2 (en) | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof | |
| AU2019237991B2 (en) | JAK inhibitors | |
| BR112021005896A2 (pt) | moduladores da monoacilglicerol lipase | |
| AU2021373162B2 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
| RU2733400C2 (ru) | Производные пиразолопиридина в качестве ингибиторов киназы | |
| KR20220042132A (ko) | 2h-이미다졸 유도체 및 질환 치료에서 그의 용도 | |
| CN110964012B (zh) | 一类稠杂环联芳基苄醇类化合物、制备方法和用途 | |
| CA3116628A1 (en) | Pyrazole derivatives as h4 antagonist compounds | |
| WO2023212535A1 (en) | Fgfr2 inhibitor compounds |